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PCNE 
Classification 
for Drug 
related 
problems 
(revised 01-05-06 vm) 
V5.01 
2003,2004,2005.2006 Phannaccutical Care Network Europe Foundation 
Thi clas ification can freely be used in Phannaccutical Care Research and practice. as long 
as the Foundation is informed of its use and results of validations. 111e classification is 
available both as a Word document and a PDF document. 
Contact: jwt\:miJ@planet.nl 
·n1is cla-;sification should be referred to as 'The PC E Classification 5.0 I · 
PCNE classi fication 29-05-06 V 5.01 
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Introduct.ion 
During the wc,rking conference of the Pham1aceutical Care etwork Europe in January I 999, 
a classification scheme was constructed for dmg related problems (DRPs). ll1e classification 
is part of a total set of instnunents. The set consists of the classification scheme, reporting 
fonns and cases for training or validation. The clas ification system is validated and adapted 
regularly. ll1e current version is V5 . It is compatible with pn:vious versions although new 
items have been added. l11e numbering of existing items has not been changed. 
l11e classification is for use in research into the nature, prevalence, and incidence of DRPs 
and also as a process indicator in experimental studies of Pharmaceutical Care outcomes. It is 
also meant to help health care professionals to document DRP-infonnation in the 
pham1acculical care process. 
l11e hierarchical classification is bit~ed upon similar work in the field, but it differs from 
existing systems because it separates the problems from the causes. 'lbe following definition 
is the basis for the classification: 
A Dr11g-Relmed Problem is a11 e1•e111 or circumsta11ce i111•0/vu1g drug therapy tllat act11ally 
or pO(elllially uueif eres wit/I desired /1eall/1 011tcomes. 
111e basic classification now has 6 primary domains for problems, 6 primary domains for 
causes and 5 primary domains for Interventions. 
However, on a more detailed level there are 21 grouped sub domailts for problems, 33 
grouped sub domains for causes and I 7 grouped sub domains for interventions. ·n1ose sub 
domains can be regarded as explanatory for the principal domains. 
In 2003 a scale has been added to indicate if or to what extend the problem has been solved. 
Zuidlaren, May 2006 
N.B. In this version 5.01 at\ ex1ra Cause is added: C4.JO Pariem takes food that Interacts with 
dmgs and an exira Outcome 00.0 Outcome nol known. 
PCNE classification 2 29-05-06 v 5.01 
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PCNE Cla ification cbcmc for Drug-Related Problem V5 .01 -Page I 
The Basic Classification 
Problems 
Causes 
lute1-ventions 
Outcome of intcrvent Ion 
PCNE classificalion 
Peter Tenni 
Code Primary domains 
VS.01 
Pl Adverse reaction(s) 
Patient suffers from an adverse drug event 
P2 Drug Choice Problem 
Pati~nt gets or is going to gd a wrong (or no drug) drug 
for his/her disea e and/or condition 
P3 Dosing problem 
Patient gets more or less than the amount of drug heh;he 
requires 
P4 Drue sc Problem 
Wrong or no drug take1 administered 
PS lntemctions 
There is a manifost or potential drug-drug or dmg-food 
interaction 
P6 Other 
Cl Drug/Dose Sdcction 
111e cause orthe DRP can be related to the selection of 
the dmg an or do age schedule 
C2 Drug se Process 
The caus" orth.: DRP can be related to the way the 
patient uses th<} dmg, in pite of proper dosage 
instmctions (on the label) 
C3 I:nfon:nntlon 
'The cause or the DRP can be related to a lack or 
misinterpretation of iufomiation 
C4 Paticnt/Psychologicnl 
1ne caus ofthc DRP can be related to the p ·rsonality 
or behaviour of the patient. 
CS (l'harmacy) Logistks 
1l1e cause of the DRP can be related to the logistics of 
the prescribing or di:pcnsing mechanism 
C6 Other 
IO No intcn·ention 
[] • t prcsc1iber level 
12 At patient (or carer) le\'ei 
13 At drug level 
14 Other 
00 Outcome intervention unknown 
0.1 Problem totally solved 
02 Problem partially solved 
03 Problem not solved 
_9-0;-06 v 5.01 
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P E Clas ification chem for Dmg-Relatcd Problem V5.01 -Page 2 
The Detailed Cla sification-1 
The Problems 
Each problem should be coded separately, but there ma be more causes or interventions to 
one problem. 
Primary Doma in Code Problem 
V5.01 
1. Ad"erse reactions P1.1 Side effect uffered (non-allergic) 
Patient uffc from an Pl.2 Side efl'ect sulT.:red (allergic) 
adverse drug event Pl.3 Toxic effects suffered 
2. Drug choice problem P2.1 Inappropriate drug (not most appropriate for indication) 
Patient gets or i. going to P2.2 Inappropriate drug fom1 (not mo t appropriate for 
get a wrong (or no dn1g) indication) 
drug for his/her disease P2.3 Inappropriate duplication of' therapeutic group or act ive 
and/or condition ingredient 
P2.4 Contra-indication fo r drug (incl. Pregnancy m:ast 
feeding) 
P2.5 1 o clear indication for drug u c 
/>2.6 No dmJ! prescribed but clear indication 
3. Dosin& problem P3.1 Dmg dose too low or dosage regime not frequent 
Patient gets more or less enough 
than the amount of drug P3.2 Dmg dos.: too high or dosage r.:gime too frequent 
h sh.: requires P3.3 l)urat ion of treatment too short 
P3.4 Duration of tr.:atm.:nt too long 
4. Drug use. problem P4.1 Drng not taken/administered at all 
Wrong or no drug P4.2 Wrong drug taken/administer.:d 
taken/administered 
5. Interacdons P5.1 Potential interaction 
TI1cre is a manifest or P5.2 Manif.:st interacti on 
potential drug-drug or 
dmg-food interaction 
6.0then P6.1 Patient dissatisfied with therapy despite taking drug(s) 
correctly 
P6.2 Insufficient a\ arenc of health and di ea es (po ibly 
leading to future problems) 
P6.3 Unclear complaints. Further clarification necessary 
P6.4 Thernpy fa ilure (r.:ason unknown) 
PCNE classification 2 -9-05-06 V 5.0 I 
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PCNE Cla ification scheme for Drug Related Problem VS.01 -Page ~ 
The Detailed Classification-2 
The Causes 
.B. One problem can have more cau e 
Primary Doma in Code Cause 
VS.01 
1. Drug/Dose selection Cl.1 Inappropriate drug selection 
The cause of the DRP is related to Cl.2 lnappropriate dosage selection 
the sdection of the drug and/or Cl.3 More cost-effective dmg available dosage schedule Ct.4 Pham1acokine1ic problems, incl. agein d tcrioration in 
organ function and interactions 
Cl .5 S nergistic/pre cnti e drug required and not given 
Ct .6 Deterioratio1 improvement of disease state 
Cl.7 cw s mptom or indication revcalcd/prcscntcd 
Cl .8 Manifest side .:Freet. no other cause 
2. D111g use process C2.1 Inappropriate timing of admini tration an or dosing 
The cause of the DR? can be intervals 
rclntcd to th way the patient uses C2.2 Drng llllderuse under-administered the drug, in pite of proper dosage C2.3 Drug overused/ over-administered ins1n1ctions (on the label) 
C2.4 TI1erapeutic dnig level not monitored 
C2.5 Dmg abused (unregulated o cruse) 
C2.6 Patient unable to use dmgffonn as directed 
3. lnfonnation C3.t Instruction.~ for use/taking not known 
Th.: cause of the DRP can be C3.2 Patient unaware of reason for drug lr.:atment 
related to a lack or C3.3 Patient ha diniculties reading/understanding Patient 
misinterpretation of mfom1ation ln.fom1ation Fom .caJ1ct 
C3.4 Patient w1ablc to understand local language 
C3.5 Lack of communication between healthcar.: 
professionals 
4. Patient/Psychological C4.t Patient forge ts to use/take drug 
The cause of the DRP can be C4.2 Patient has concerns with drngs 
related to the p.:rsonality or C4.3 Patent sLL~pccts side-elTcct behaviour of the patient. C4.4 Patient unwilling to carry financial costs 
C.4.5 Patient unwilling to bother physician 
C4.6 Patient rnn illing to change drugs 
C4.7 Patient unwilling to adapt life- ·tylc 
C4.8 Burden of therapy 
C4.9 Treaunent Llot in line with health bdiefs 
C4.10 Patient takes food that interact~ with drugs 
5. Logistics C5.t Prescribed drug not available (anymore) 
The cause of the DRP can be CS.2 Pres ribing error (only in case of slip of the pen) 
related to the logistics of the C5.3 Dispensing error (wrong drug or dose di pen ed) prescribing or dispensing 
mechanism 
6. others C6.l Other cnuse; specify 
C6.2 No obvious cause 
PCNE classification 3 :9-05-06 v 5.01 
Peter Tenni 506 I Page 
Clinical Interventions in Australian Community Pharmacies 
PCNE Clas ification chcmc for Drug-Related Problems V5.01 -Page 4 
The Detailed Classification-3 
The Interventions 
.B. One problem can lead to more interventions 
Primary Domain Code lntervention 
V5.0l 
No lnten•ent.ion JO.O No Intervention 
1. At prescriber level 11.1 Prescriber infom1ed only 
11.2 Prescriber a5ked fo r infom1ation 
11.3 Intervention proposed. approved by Prescriber 
11.4 Intervention proposed, not approved by Prescriber 
11.5 Intervention orooosed. outcome unknown 
2. At patient/c-.irer level 12.1 Patient (medication) cow1selling 
12.2 Written in fonnation pro idcd onl 
12.3 Patient n:fern:d lo prescriber 
12.4 Spoken to family member/caregiver 
3. At drug le, •cl 13.1 Dntg changed to .. .. 
13.2 Dosage changed to . ... 
13.3 Fommlation changed to .... . 
13.4 Instructions for use changed to ... .. 
13.5 Drug stopped 
13.6 New dnag started 
4. Other intervention or 14.1 Other intervemion (specify) 
activity 14.2 Side effect reported to authorities 
O u.tcome of intervention 
.B. One problem (or the combination of interventions) can onl lead to one level of solving 
the problem 
Primary Domain Code Outcome of lnten•entlon 
V5.01 
0. Not known 00.0 Outcome intervention not known 
1. Sol,•ed 01.0 Problem totally solved 
2. Partially solved 02.0 Problem partially solved 
3. Not solved 03.1 Problem not solved, lack of cooperation of patient 
03.2 Problem not solved. lack of cooperation of prescriber 
03.3 Problem not solved, intervention not eflective 
03.4 No need or possibility to solve problem 
PCNE classification 4 -9..05..()6 v 5.01 
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PCNE 
Classification 
for Drug 
related 
problems 
Help 
(revised 01-02-06 vm) 
V5.01 
2003,2004,2005.2006 Phamiaceutical Care etwork Europe Foundation 
Thi clas ification can freely b used in Pharmaceutical Care Research and practice, as long 
a5 the foundation is informed of its use and result!· of validations. 1'11e c)a5silication is 
available both as a Word document and a PDF document. 
Contact: jwfvmil Gplanet.nl 
This help document is rdated to ··111e PCN E Classification V 5.01 ' 
PCNE classification Help 29--05-06V 5.01 
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Finding or selecting codes in the PCNE classification 
'A Dr11g-Related Problem is 011 ewmt or circ11msta11ce involvillg dmg tllerapy tliat actually 
or p<ne11tially i11terferes wit/z desired l1ea/Jl1 011tcomes. -
For the use of the PCNE classification it is important to separate the real problem (that affects 
or is going to affect the outcome) from its cause. Often such problems are caused by a certain 
typ_e of error e.g. prescribing errors or drug-use or admin-istration errors. But there might be no 
error al all involved. Also, a medication error does not necessarily have to lead to a drug-
related problen1. · 
TI1e cause is usually the behaviour that has caused the problem. A cause or a combination of 
causes and a problem together, will 1.isually lead lo one or more interventions. 
TI1e classification can ~e lJS~d in t~o ways, depending on the .level of infonnation needed. 
• If only the main domains are used, there is in general eno~gh information for rei;;earch 
purposed 
• If the system is used for documenting,phannaceulical care activities in practice, the 
sub domains can-be used. -
Problem section 
Basically, the problem is defined as 'the expected or unexpected event or circumstance-that is, 
or mig11fbe wrong, in_therapy with medicines'. (the P-c~des) 
TI1ere are 6 major domains in the problem section. TI1e following descriptions could help to 
find the right problem domain: 
Patient suffers or is go~g to suffer from ~ adverse drug event such as a side effect See Pt 
or toxicity. Tiiis can be proscribing error, but unexpected ADR.<i may also occur at 
· normal dosa2es of a well selected dru2. 
Patient gets or is going to get a wrong (or no drug) drug for his/her disease and/or SeeP2 
condition. Titis is usuallv a orescribinl! error. 
Patient has or gets the right drug, but gets more ~r less than the amount of drug SeePJ 
than he/she requires. This can be a urescribinl! error but also a drul! use error. 
Patient uses or gets administered the wrong drug or no drug. This can be drug use SeeP4 
<>r administration errors but also a fillin2 error in the ohannacv. · 
111ere is a manifest or potential drug-drug or drug-food interaction. This is a form ljjeePS 
of orescribinl! or drul!-use error. 
Anv other oroblem SeeP6-
PCNE classification Help_ 2 29-05-06V 5.01 
Peter Tenni 509 I Page 
Climcal Interventions in Australian Community Pharmacies 
Causes section 
Each problem has a cause. TI1e cause is the action (or Jack of action) that leads up to the 
occurrence _of a potential or real problem. 111ere may be more causes for a problem. (The·C-
code) 
The cause of the DRP can be related to the selection of the drug and/or dosage See Cl 
schedule 
TI1e caIL~c of the DRP can be related to the way .t\lc patient uses the drug, in spite SeeC2 
of proper dosage instructions (on the label or in the information leaflet) 
TI1e cause of.the DRP can be related to a lack or misinterpretation of information Sec CJ 
bv the natient 
TI1e cause of the DRP can be related to·the personalitv or behaviour of the patient. SeeC4 
Tue cause of the DRP can be related to the logistics of the prescribing or SecC5 
disoensine: mechanism 
Anv other cause SeeC6 
Inten•ention section 
the_ problem will usually lead to one or more in interventions to correct the cause of the 
problem. (TI1e I-code) 
1l1ere is or can be'no intervention SeeIO 
Intervention through the orcscribcr Seell 
Intervention through the oatient. his carers or relatives Seel2 
Intervention dircctlv bv changing drug or indicating change in drug use Secl3 
Other intervention Sccl4 
eutcome section 
For evaluation purposes it is desirable to indicate if the problem has been !!Olved by doing the 
intervention (the 0-code). This scale has been ~dded in V5 (2003) 
Problem totallv solved See OJ 
Problem partially solved Sce02 
Problem not solved See03 
PCNE classification Help. 3 29-05-06V 5.01 
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9.2 APPENDIX 2: PILOT STUDY PHARMACY 
INSTRUCTION MANUAL 
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. ~·r 
t::: 
PROMISe ·~> 
Pharmacy Recording of Medication Incidents anc:i. ·~er.v.ices 
electronic documentation system 
Pilot 
Study 
Instructions and 
Help Manual 
UTAS 
PHQENIX 
COMPUTE R SYSTEM S School of Pharmacy 
Peter Tenni 512 I Page 
Clinical Interventions in Australian Community Pharmacies 
. ''! ~,J: 
PROMISe _; . "{::~,~-~ ''1'._~~:'-
Pharmacy Recording of Medication Incidents and Ser.'lices 
electronic documentation 'system 
This project is funded by the Commonwealth 
Department of Health and Ageing as part of the 
Third Community Pharmacy Agreement. The 
Pharmacy Guild of Australia manages the Third 
Community Pharmacy Agreement Research and 
Development Grants (CPA R&D Grants) Program. 
Project web site: www.promise.id.au 
Chief Investigator: Prof Greg Peterson 
Project Managers Dr Omar Hasan 
Mr Peter Tenni (62261005 or 0439 850 086) 
Team members Mr Chung Liauw 
Observers 
Peter Tenni 
Mr James Reeve 
Ms Brita Pekarsky 
Mr John Elkerton 
Dr Paul Turner 
Assoc Prof Janet Vial 
Dr Roger Rumble 
Prof Michael Roberts 
Dr Julie Stokes 
Rachel Dienaar 
Helen Kruup 
Kim Fitzmaurice 
0419 529 024 
0413 499 187 
0417 395 496 
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Backgroun~ lnfonnation 
Detection and resolution of drug related problems has been demonstrated 1n hospital and medication review 
settings. However, very little 1s known about detection and resolution of drug related problems (interventions) in 
community pharmacy practice. 
At present, the documentation of cognitive services and medication incidents in community pharmacy practice in 
Australia is virtually non-existent, yet quality care cannot be provided without complete documentation. The 
future of our profession lies in our ability to document the benefit of pharmaceutical care for our patients. 
This project is a Pharmacy Guild tendered research project, funded by a Third Community Pharmacy 
Agreement Research and Developn:ient (CPA R&D) grant. This project is to be ~ompleted in two phases; 
• Phase 1: to develop and build an e-record for the documentation of community. pharmacists clinical 
services, and test this with two types of dispensing software 
• Phase 2: to determine the nature and frequency of these clinical services, and to determine the potential 
benefit of the activities in economic and health.benefit terms. 
Being able to document the frequency and nature of such ~linical activities over a significant period of time a!Jd 
then being able to assess these activities for economic and patient focused benefit would provide extremely 
useful information which would inform decisions at many organisational levels. This pilot study is part of the 
testing of the systems developed in Phase 1. 
Some members of 'the project team have previously developed and evaluated a convenient, computerised 
process for the recording of medication incidents and community pharmacists' cognitive services. This system 
was devised after an extensive literature evaluation and it underwent several pilot phases \iyith many iterative 
modificatiol')s. It was initially developed for incorporation into the Rex system (Phoenix Corp), and this version of 
the intervention recording system is now part of Rex dispensing system. 
This project aims to build upon the team's existing research to establish a sustainable, nationwide system for the 
ongoing 'collection of information from community pharmacies identifying incidents related to medication safety 
and subsequent clinical interventions by community pharmacists. 
PAGE30F50 
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Phase 1 so far ... 
The first major task was the production of a system for appropriately classifying interventions and related 
pharmacists' cognitive services. With the guidance of both a local reference group and national panel of experts, 
there has been a comprehensive review of the previous definitions and classification of medication incidents, 
and of similar medication-related reporting systems from overseas. This review process lead to the 
development of the D.O.C.U.M.E.N.T. system. The current version of the classification scheme maintains its 
original parameters in recording the type (and subtype) of drug related problem, actions to investigate the 
problem, recommendations to resolve the problem, acceptance of pharmacist's resolution of the problem, 
clinical significance (severity), and a free text notes area. To gain an insight into the cost of generating the 
intervention to the pharmacist, a 'time' field has been added to the record. 
For the classifications to be scientifically valid, a large number of people need to have used the system, and to 
facilitate this, we have developed a web-based simulation . Twenty scenarios have been written and interested 
participants, after recording some basic demographic data, are able to interpret the scenarios and classify the 
interventions required as they see fit. The simulation is available from the project's website www.promise.id.au 
which is also accessible from the University of Tasmania Pharmacy QUM group web portal 
www.medsafetv.com.au . To encourage wide participation, two participants will be randomly selected to receive 
a prize of $1000. Also, CPE points will be awarded to all participants who complete the presented cases. The 
results of this validation exercise will be used as a further input into the final structure of the intervention 
classification scheme recommended at the end of this project, and as a training process for all pharmacists 
taking part in the pilot study. 
Feedback from community pharmacists involved in the previous project indicated that the recording system had 
to be as streamlined as possible for it to be a realistic addition to their daily work practices. The record should 
have sufficient information for other pharmacists to understand the problem and outcome, and therefore be able 
to follow-up on the problem if necessary. The system developed has taken all these considerations into account. 
The second major task in Phase 1 was developing the mechanism for recording, collating and presenting the 
data. The intervention data is de-identified and encrypted and then sent via the Internet to a central repository 
which is located on a secure server at the Tasmanian School of Pharmacy. Data files can then be downloaded 
and the details of the provision of clinical services can be easily collated and summarised, at a local, state and 
national level. 
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Your role in the Pilot StU~ 
As part of the pilot. phase, we ask you to_ document the clinical services and interventions. you perf~rm during 
your daily duties. We are not asking you to perform any extra duties, but just to record those activities that you 
normally do. This does not mean documenting every time you reinforce the dosage details of an antibiotic to a 
patient, or when you simply counsel on the appropriate use of a product. Examples are given later in this 
document. Extensive, Help Notes have been incorporated into the program, and can be accessed when 
recording an intervention or clinical serv!ce. 
The pilot study will be conducted in seven test pharmacies. Four days of which will include assistance by the 
obs~rver team. This will enable each pharmacis~ to become familiar with the system in an enviro~ment where 
immediate help is available. Hopefully this will minimise the effect of the learning phase on pharmacist . 
productivity.·· Pharmacists from each test pharm?cy will be able to provide feedback on the useability and 
. ' 
interactivity of the system. The data communications and repository functionalities of the system will 'be tested in 
a 'live' scenario. 
The Observation Team · 
The Observation Team consists of three pharmacists who currently work at the university in a research. capacity; 
Helen Kruup, Rachel Dienaar ·and Kim Fitzmaurice. The role of the observers will be quite involved. They are 
there to assist you .to detect ~nd record relevant clinical activities. They will also be attempting. to keep track of 
script volume and work load so that these factors can be utilised 'in -the .statistical analysis of the collected data: 
To enable all ·of these activities to occur, the observers will need to be working closely Vl(lth the pharmacist and 
within the dispensary .. 
All _of the observers are current practising communify pharmacists, and therefore understand the i111portance of 
discretion and .uninterrupted '{I/Ork-flow. They will endeavour to have minin:ial impact on your normal a.ctivities, 
but still assist as much as po~sible. 
PAGES OF SO 
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What is &;ln intervention or clinical service? 
A pharmacisfs.responsibilities indude identifying, resolving and preventing health problems, in particular drug 
related problems. In different studies and research projects, va.rious definitions of ~dverse drug reactions, drug 
related problems and interventions have been used. For example: 
"A drug therapy problem is any undesirable event experienced by· the 
patient ·that involves or is suspected to involve drug therapy and that 
actually or potentially interferes with a desired patient outcome." 1 
1C1polle RJ, Stiand LM, Morley PC. A reimbursement system for phannaceu!ical care Phannaceut1cal care practice. 
N~wYork: McGraw-Hill, 1998:267-96. 
We would like to push the_ boundaries of recordable events beyond just. 'drug related problems'. In the past, 
similar studies have restricted recordable events to drug related problems, or actual adverse events. These 
' ' 
boundaries do not allow for the recording of potential events or near misses. Nor does it allow for the recording 
of s_uch things as blood pressure or blood ~ugar monitoring •. which are becoming more commonplace in 
community pharmacy. These professional services are time consuming, and may involve· financial outlay. They 
have also been shown to be valuable services in the .community pharmacy setting. 
A clinical service encompasses many aspects of a pharmacist's activities. 
' . 
• Identifying Drug Related Problel!l and Adverse Drug Reactions 
• Health management advice (eg smoking cessation, weight loss plan) 
• Working in conjundion with 'the entire health care team to provide the best possible · 
outcome for patients. (eg·care plan meeting) 
• Monitoring response to therapy. (eg monitoring BP/weight/temperature) 
So, an overall definition of the types of activities that are recordable for this research project is: 
Peter Tenni 
."Any professional activity directed towards 
improving health outcomes or the quality 
u_se of medicines~ or the provlsio.n of health-
related information." 
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How do I document an intervention or clinical service? 
This process is fully integrated with your dispensing program and is very similar to the original intervention 
program. Much of the information that needs to be recorded is automatically transferred to the intervention 
. . 
record, thereby minimising the amount of data that you need to input, and also the amount of time taken. 
The recording procedure has 8 stages or components of data entry: 
K ey c t a egory E f xp:ana ion 0 f 1p·1ons 
F1 SCRIPT DETAILS Name of patient, prescnber, date, drug 
name 
F2 CATEGORY/TYPE Categorise the intervention via the root See table 1 and 
cause of the need to perform the Appendix 1 
intervention. 
F3 ACTION What did you do to deal with the See table 2 and 
problem? {there_ may be more than Appendix 1 
one action) 
F4 RECOMMENDATION What did you recommend as a See table 3 and 
solution to the problem? {there may be Appendix 1 
more than one recommend.ation) 
FS OUTCOME Did your intervention actually result in * Unknown 
a change of therapy, or was the 
suggestion deemed not relevant in this * Accepted 
case? 
* Partially accepted 
* Not accepted 
F6. SIGNIFICANCE If you had not intervened, what was * Nil 
the possible/potential outcome. 
* Low 
* Mild· 
* Moderate 
* High 
F7 NOTES This section is for you to add free text_ 
notes, to more thoroughly explain your 
~ction(s) or the reason(s) for them. 
. -
F7 TIME How long did it take you to perform the 
clinical activity? 
It has been set up in· this way to enable the collection of the most complete data possible, with the minimum_ 
amount of data enb)t. This process is expanded upon further in the following pages. 
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Category (Type) Sub-Type Subtype Code 
Duplication D1 
Drug Interaction D2 
D Drug selection Wrong drug D3 Wrong dosage form D4 
Previous ADR/allergy D5 
Other Drug selection problem (specify) DO 
Dose too high 01 
0 Over- or under-dose Dose too low prescribed 02 prescribed Incorrect frequency 03 
Other Dose related Problem (specify) 00 
Potential drug abuse C1 
Taking too little C2 
c Compliance Taking too much C3 
Difficulty using dosage form C4 
Other Compliance problem(specify) co 
Condition not adequately treated U1 
u Untreated indications Preventive therapy required U2 
Other Untreated indication problem uo (specify) 
Drug levels M1 
M 
Laboratory Monitoring M2 
Monitoring required Non-Laboratory monitoring M3 
Other Monitoring problem (Specify) MO 
Patient drug information requests E1 
Confusion about therapy or condition E2 
E Education or Demonstration of device E3 information 
Disease management or advice E4 
Other Education/Information problem EO (Specify) 
N Non-clinical Not sub-classified NO 
Caused by dose too high T1 
T Toxicity or Caused by drug interaction T2 Adverse reaction 
Other Toxicity problem (Specify) TO 
Table 1: Category of clinical service 
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Table 2: Actions to Investigate the Problem 
Actions What did the pharmacist do in Action Code order to S<?rt out the problem? 
lnvestiaation: Written material A1 Note 1: multiple actions possible for 
one sit,uation 
lnvestiaation: Software A2 
Note 2: Each of these actions will A3 have a time value allocated to them lnvestiaation: Internet 
Contacted NPS or State Drug Information Service A4' 
Investigation: Other (eg. consulted other A5 pharmacist)( specify) 
Contacted prescriber A6 
Discussion with patient/carer A? 
Corrected without discussion A8 
Other Action (specify) AO 
Table 3: Recommendations to Resolve the Problem 
Recommendations What did the pharmacist Recommendation Code 
recommend as a solution to the Education/counselling session R1 problem? 
Dose change R2 
Drug change R3 
Note_ 1: multiple recommendations Drug cessation R4 po~sible for: one situation 
Drug formulation change R5 
Monitoring: non-laboratory R6 
Drug addition R7 
Drug brand change R8 -
Dose frequency/schedule change R9 
Refer_to prescri~er R10 
Refer to hospital R11 
Monitoring: Laboratory test 
. R12 
Refer for medication review R13 
Commence dose administration aid R14 
No recommendation necessary RO 
Other recommendation (specify) R15 
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Table 4: Acceotance of Pharmacist s eso ut1on o the Prob em .. ' R I . f 
Outc::omes Did the clinical activity actually result in a change of management, 
or was the suggestion deemed not relevant in this case? 
Unknown 
Note 1: If at the time of clinical activity the outcome is not known, 
Accepted the incident Is flagged for later addition of the outcome. 
That is: Was the pharmacist's resolution implemented? Partially Accepted 
Not accepted 
Table 5: Clinical Significance of the Problem 
Significance If the pharmacist had not intervened/provided a clinical .. 
act1vitY, what was the possible/potential outcome if Significance Code 
(to Patient) therapy had continued? (a subjective rating, predicting 
thedinical severity 1f action was not taken). 
That is: How serious was/could have been the Nil (admin only) so 
problem? 
Note 1: Situations rated as high (S4) will require Low (cost saving to pi:itient additional information to be entered into a notes field 
or information only) 81 
Mild (Improvement in 82 therapy or QOL) 
Moderate 
(required/potentially 83 
prevented GP visit) 
High (required/potentially 
prevented hospital' S4 
admission/death) 
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Documenting an Intervention of Clinical Service 
In this screen, information on the left hand side is imported from the dispensing 
system when the intervention is related to a prescription. If the clinical activity is not related to 
a the prescription, the information needs to be entered manually. 
On the top left-hand side of the screen, information relating to the demographics of 
the patient (once selected) appears and is carried forward through subsequent screens. 
On the top right-hand side of the screen is a series of traffic lights which change from 
red to green when the particular information has been entered. 
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Patient details screen 
This screen shot shows how the information from the dispensing system has been 
incorporated into the intervention recording data file. Note the information transfer that has 
occurred to save you from re-entering the patient's demographic details and the script 
details. This information now appears on the top left corner of the screen. 
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Category Screen 
On this screen the main category or type of clinical activity is determined, with the sub-type 
on the right-hand side panel. Note; the Help Information screen which is available for each of 
the codes. This can be enlarged for easy viewing by clicking on that section . 
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Action screen 
In the Action screen below, the actions possible in relation to a clinical activity need to be 
selected. Actions are to be entered in the order that they occur during the intervention 
process. Multiple actions are possible for each clinical activity, so the selection process 
allows for multiple selections to be made. The same action may be undertaken more than 
once in a particular clinical activity. 
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Recommendations and Outcome screen 
This screen is used to document the recommendations that you make to resolve the 
problem. Multiple recommendations can be documented, although it is not possible to select 
the same recommendation more than once. 
The outcome of the intervention is included on this same screen and is related to a 
composite outcome for all of the recommendations made. 
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Significance Screen 
' Relevant Medical Conditions : 
' Any other clarifying notes 
t'fotal dose prescribed the Is a danger of accumulation of a toxic 
metabolite 
The clinical significance screen, allows the selection of the appropriate level of clinical 
significance for the intervention. The clinical services that are rated as moderate or high will 
require additional information to be collected to enable adequate examination of the activity 
by an external clinical panel. On the interface, a reminder of the importance of this additional 
information is presented when either moderate or high clinical significance is selected . 
PAGE 160F 50 
Peter Tenni 527 I Page 
Clinical Interventions in Australian Community Pharmacies 
Notes and Time Screen 
In the notes and time screen any additional clarifying notes and the total estimated time for 
the clinical activity is entered. The time indicated should not include any additional time it 
took you to document the activity. 
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Summary Screen 
In the final summary screen, a summary of all information (including notes) is shown to the 
user prior to a submission to the PROMISe database. Any items that have not been entered 
are shown in red. 
Peter Tenni 
Intervention Summary ~ 
IO: e7 - 2B "'9r3X>4 
"='-'='""'-'=-~~~--~~~~~~~~/ 
Patient and Script: 
i 
LJ100mgSR 
Category: 
: Ower or unda"dose Presaibed 
Actions: 
l ~"'"tlg.ilon : SOll\lqr1 z:~~i! ;nc::i~ SW Cf'tl 
Ad:ion Note.-: 
Recommendations: 
Select.et Recornmend• ions: 
IDonch.,ge 
P• lof2 
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FAQ I Trouble shooting 
Do I have to enter all the information at once? 
No, you can save the intervention.entry at any time and come back to 
it when you have time 
What it the_ intervention is related to a script not from my pharmacy? 
When recording this intervention enter as much information as you 
can into the patient and script fields, then proceed to classifying.etc 
· In the.situation wher.e the intervention is related.to.dose (or any 
other category) but doesn't fall into any of the subcategories 
Here it is appropriate to use one of the other subcategories and enter 
notes to support this.selection, use the 'help notes if you are having a 
problem. " 
-Do I need to document interventions that relate to 'pharmacist 
only' and 'pharmacy only' items? 
No, This project is aimed at recording Prescriptions interventions. 
Anpther project has recently been completed relating to these items. 
What if I have no idea how to_start categorising my intervention? 
- . 
Please refer to the help notes for each category or use the flow chart 
on the next page. · 
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1. Type of Drug Related Problem 
Category (Type) Sub-Type Subtvpe Sc()pe Notes (When the code should be used, when hot to use it and examples) Code . -
When to Use: : 
When there are no obvious adverse clinical effects of the two drugs together, but it is 
either inappropriate or_ vel}' unusual to see them prescribed or used together as they are 
from the same therapeutic class. 
This also·covers the specific compliance situation where a person may be inappropriately 
D taking two brands of the same drug. Examples of when to use: Duplication D1 • Patient prescribed ranitidine plus pantoprazole 
• Patient prescribed Berotec and Vento/in inhalers 
Drug selection • Patient taking Aratac and Cordarone at the same time · 
(Problems related to the choice • Patient taking Vioxx sample provided by doctor as well as the Vioxx dispensed at· 
of drug prescribed or taken) the pharmacy 
When Not to Use: 
If the drugs involved are not of the same therapeutic class, then use "Drug Interaction 
--· 
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When to Use: 
When there are no obvious adverse clinical effects of the drug interaction, but the 
interaction is serious enough to check if the doctor knows of it. -
When there is a likely serious interaction between the patient's existing therapy and a 
newly prescribed-or u~ed drug, but the patient hasn't yet commenced taking the new drug. 
Examples of when t<? use: 
• Patient commenced on ·tramadol who is already taking fluoxetine Drug interaction D2 
• Patient ceases.amiodarone while continuing on warfarin 
• Patient requests to purchase an over the counter antacid when taking tetracycline 
When Not to Use: 
If the interacting drug is of the same therapeutic class as part of the patient's existing 
therapy, then use "Duplication (D1)''. 
If the interaction is causing, or is suspected of'causing a noticeable effect of any sort, then 
use "Caused by drug interaction. (T2)". 
When to Use: 
When the prescription was intended to mean a different drug and there was an error 
When the drug being taken was.prescribed correctly but was dispensed as the wrong 
drug 
Exa!llples of when to use: : 
• Patient supplied with and taking Hydrea 2 m, labelled as Hydrene 2 m 
Wrong drug D3 
• Doctor prescribes chlorpromazine 200mg bd but intended carbamazepine 200mg 
bd 
When Not to Use: 
If the drug is felt to be inappropriate because of specific patient parameters such as poor 
renal function, then use "Other Drug selection problem (DO)''. 
If the drug prescribed is unavailable for dispensing (either because your pharmacy has no 
stock or the manufacturer/distributor has no stock) then use "Non-clinical (NO)''. 
- -
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Wrong dosage form 04 
Previous AOR/allergy 05 
When to Use: 
When the formulation of the product is inappropriate or incorrect in terms of the intended 
use of the product. -
Also covers the specific situation where an error by the prescriber results in an absurd set 
of instructions (eg, ventolin inhaler, apply three times a day). 
Examples of when to use: 
• Vancomycin oral capsules prescribed to treat systemic infection 
• Ear drop product ordered or supplied for an eye problem 
When Not to Use: 
If the patient has a physical problem with the administration of the dosage form as it is 
intended to be used (eg. swallowing a particular form of the medication whole, cannot 
appropriately insert suppositories, arthritis limiting the use of an inhaler) then use "Difficulty 
using dosage form (C4)''. 
If the dif(iculty is related to a technical problem with the use of an administration device 
such as an aerohaler, then use "demonstration of device (E3)''. 
If the difficulty is not a technical one, and related to lack of understanding of the use of the 
dose form, then use "Confusion about therapy or condition (E2)" 
When to Use: 
When a drug or drug group is prescribed for the patient to which there has previously 
been a major adverse reaction. 
Examples of when to use: 
A patient is prescribed Augmentin Duo who has a documented allergy to penicillins 
When Not to Use: 
If a patient develQps an adverse effect after commencing a drug, then "other adverse 
effect problem (TO)" would be the best code to use. 
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Clin~ca/ Interventions in Australian Community Pharmacies' 
When to Use: ·. · - . 
When there is a contraindication to the use of a drug because of an underlying condition 
~~~~~ ' 
When a less expensive or alternative brand is substituted purely for cost reasons. 
When a drug is felt to be unnecessary based on the conditions the patient has. 
When the _drug being used is out of date or deteriorated in some other way. 
When you believe a more .effective drug Is available. and you suggest it instead of the 
current therapy. · · 
Other drug sel~cti6n DO · Examples of when to use: 
problem (Specify) . . • Maxolon prescribed and doctor contacted to change to Pramin 
• Patient has Anginine tablets for use that are over 2 years old and have been 
stored incorrectly. · · . - · 
• Patient commenced omeprazole when they were taking Ce/ebrex fbr a sore 
knee. Celebrex has been ceased, but they are_ stiU-tak.ing omeprazole. 
When Not to Use: · 
If a less expensive brand is substituted because the ordered brand is unavailable, then 
use "Non"clinical (NO)" 
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When to Use: 
When the total daily dose of a'medication prescribed is-too high for the patient, either 
based on previous dosage or reference dose ranges. 
Includes the situation where the dose is too high because of a particular parameter of the 
) patient such as renal function weight, age. 
This includes situations where the dose that is prescribed is too high by unintentional 
error. 
Dose too high 01 Examples of when to use: 
• Patient is prescribed Diamicron MR 180mg in the morning 
• Patient is prescribed dexamethasone 50mg daily (doctor was thinking of 
prednisolone dose) 
• Patient prescribed spironolactone 1 OOmg bd for heart failure 
When Not to Use: 
If the patient is taking too high a dose as a result of not following the appropriate 
directions, then use 'Taking too much (C3r 
When to Use: 
When the dose prescribed is either too low based on reference dose ranges or too low 
based on previous therapy. 
This includes situations where the dose that is prescribed is too low by unintentional error 
Examples of when to use: 
• Locum doctor prescribes Karvea 150mg daily, when previous therapy was 
Dose too low 02 meant to be 300mg daily 
~ Prescription for prazosin 0.5mg bd for hypertension 
When Not to Use: 
If the actual dose per day is suitable, but the duration is too short, then use "Other Dose 
problem (00)" 
If the patient is taking-too low a dose of a drug as a result of not following the appropriate 
directions, then use 'Taking too little (C2)''. 
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Clinical Interventions in Australian Community Pharmacies 
When to Use: 
When the total dose of a medication is suitable, but the frequency or the dosage schedule 
is inappropriate. 
Examples of when to use: 
• Simvastatin ordered as 40mg in the morning . 
· • Diamicron MR prescribed as three times daily 
Wrong frequency 03 
• Phenytoin prescribed as 1 OOmg three times a day, previously been on 300mg at 
night. 
When Not to Use: 
If the frequency prescribed results in an excessively high a dose of the drug being 
prescribed, then use "Dose too high (01)''. 
If the frequency prescribed results.in an excessively low· dose of the dr:ug being 
prescribed, then.use 'Vose too low (02)''. 
When to Use: 
When the duration of use of the product is too short or too long. 
' Ex~mples of when to use: 
Othe~ Dose Problem 00 • Patient prescribed cephalexin 500mg tds for 3 days for cystitis . (Specify) 
When Not to Use; ._ 
If the patient is not taking the appropriate dose of a product as a result of a lack of 
understanding of the dosage regimen, then a compliance related code would be more 
aooropriate . 
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When to Use: 
When there is suspected overuse of a particular, potentially abusable, product is 
intentional. Includes the situation where the prescription appears to be a forgery. 
Examples ofwhen'to use: 
Potential drug abuse C1 • Patient presents'a third prescription for Panadeine Forte wi~hin 2 weeks, each of 
the prescriptions was written by a different doctor. 
Patient lives in one town, sees a doctor for a prescription for oxazepam in 
another town and presents it fqr dispensing in a third town. 
When Not to Use: 
If the overuse is due to an appropriate increase in use because of increased symptoms, 
then use "Condition not adeauatelv treated (U1)" 
When to Use: 
When the patient uses too little of a medication as a result of forgetfulness or lack of 
understanding of the dosage regimen prescribe~. 
Examples of when to use:. 
• Patient taking metformin only when required ra,ther than regularly_ 
· • Patient using. Transidemi-Nitro patches only every few days, not regularly 
Taking too little· C2 
When Not to Use: 
If the underuse is appropriate because of the resolution of symptoms or a condition, then 
use "Other Drug selection problem (DO)°" and specify that the drug may no longer be 
required. 
ff the patient has a physical problem 'vitth the administration ofthe dosage form as it is 
intended to be used (eg. swallowing a particular form of the medication whole, cannot_ 
appropriately insert suppositories, arthritis limiting the use of an inhaler)then use "Difficulty 
usina dosaae form (C4)" 
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Clinical Interventions in Australian Community Pharmacies 
When to Use: 
When the patient uses too much of a medication as a result of forgetfulness or lack of 
understanding of the dosage regimen prescribed. 
Examples of when to use: 
• - Patient presents requesting a second ventolin inhaler 11 days after the-
previous one was provided. 
• Patient e<;>ntinuing to take 50mg daily of prednisolone, had forgotten to 
Taking too much C3 - __ commence a dose reduction schedule -as instructed by the doctor. 
• Patient believes they have forgotten a medication a_nd takes a second dose 
on the same day. 
When Not to ·use: 
If the overuse ls due to an appropriate increase in use because of increased symptoms, 
then. use "Condition not adequately treated (U1)" 
If the overuse consists of inappropriately taking two different brands or forms of the same 
ingredient unknowingly, then use "Duplication (01)''. 
When to Use: 
When the patient has a phvsical problem with the administration of the dosage form or 
device as it is intended to be used (eg. swallowing a particular form ofthe_medication 
whole, cannot appropriately inse.rt suppositories, arthritis limiting the use of an inhaler) 
Examples of when to use: 
• Patient cannot swallow her slow release diltiazem capsules 
Difficulty using dosage C4 • Patient with scoliosis cannot insert S).Jppositories form 
• Controlled release tablet ordered for a patient who must crush all oral 
medications 
When Not to Use': 
If the difficulty is related to a technical problem with the use of an administration or 
monitoring device such as an aerohaler, then use "demonstration of device (E3) ''. 
If the difficulty is not a technical one, and related to lack of understanding_ of the use of the 
dose form, then use "Confusion about theraov or condition (E2)" 
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When to. Use: 
When the patient is aware of the way to take the drug, is physically able to take the drug, 
and understands its purpose, but does not wish to take it. 
Examples of when ·to use: 
Other Compliance co • Patient unwilling to use mirtazapine after reading the package insert .. Problem. (Specify) 
When Not to Use: .. 
If the compliance issue results in two dri.Jgs of the same therapeutic class being taken 
inadvertently, then use "Duplication (01)': · . 
If the patient does not wish to take the medication because it is causing an adverse event 
of some sort, then a toxicity or adverse event category m would be aooropriate. 
When to Use: 
When the patient has a symptom or disease condition that is either not being treated, or 
not being treated adequately. 
Examples· of when to use: 
Condition not • Patient taking Hydre,ne and Coversyl for high blood pressure, but blood 
adequately treated U1 pressure continues to be high 
• Patient develops nausea as part of a viral illness and requires addition of 
antinauseant medication. 
When Not to Use: 
If the patient requires additional therapy as a preventative strategy (eg potassium when on 
a loop diuretic), then use "Preventive theraov reauired (U2) ·: 
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Clinical Interventions in Australian Community Pharmacies 
When to Use: 
When the patient requires additional therapy to prevent a likely adverse event as a result 
of the patient's therapy, coexisting diseases or risk factors. 
Examples of when to use: 
Preventive therapy •· . Patient commences on morphine slow release and you suggest the addition 
required U2 of a stool_ softener 
• You suggest the addition of antiplatelet therapy in an elderly, obese,_male 
patient with type two diabetes and. hypertensior:i 
'. 
When Not to Use: 
If the patient already has treatment for a particular problem, but it is not effective enough, 
then use "Condition not adequatelv treated (U1) ''. - · 
Other Untreated When to Use: 
indication Problem· uo When you think the patient has any other problem relating to actual or potential conditions 
(Specify) that requires manaaement. 
When to Use: 
When, in the absence of any adverse effects, you believe ·that drug level monitoring is 
required . 
. ' 
Examples of when to use: 
.. Elderly woman on digoxin, wh.o has not had a blood test for two years 
• Patient on carbamazepine 200mg Jwice daily who has not had ·a blood test 
- for 12 month~. 
Drug levels M1 
• Patient commenced-pn phenytoin 3 weeks ago and you recqmmend a blood 
level. 
When Not to Use: 
. ' If the patient is experiencing an adverse effect of some sort, which you believe is due to 
elevated drug levels, then use "Caused by dose too high (T1 )''. 
If the need for drug level monitoring comes about as a result of a newly commenced drug, 
then. use "Drug interaction (02)". The monitoring then becomes a recommendation, not 
the primary problem. 
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Clinical Interventions in Australian Community Pharmacies 
When to Use: . . 
When, in the absence of any adverse effects, you believe that a laboratory test is required 
(e.g. Potassium, creatinine, white cell count, INR) 
Also covers the situation where you undertake the monitoring in question and provide a 
recommendation following the result. (eg INR monitoring and suggesting a change of 
warfarin dose) 
Examples of when to use: 
• Patient recently increased frusemide dose from 40mg daily to 120mg daily 
. Laboratory Monitoring M2 without a change in potassium replacement. 
• Patient commenced on Amiodarone and you recommend a thyroid function 
test 
When Not to Use: 
If there are adverse effects associa.ted with the parameter, then use "Other Toxicity 
problem (TO)'; and specify the parameter to Re tested and the symptom or sign. (eg, 
patient with leg cramps, suggest magnesium level) 
If the need for laboratory level monitoring comes about as a result of a newly commenced 
drug, thefJ use "Drug interaction (02)': The monitoring then becomes a recommendation, 
not the primary problem. 
When to Use: 
When, in the absence of any adverse effects, you believe that non-laboratory monitoring 
is required. (eg BP, BSL, temperature, weight) 
Also covers the situation where the test is undertaken as a screening process. 
Non-Laboratory· Examples of when to use: M3. • A patient with heart failure has an appropriate increase in his dose of monitoring · frusemide and you advise him to weigh himself each day for the next week. _ 
When Not to Use: 
If you recommend monitoring of a parameter (eg weight, BSL) as a result of another drug 
problem, then that recommendation should be recorded in the Recommendation code 
section. The tvoe of problem that leads to this recommendation mav varv. 
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When to Use: 
Other Monitoring MO 
When the patient has another problem related to the monitoring of his drugs for either 
Problem (Specify) efficacy or adverse effects. - · When the patient should be having monitoring done, but has problems with attending the 
laboratorv, or oaving for the test or eauioment needed. -
When to Use: 
When the patient has a reasonable understanding of their condition, but requests furjher 
information about their medication. 
Examples of when to use: 
• Patient requests information about alendronate and you provide a CMI 
Patient drug information E1 
request When Not to Use: 
If the patient request~ information primarily about the disease state, rather than a drug, 
then use "Disease management or advice_ {E4)" 
If the patient does not request the information, but you discover that they need the 
information in the course of your routine dispensing, then use "Confusion about therapy or 
condition (E2) ''. · 
-If the request is not about a specific drug, but a therapeutic device, then use 
"Demonstration of device (D3)" 
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Clinical Interventions in Australian Community Pharmacies 
When to .Use: 
When the patient does not understand the reasons for the use of a medication or a 
fundamental aspect of the condition they have, but they still take the medication as 
directed (ie correct dose· and time). 
Examples of when to 1,1se: 
• When providing a new prescription for metoprolol for a patient with newly · '.' 
diagnosed hypertension, you find that she believes that the drug may cure 
Confusion about E2 '. the condition and she can stop the drug in a few months. therapy or condition 
When Not to Use: . · · 
If the patient requests further infof"fr/ation, (hen use either 'Drug information request (E1 )" 
_ or "Disease management or advice (E4)" as appropriate. 
ff the confusion would have (or did) resulted in a change in compliance (either taking too 
much or too little of the medication), then an appropriate compliance code should be 
selected. · 
If the reql!est is not af;Jout a specific drug, but a therapeutic device, then use . 
'Demonstration of device (03) 
When to Use: 
When the patient has a technical problem with the use of an administration or monitoring -
device.(eg inhaler, BSL Monitor, turbuhaler) 
Demonstration of Examples of wh~n to use: 
device E3 • A patient is changed from a metered dose inhaler to an. aerohaler and 
requests a demonstration of how to use the device. 
When Not to Use: 
If the patient understands how to use the device, but has a physical reason for not being 
able to use it, then use "Difficulty usinq dosaqe form (C4)''. 
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When to Use: 
When the primary purpose of the interaction with the patient was to inform them of critical 
aspects of the management or prevention of a disease or condition. 
Also covers the situation where the patient requests the information. 
· _Disease management 
Examples of when to. use: 
E4 -- You counsel a pati~nt with heart failure about fluid restriction 
or advice • 
• You provide information about weight loss or smoking cessa!ion for a person 
who has cardiovascular disease. 
When Not to Use: 
If the patient request information primarily regarding a drug, then use "Drug information 
request (E1 )". 
Other Education or When to Use: 
Information Problem EO _ When another health care worker (e.g. a doctor or another pharmacist) requests 
(Specify) information. Also covers anv other education or information related problem. 
When to Use: 1 
When an illegible prescription requires clarification. 
When the prescription does not meet PBS requirements. 
: 
When the drug is unavailable from the manufacturer qr is out of stock temporarily. 
When the dose of the medication is nqt specified on the prescription. 
When the prescriber is not authorised to prescribe that particular medication. 
When the patient has problems getting to pharmacy or collecting prescriptions. 
Not sub-classified NO 
Examples of when to use: 
• Physeptone Smg tablets not available, substitute 1 Omg .tablets with dose 
adjustment 
When Not to Use: 
If a less expensive or alternative brand is substituted purely for cost reasons, .then use 
"Other drua selection problem (DO)" and specify brand substitution for cost reasons. 
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Clinical Interventions in Australian Community Pharmacies 
When to,Use: 
When the patient has signs or symptoms that suggest an adverse reaction that is likely to 
be dose related. 
Examples of when to use: 
• Patient has increased their dose of tramadol and develops headache, sweating 
Caused by dose too T1 and agitation high • Promethazine and amitriptyline together causing worsening of dry mouth 
• Patient prescribed diamicron MR three times daily and has significant 
hypoglycaemic symptoms 
When Not to Use: 
If the patient does not have any signs or symptoms of adverse effects and you believe the 
dose is too high, then use "Dose too high (01)" 
When to Use: 
When the patient has signs or symptoms that suggest an adverse reaction that relates to 
the presence of an interacting drug 
Examples of when to use: -
Caused by drug • Patient taking warfarin develops an elevated INR after commencing 
interaction T2 metronidazole 
• Patient taking perindopril and frusemide, who commences diclofenac and 
develops renal dysfunction 
When Not to Use: 
If the patient has an interacting drug present, but there are no signs or symptoms of the 
interaction causing an adverse effect, then use "Drug interaction (D2J" 
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Clinical Interventions in Australian Community Pharmacies 
When to Use: 
When the patient has signs or symptoms that suggest an adverse reaction that is likely to 
be related to a particular_ drug, but doesn't seem to be dose related or related to an 
interaction. 
Covers the situation where the patient develops an adverse reaction such as a rash after 
Other Toxicity/Adverse 
commencing a drug. 
Effect problem TO Examples of when to use: (Specify) 
• Patient develops a rash after commencing on Augmentin Duo 
• Patient develops hypotension after commencing prazosin, even though the dose 
is controlling the prostatic·hypertrophy -
When-Notto Use: 
Should not be used if there are no signs or symptoms of adverse effects: 
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Clinical Interventions in Australian Community Pharmacies 
2. Actions to Investigate the Problem 
What did the pharmacist do in order Scope Notes 
to sort out the problem? Action Code (When the code should be used, when not to use it and 
examples) 
Note 1: multiple actions are possible for When to Use: 
one situation and each action may occur When the pharmacist consults a textbook or other written reference 
multiply material) 
Investigation: 
Examples of when to use 
Note 2: Each of these actions will have a A1 • Printed versions of Martindale, AMH or PP guide 
time value allocated to them after the Written material 
pilot study When Not to Use: 
If the reference material is electronically accessed from the local computer 
system, use "lnvestigation:software (A2)". 
When to Use: 
When the pharmacist consults decision support software that is located on 
the computer or server in the pharmacy. 
Investigation: A2 
Examples of when to use 
Software • eMims, electronic AMH , Electronic therapeutic Guidelines 
When Not to Use: 
If the electronic resource requires an internet connection to obtain it, then 
use "lnvestiqation: Internet (A3) ''. 
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Clinical Interventions in Australian Community Pharmacies 
When to Use: 
When the pharmacist consults decision support software that is located on 
the internet. 
Examples of when to use 
• Pharmacist conducts a PubMed search 
• Pharmacist is a subscriber to an internet based set of resources such 
Investigation: A3 
as Medscape, or a University library service 
Internet 
When Not to Use: 
If the information source is not from the internet, then use another 
investigation source (either A 1, A2 , A4 or A5). 
If the internet is used to make email contact with another healthcare 
professional for assistance, then use "Investigation: Other (A5)". 
If the internet is used to make email contact with the National Prescribing 
Service or other State or National information support service, then use 
"Contacted State or National Drua information service (A4) ''. 
When to Use: 
When the pharmacist contacts the National Prescribing Service or one of 
the State Drug Information Services for information. 
Contacted Drug Examples of when to use 
Information A4 • Pharmacist emails the NPS to determine information about a new drug 
Service that has not yet been released. 
When Not to Use: 
If the pharmacist contacts a colleague who they think may know something 
about the problem, then use "Investigation : Other (A5)". 
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Clinical Interventions in Australian Community Pharmacies 
When to Use: 
When the pharmacist consults another pharmacist or health professional to 
investigate the problem. 
When the pharmacist contacts the manufacturer or supplier of the product 
for information. 
Examples of when to use 
• Pharmacist rings the pharmacy where the prescription was previously 
Investigation: Other A5 
dispensed to clarify an issue. 
(specify) • Pharmacist contacts a colleague who works at the same pharmacy to 
clarify the problem. 
• Pharmacist contact the HIC to determine the details of a particular 
Authority script arrangement. 
When Not to Use: 
If the health professional that is contacted is someone who works for the 
NPS or a state or national drug information service, then use "Contacted 
State or National Drug information service (A4) ''. 
When to Use: 
When the pharmacist needs to contact the prescriber in order to clarify the 
prescriber's intent, provide new information from a patient encounter or to 
discuss recommendations the pharmacist may wish to make. 
Examples of when to use 
Contacted prescriber A6 • Pharmacist rings the doctor to confirm that the dose increase for 
tramadol was intentional, as the patient was unaware of any change. 
When Not to Use: 
If as a result of investigating the problem you refer the patient to the 
prescriber, but do not contact the prescriber first, then the referral is a 
recommendation and you should use "Refer to prescriber (R10) " 
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Clinical Interventions in Australian Community Pharmacies 
When to Use: 
When a discussion with the patient takes place that is primarily aimed at 
clarifying a drug related problem. 
Examples of when to use 
Discussion with • Pharmacist receives a script from the patient and finds the dose is 
patient A7 different from the last time the patient had the drug dispensed, then 
or carer checks with the patient that the dose change was intentional. 
When Not to Use: 
If the discussion with the patient is within the usual course of the 
prescription being received or giving out, then it is not considered an action. 
For example, "Can you please wait while I contact the doctor" is not a 
discussion with the patient/carer. 
Corrected When to Use: 
without discussion A8 When the problem is a simple issue that requires correction (often 
administrative). 
When to Use: 
When the pharmacist undertakes any other investigation or activity in order 
to clarify the actual or potential drug related problem. 
Other Action 
Examples of when to use 
(specify) AO • Pharmacist contacts the hospital to determine the dosages of the 
discharge drugs that were supplied. 
When Not to Use: 
When the action can be entered under any one of the other action 
cateaories. 
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Clinical Interventions in Australian Community Pharmacies 
3. Recommendations to Resolve the Problem 
What did the pharmacist Scope Notes 
recommend as a solution to the Recommendation Code (When the code should be used, when not to use it and examples) 
problem? When to Use: 
When the pharmacist conducts a detailed counselling or education session with the patient 
or carer that is specifically targeted at resolving the problem that has been identified. 
Includes the provision of a written summary of medications and their timing such as a 
Note 1: multiple recommendations medipal or medprof. 
possible for one situation 
Examples of when to use 
• Patient was not taking metformin correctly, pharmacist gave details of how to take it in 
Education/counselling R1 relation to food , how long it lasts and also gave information regarding the complications 
session and management of diabetes. 
When Not to Use: 
If the discussion with the patient is to determine the nature of the problem, rather than 
propose a resolution recommendation or furlher education, then it is an investigative action 
and you should use "Discussion with patient or carer (A 7)". Note that a conversation or 
discussion with the patient may involve both investigation of the problem ("discussion with 
patienVcarer(Al)) and an education/counselling session to resolve the problem identified 
(Educationlcounsellinq session (R1 ). 
When to Use: 
When the pharmacist recommends that the total daily dose of the medication is either 
increased or decreased. 
Dose change R2 
Examples of when to use 
• Pharmacist recommends that the dose of Diamicron MR be reduced . 
When Not to Use: 
If the total daily dose of the product does not change, but you recommend the schedule 
chanqes, then use "Dose frequency or schedule chanqe (R9)". 
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Clinical Interventions in Australian Community Pharmacies 
When to Use: 
When the pharmacist recommends a change in medication. 
Examples of when to use 
• Patient describes ongoing drowsiness in the mornings with nitrazepam, and the 
Drug change R3 pharmacist suggests a change to temazepam. 
When Not to Use: 
If the change in medication is simply a brand change, then use "Drug brand change (RB) ''. 
If the change in medication is a change in the formulation (eg from cream to ointment, or 
plain tablets to controlled release), then use "drua formulation chanae (RS) ". 
When to Use: 
When the pharmacist suggests that the drug is ceased, either temporarily or permanently. 
Examples of when to use 
• Pharmacist suggests patient does not take a medication for a day and to go to the 
doctor to discuss the problem. Note in this case you should also select "Refer to 
Drug cessation R4 prescriber (R10)" 
When Not to Use: 
If the drug dose is changed or some other manipulation of the drug or dose is undertaken, 
then the appropriate code should be used. 
If a drug is stopped in order to start another one for the same indication, then use "Drug 
change (R3)" 
When to Use: 
When the active ingredient of the medication and its total daily dose is not changed, but the 
formulation is changed. 
Examples of when to use 
Drug formulation R5 • Pharmacist suggests a change from a metered dose inhaler to an aerohaler 
change 
• The pharmacist suggests a change from cream to ointment as the cream is not 
available 
When Not to Use: 
If the formulation change also results in a change in the total daily dose of the medication, 
then use "Dose chanae (R2)". 
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Clinical Interventions in Australian Community Pharmacies 
When to Use: 
When the pharmacist suggests that the patient undertake some non-laboratory monitoring 
for efficacy or adverse effects from the medication. 
Monitoring: 
Examples of when to use 
non-laboratory R6 • Pharmacist suggests the patient weigh themselves daily while they are taking an 
increased dose of frusemide for heart failure. 
When Not to Use: 
If the monitoring involves laboratory-based test of some sort, then use "Monitoring: 
Laboratory test (R12) ''. 
When to Use: 
When the pharmacist recommends that a new drug be commenced. 
Examples of when to use 
• Pharmacist recommends the addition of aspirin in a patient that is at risk of 
Drug addition R7 cardiovascular events 
When Not to Use: 
If the addition of a drug involves the change from a single drug to a combination product 
(say from Avapro to Avapro HGT), then use "Drug Change (R3)''. 
If a drug is commenced and another was ceased for the same indication, then use ''Drug 
chanae (R3) " 
When to Use: 
When the pharmacist suggests a change in brand of the drug (same drug same dose). 
Examples of when to use 
Drug brand change R8 • Maxolon unavailable, pharmacist suggests that Pramin could be substituted . 
When Not to Use: 
If the change in brand is to a different formulation of the same active ingredient, then use 
"Druq formulation chanqe (R5)". 
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Clinical Interventions in Australian Community Pharmacies 
When to Use: 
When the total daily dose of the product remains the same, but the pharmacist suggests a 
change in the number of times a day, or the timing of the doses each day. 
Examples of when to use 
Dose • Pharmacist suggests changing valproate from 1 g twice daily to 500mg four times daily 
frequency/schedule R9 to reduce gastric upset. 
change 
• Pharmacist suggests change in timing of lsosorbide mononitrate from morning to night 
to cover unstable angina during the night. 
When Not to Use: 
When the change results in a change in the total daily dose of the medication, use "Dose 
chanqe (R2)" 
When to Use: 
When the problem is of sufficient seriousness for the patient to see the prescriber again in 
order to resolve the problem. 
Examples of when to use 
• Patient presents with a rash from the recently commenced antibiotics. You tell the 
Refer to prescriber R10 patient to cease the capsules and refer her back to the prescriber for some different 
antibiotics. Note should also select "Drug Change (R3)" and "Drug cessation (R4)". 
When Not to Use: 
If the patient goes back to the prescriber simply to get a new prescription, as a result of you 
discussing the problem with the prescriber then this code should not be selected. 
If the pharmacist discusses other issues with the prescriber, this is an action and you 
should select "contacted prescriber (A6)". 
When to Use: 
When the problem is of sufficient seriousness for the patient to go to hospital in order to 
resolve the problem. 
Refer to hospital R11 Examples of when to use 
• Patient presents with melena after commencing a non steroidal medication . 
When Not to Use: 
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Clinical Interventions in Australian Community Pharmacies 
When to Use: 
When the pharmacist suggests to the prescriber that they undertake some laboratory 
monitoring for efficacy or adverse effects from the medication. 
Monitoring: 
Examples of when to use 
Laboratory test R12 • You contact the prescriber to suggest that he check the INR in a patient taking warfarin 
who has commenced amiodarone. 
When Not to Use: 
If the monitoring relates to a test that can be done at home (eg BSL) then use "Monitoring: 
non-laboratorv (R6) ''. 
When to Use: 
When the pharmacist commences the process for a Home Medicines Review for the 
patient. 
Refer for 
Examples of when to use 
medication review R13 • You recommend a HMR for patient who has significant problems with understanding 
of their medications. 
When Not to Use: 
When you undertake an "ad hoe" review of the medications and generally assist with the 
patient's understandina, use "Education Counsellina session (R1) " 
When to Use: 
When you suggest the use of a dose administration aid such as a Dosette box or a 
Webster pack. 
Examples of when to use 
Commence dose R14 • You recommend a Webster pack for a patient who has significant problems with 
administration aid understanding of the schedule and timing of their medications. 
When Not to Use: 
If you provide a written summary of the patients medications and their schedule (eg 
medprof or mediPal) in addition to the dose administration aid, then also select 
"Education/Counselling session (R1) ''. 
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Clinical Interventions in Australian Community Pharmacies 
When to Use: 
When you have investigated a problem, but find that the problem does not need to be 
addressed with any changes or monitoring. 
No recommendation RO 
necessary Examples of when to use 
Pharmacist receives a script from the patient and finds the dose is different from the last 
time the patient had the drug dispensed, then checks with the patient that the dose change 
was intentional. 
When to Use: 
Other recommendation When the pharmacist makes any other recommendation that is not mentioned on this list to 
(specify) R15 resolve the problem. 
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Clinical Interventions in Australian Community Pharmacies 
4. Acceptance of Phannacist's Resolution of the Problem (Outcome) 
Did the clinical activity actually result in Outcome Scope Notes 
a change of management, or was the (When the code should be used, when not to use it and examples) 
suggestion deemed not relevant in this When to Use: 
case? When the pharmacist is unaware of what happened after he made the recommendation(s). 
Unknown Examples of when to use 
• You suggest that the patient go and see the doctor and they say they will think about it. 
• You leave a messaqe for the doctor to contact the patient about a problem . 
That is: Were the pharmacist's When to Use: 
recommendations implemented? When all of the recommendation(s) that the pharmacist makes are accepted 
Examples of when to use 
Accepted • You contact a doctor to suggest reduction of the dose of tramadol and he accepts your suggestion. 
• You take the time to explain fully the medications and disease a patient has (Education Counselling (R1 )) . 
When Not to Use: 
If vou make multiple recommendations and not all of them are accepted, then use "Partiallv Accepted" 
When to Use: 
When the pharmacist makes multiple recommendations, and only some of the recommendations that were mao 
accepted. 
Partially Examples of when to use 
Accepted 
• You contact a doctor to suggest reduction of the dose of digoxin and a repeat blood level of digoxin. He agrE 
the reduction in dose, but thinks the blood level would be a waste of time. 
• You suggest to the patient that they withhold their ibuprofen for a few days and go back to the doctor and as 
different medication. They decide to stop the druq for a while, but choose not to qo to the doctor. 
When to Use: 
When all of the recommendation(s) that the pharmacist makes are rejected 
Not accepted Examples of when to use 
• You contact a doctor to suggest reduction of the dose of tramadol and he says that he still wants to use that 
the patient's pain warrants it. 
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Clinical Interventions in Australian Community Pharmacies 
5. Clinical Significance of the Problem 
If the pharmacist had not Significance Code Scope Notes intervened/provided a clinical 
activity, what was the When to Use: 
possible/potential outcome if 
Nil so When there is no consequence to the patient. therapy had continued? (a Examples: 
subjective rating, predicting the 
• Prescription incomplete, contacted doctor and obtained directions 
clinical severity if action was not When to Use: 
taken). When the consequence to the patient are related to costs or information only 
That is: How serious Low S1 Examples: 
was/could have been the • Pramin substituted for Maxolon 
problem? • Provided CMI on Fosamax at request of patient. 
When to Use: 
Note 1: Situations rated as When the consequences to the patient are that they have improved a minor symptom, or if the 
high(S4) or moderate (S3) will intervention had not occurred they would have developed a minor symptom. The symptom should 
require additional information to Mild S2 be such that it does not require a doctor's visit to treat. 
be entered into a notes field Examples: 
• Patient commences on a codeine based analgesic and you recommend to take prophylactic 
stool softeners 
When to Use: 
When if the intervention did not occur, it was likely that the patient would have had to go to the 
doctor because of the consequences. Also covers the situation where you need to refer the patient 
Moderate S3 to the doctor because of the seriousness of the situation. 
Examples: 
• The patient was inadvertently taking twice the dose of sulphonylurea tablets and would have 
developed hypoglycaemia that required a trip to the GP to treat the symptoms. 
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Clinical Interventions in Australian Community Pharmacies 
When to Use: 
When if the intervention did not occur, it was likely that the patient would have had to go to a 
hospital because of the consequences. Also covers the situation where you need to refer the 
patient to a hospital because of the seriousness of the situation. 
When if the intervention did not occur, it was likely the patient would have had to receive assistance 
84 from a regular nurse visit, or would have had to been placed into residential care of some sort. Also 
includes the situation where the intervention prevents the additional nursing care or delays the 
admission to residential care. 
Examples: 
• The patient was inadvertently taking double the dose of amiodarone and was taking warfarin . 
Presented with bleeding. 
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Clinical Interventions in Australian Community Pharmacies 
5. Other lnfonnation Regarding the Problem 
Notes This section is to add free text notes, to more thoroughly explain action(s) or the reason(s) for them. 
Note 1: Notes may be required to clarify any of the "other" categories in the Type, Action and Recommendation sections 
Note 2: Situations rated as of high or moderate clinical significance will require additional information 
Time How long did it take to perform the clinical activity? (Approximate time spent conducting the clinical activity) minutes 
PAGE490F 50 
Peter Tenni 
Clinical Interventions in Australian Community Pharmacies 
9.3 APPENDIX 3: PILOT STUDY PHARMACIST 
DEMOGRAPHICS QUESTIONNAIRE 
561 I Page 
Clinical Interventions in Australian Community Pharmacies 
DOCUMENT Pilot Validation Questionnaire 
' ' 
1. About You and Your Background 
The following information is important to enable us to determine how your background 
influences the way the intervention scenarios are classified. 
1. 1 Gender (please tick appropriate box) 
Male 
Female 
1.2 Age (please tick appropriate box) 
20-25 
26-30 
31-40 
41-50 
51-60 
over 60 
1.3 Year of Graduation 
Please enter the year you completed your undergraduate pharmacy degree. 
Not yet graduated 
.1.4 Undergraduate Institution 
Please tick/enter the institution where you undertook/ are undertaking your undergraduate · 
pharmacy training. 
University of Tasmania 
Charles Sturt University 
Curtin University 
James Cook University 
Monash University 
University of Queensland 
Univer~ity of South Australia 
University Of Sydney 
Other (p.Jease specify) _______ _ 
Peter Tenni 562 I Page 
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1.5 Preregistration Training 
Please tick/enter the type of pharmacy where you undertook/ are undertaking your pre-
registration pharmacy training. 
City community pharmacy 
Suburban community pharmacy 
Rural community pharmacy 
Tertiary teaching hospital 
Rural/secondary hospital 
Not yet commenced pre-registration (go to question xxx) 
Other (please specify) 
~~~~~~~~~ 
1. 6 Practice Profile 
Please enter the approximate number of full-time years (that is, adjust for part-time work) 
in each of the different practice settings where you have worked. 
Practice Setting Number of full-time years 
City community pharmacy 
Suburban community pharmacy 
Rural community pharmacy 
Tertiary teaching hospital 
Rural/secondary hospital 
Medication Reviews in ursing Homes 
Other (please specify) 
Other (please spec ify) 
1. 7 Continuing Education 
Please tick how many hours of CE/CPD you completed in the 12 months prior to this 
survey: 
1-9 hours 
10-19 hours 
20-29 hours 
30+ hours 
Don't know 
Peter Tenni 563 I Page 
Clinical Interventions m Australian Community Pharmacies 
1.8 Further Qualifications 
Pleas~ indicate which or'the following 'types or' further qualifications you have co~pleted 
since you registered. · 
Practice Setting· 
+ Postgraduate Diploma by coursework 
+ Masters Degree by coursework 
-
+ Masters or PhD by research 
.+ Accredited for Medication'Reviews (AACP) 
+ Accredited for Medication Re:views (SHP A) 
·. 2 .. About vo·ur· Main Area of Work, 
The following questions relate to the practice setting where you spend the majority of your 
· time practicing as a phari:nacist. 
2. 1 Current Area of Practice 
' . 
Please tick the area of practice where you spend the majority of your time practicing as a 
pharmacist. · , · · 
City community pharmacy 
Suburban community pharmacy 
Rura~ c<;>mrriunity phanp.acy 
Tertiary teaching hospital 
Rural/secondary hospi~l 
Medication Reviews · 
University or other tertiary educ£!tional instifution 
Undergraduate student 
Other (please specify) ________ _ 
2.2 What is the post code of the main area ~h~re you work 
2.3 When you are at work, .how many other pharma~ists also are· 
present at your practice at the same time? 
• 
•• 
• 
• 
Peter Tenni 
None, I am the_sole pharmacist 
One other pharmacist 
2-4·other ph1!1rmacists · 
5· or more othe~ pharmacists 
564 I Page · 
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· 2.4 Ownership of .the pharmacy 
This refers to ownership of the practice entity not the premises. 
+ Individual 
+· . . Partnership · 
+ Corporate (one of a number of practices owned by a corporation) 
+ Associateship · 
·+ Franchise 
+ Don't know/Not applicable . 
2. 5 Position 
Please tick the ~ost appropriate description of your current position where you spend the 
majority of your time practicing as a pharmacist. , 
Ownership of a community pharmacy 
Employed in a community pharinacy ~etting 
ciinical pharmacist in a hospital setting 
Other pharmacist in a hospital setting 
Locum Pharmacist 
Other (:i>Iease specify) 
~~~~~~~~-
2.6 How many hours do you work at this practice on average per 
week? 
<10 hours 
1.0 to .20 hours 
20 to 40 hours 
over 40 hours 
2. 7 On average, how many prescriptions would you 'dispense or 
check per week? 
<100 
100-300 
300-600 
600 or more 
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2.8 Which of the following activities do you undertake at least 
daily while you are at work? 
Dispensing of prescriptio:t?-s 
Packing or checking of dose administration aids ( eg Webster packs) 
Counselling of patients 
Reading I searching internet for further education 
Supervising daily pickup of medications 
2.9 How often do you counsel patients ? 
+ Very often 
+ Often 
+ ·Sometimes 
+ Seldom or Never 
. 2.10 How often are you. interrupted while.filling a prescription 
order? 
+ Very often 
+ Often 
+ . Sometimes 
+ Seldom or Never· 
3. More Gen.erally about your View of pharmacy and 
Pharmacists · · 
3. 1 As a pharmacist, I wish for an increased status within the 
·primary health care team.· 
• 
• 
• 
• 
Strongly agree 
Agree 
Disagree 
Strongly disagree 
3.2 . Pharmacy represents an excellenfcareer choice. 
• 
• 
•• 
• 
Peter Tenni 
Strongly agree 
Agree 
Disagree 
Strongly disagree 
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3.3 I am happy with my choice of pharmacy as a career. 
• 
• 
• 
• 
Strongly agree 
Agree 
Disagree 
Strongly disagree 
3.4 I would recommend pharmacy as a career to others 
considering it. 
• 
• 
• 
• 
Strongly agree . 
Agree 
Disagree 
Strongly disagree 
3.5 Which of the following factors would you nominate as being 
important in choosing where you work as a· pharmacist? 
(a) Income 
• Strongly agree 
• Agree_ -
•• Disagree 
• Strongly disagree 
(b) Reasonable workload 
• Strongly agree 
• Agree 
•• Disagree 
• Strongly disagree 
(c) Having more than one pharmaCisf on duty 
Peter Tennr 
• 
• 
• 
• 
Strongly agree 
Agree 
· ·rnsagree 
Strongly disagree 
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(d) Flexibility and ability to pick on~'s own hours of work 
• Strongly agree 
• Agree 
• Disagree 
• Strongly disagree 
(e) Intellectual stimulation 
• Strongly agree 
• Agree 
• Disagree 
• · Strongly disagree 
(f) Helping people 
• Strongly agree 
• Agree 
• Disagree 
• Strongly disagree 
(g) Good work conditions 
• Strongly agree 
• Agree 
• Disagree 
• Strongly disagree 
(h) Job security 
• Strongly agree 
• Agree 
• Disagree 
• Strongly disagree 
(i) Interesting and challenging work 
·• Strongly agree 
• Agree 
• Disagree 
• Strongly disagree 
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3.6 What do you see as the major change in pharmacy sector in 
the next two to five years? · · 
3~ 7 . Hypothetically, if you were to receive a windfall of $100,000 
and could only use it on one of the foll()wing things, what 
would you use it for? -
For my business 
+ More employees 
+ More technology 
• Skill development 
• Debt reduction 
+ Buildings/equipment 
For my financial security 
• Debt reduction 
+ Buildings/renov~tion additions 
• Investment of some sort · 
For my leisure activities 
• A holiday I yacht I sports car or similar 
Altruistic Purposes 
+ Donate to Charity or similar 
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9.4 APPENDIX 4: PILOT STUDY PARTICIPANT 
QUESTIONNAIRE 
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' . 
PROMISe Pilot Study Participant Questionnaire 
1.About You and Your Background 
The following information is important to enable us to determine how your background 
influences the way the iI;1.teryention scenarios are classified. · 
1. 1 Gender (please tick appropriate box) 
Male 
Female 
· 1.2 Age (please tick appropriate box) 
20-25 
26-30 
31-40 
41-50 
51-60 
over 60 
1.3 Year of Graduation 
. Please enterthe year you completed your ·undergraduate pharmacy degree. · 
Not yet graduated 
1.4 Undergraduate Institution 
Please tick/enter the institution where you undertook/ are undertaking your undergraduate 
. pharmacy training. 
University of Tasmania 
Charles Sturt University 
Curtin University 
James Co.ok University 
La Trobe University 
Monash University 
University .of Queensland 
Univ~rsity of South Australia 
University of Sydney 
Other (pleas~ specify) 
~~~~~~~~ 
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1.5 Preregistration Training 
Please tick/enter the type of pharmacy where you undertook/ are undertaking your pre-
registration pharmacy training. 
City community pharmacy 
Suburban community pharmacy 
Rural community pharmacy 
Tertiary teaching hospital 
Rural/secondary hospital 
Not yet commenced pre-registration (go to question xxx) 
Other (p lease specify) 
~~~~~~~~~ 
1. 6 Practice Profile 
Please enter the approximate number of full-time years (that is, adjust for part-time work) 
in each of the different practice settings where you have worked. 
Practice Setting Number of full-time years 
City community pharmacy 
Suburban community pharmacy 
Rural community pharmacy 
Tertiary teaching hospital 
Rural/secondary hospital 
Medication Reviews in Nursing Homes 
Other (please specify) 
Other (please specify) 
1. 7 Continuing Education 
Please tick how many hours of CE/CPD you completed in the 12 months prior to this 
survey: 
1-9 hours 
10-19 hours 
20-29 hours 
30+ hours 
Don' t know 
1.8 Further Qualifications 
Please indicate which of the following types of further qualifications you have completed 
since you registered. 
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Practice Setting 
+Postgraduate Diploma by' coursework 
+ Masters Degree by coursework 
+ Masters or PhD by research 
+ Accredited for Medication Reviews (AACP) 
+ Accredited for Medication Reviews (SHP A) 
+ Other, please specify. 
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2. About Your Main Area of Work 
The following questions relate to the practice setting where you spend the majority ofym.ir 
time practicing as a pharmacist. 
. 2. 1 Current Area of Practice 
Please tick ~he area of practice where you spend the majority.of yolir time practicilig as a 
pharmacist. 
City community pharmacy 
Suburban community pharmacy 
Rural community pharmacy 
·Tertiary teaching hospital 
RuraVsecondary hospital 
. Medication Reviews 
University or other tertiary educational institution 
Undergraduate student 
Other (please specify) 
~~~~~~~~-
2.2 What is the post code of the main area where you work 
2.3 When you are at work, how many other pharmacists also are 
present at your practice ~~the same· time? 
+ None, I am the sole pharmacist 
+ One other pharmacist 
+ 2-4 other pharmacists 
+ 5 or more other pharmacists 
2.4 Ownership. of the pharmacy 
This refers to ownership of the practice entity not the premises. 
Individual 
Partnership 
• 
• 
• 
•• 
Corporate (one of a number of practices owned by a corporation) 
Associateship 
• 
• 
2. 5 Position . 
Franchise 
Don't know/Not applicable 
Please tick the most appropriate description of your current position where you spend the 
majority of your time practicing as a pharmacist. 
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Ownership of a community pharmacy 
Employed in a community pharmacy setting 
Clinical pharmacist in a hospital setting 
Other pharmacist in a hospital setting 
Locum Phartnacist 
Other (please specify) 
~~~~~~~~-
2. 6 How many hours do you work at this practice on average per 
~~? ' 
<10 hours 
10 to 20 hours 
20 to 40 hours 
over 40 hours 
2. 7 On average, approximately how many prescriptioris would 
you dispense or check per hour at work? 
<l 
1-6 
7-15 
16-30 
31-45 
Over45 
2.8 Wh.at proportion of a typical week at work would be filled by 
each of the following activities? 
(we are aware there are many other activities, but we are primarily interested in 
these activities) 
Approximate 
Activity Proportion 
ofweek(%) 
Dispensing of prescriptions 
Packing or checking of dose administration aids ( eg Webster 
· packs) 
Counselling of patients 
Reading I searching internet for further education 
. Supervising daily pickup of medications 
Supervising/selling S2/S3 products 
Medication reviews (Domicilliary or Nursing homes) 
Hospital based clinical activities (ward visits etc.) 
Administrative tasks (HIC claim, accounts, ordering·etc.) 
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2.9 How often do you counsel patients ? 
" ' 
• 
• 
• 
• 
Very often 
Often 
Sometimes 
Seldom or Never 
2.10 How often are you interrupted while filling a prescription 
order? 
• ., 
• 
• 
Peter Tenni 
Very often 
Often 
Sometimes 
Seldom or Never 
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3. About the Computer System at your pharmacy 
3. 1 Do you have someone in the practice responsible for the 
computer system? 
Yes Go to next question 
No Go to'question 3.26 
3.2 How would you rate the IT skills of the person responsible 
for the computer system? · 
• Expert 
• Pretty Good 
• Gets by 
·+Novice 
3.3 Do you have an agreement (formal or otherwise) with an IT 
service provider? 
Yes" 
No 
Don't know 
3.4 Is the pharmacy netw_orked? 
Yes · 
No 
3.5 What Server Operating System do·you_have? 
Peter Tenni 
No Server 
NT 2000 Server 
Apple Mac 
NT 4 Server 
Linux 
Other (please specify) 
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3.6 Is you server protected by uninterrupted power supply 
(UPS)? 
Yes 
No 
Don't know 
3. 7 Do you have a firewall? 
Yes 
No 
Don't know 
3.8 Do you backup your data? 
Yes - How Often 
Daily 
Weekly 
Monthly 
Other 
No - go to question 3. 34 
3.9 What types of files do you back up? 
Server 
All workstatons 
Some workstations 
Financial records 
Patient records 
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3.10 When did you last check that your backup worked? 
Never 
Lastyear · 
Last month 
Last week 
3.11 l!V_here do you keep.your backup disks/tapes? 
On-site -
Off-site 
3.12 Do you have Antivirus software? 
Peter Tenni 
Yes. 
No 
If Yes how often do you update. it? Daily 
Weekly 
Monthly 
Other 
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3 .. 1'3 Do you use login passwords for all your workstatio_ns? 
Yes 
·No 
3.14. Do you carry out .regular maintenance on your computers? 
Yes 
No 
3. 15 Do you have the Internet connected? 
No 
On one computer 
On all of the network 
. 3.16 What type of internet connection do you have? 
Dial up Modem· 
ADSUBroadband 
Satellite 
3.17 Are you PKl_enabled'i 
Ye.s 
No 
Don't know 
4. A~out the use of Computers at your pharmacy 
4. 1 Have you explored any of the following uses for IT? If yes, 
have you succeeded and.what is your measure of success? 
Measure of.Success 
f0 a nag mg fmance and adm in1strat1on ~]O~V-e-s~O~N-o-~ [s.tr.ilt!l9.Y. fl/1.:;,tD.C<.\l 1'lµ.f:.<1!l1'l.l! ............... I 
Managing d1~tribut1on :lOV.es ONo !ls.trftt!l9Y._Q!l!.ff.1.b_u!.19..0_ey]Jp_c!J.§ey ............... 1 
Stock contr~I :loves O No [l!!rflt!l9L~!l.9"'(1!lft . .9.\l_eyupqes.!! .............. I 
Security control .""'.lo""'v"'"'e_s__,.0,.....,N..,...o--. 1(st~aJ!l9.Y §.!l.9.~nty cor:iJrq] !!\!9.C\l.S.L .......... I 
Managmg_customer 1nformat1on :loves 0No ll!.!~flt!l9Y._<;!J§t.QIJ1~f-sµ_c<;!l_ey1'l ... ~ ............ .I 
Controlling work flow JOVes 0No 1s.trat!l9Y._P!QC~~-s_sus:.«~.l!!' ........ .' ........ I 
Marke~1ng lOVes 0No l!!.!~at!JgLm.:;,i.~k.et1rig __ !\VC<.9..~H ............... I 
4.2 Are you looking at using IT in any new areas~ if so which? 
Yes Please specify 
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No 
4.3 For the last piece of software you purchased how did you 
decide what to buy (you may tick more than one box)? 
Sales representative/vendor approach 
Peer recommendation 
Conference/Trade Fair 
Solved current problem 
Perceived ease of use 
Compatibility (with other software/hardware) 
Support provided 
Training-
Price 
Other, please specify ___________ _ 
4.4 Which of the following statements best describes your 
approach to changing softw,are? 
Peter Tenni 
I am loathe to change software once it's implemented on my 
system 
I often look for better ways of doing things 
If it doesn't do/can't do what I want then. I'll shop around 
I would change software if I could clearly ~ee the benefit in 
doing so 
None.of the Clbove - any comment? _____ ~---
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4.5 On average how would you rate the proficiency of staff in_ 
using IT? 
For Pharmacists .-_ Experts 
'' 
Pretty Good 
Get by 
Novices 
For non-pharmacist staff Experts 
· Pretty good 
. Get by 
Novices 
5. More Generally about your V_iew of Pharmacy and 
Pharm·acists 
5.1 As a pharmacist, I wish for an increased status within the 
primary health care team. 
• 
•• 
• 
• 
Strongly agree 
Agree 
Disagree 
Strongly disagree 
- -
5.2 Pharm.acy represents an excellent career choice. 
·• 
• 
•-
• 
Strongly agree 
Agree 
Disagree 
Strongly disagree 
- ' 
5.3 I am happy with my choice ~f pJ:Jarmacy as a career. 
• 
•• 
• 
• 
Peter Tenni 
Strongly agree 
Agree 
Disagree 
Strongly disagree 
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5.4 · I would recommend .pharmacy as a career to others 
considering it. 
• 
• 
• 
• 
Strongly agree 
Agree 
Disagree 
Strongly disagree 
5.5 Which of the following factors would you nominate as being 
· · important in choosing where you work as a pharmacist? 
(a) Income 
• Strongly agree 
• Agree 
• Disagree 
• Strongly disagree 
(b) Reas·onable workload 
• Strongly agree 
• Agree 
• Disagree 
• Strongly disagree 
(c) Having more than one pharmacist on duty 
• 
• 
• 
• 
Strongly agree 
Agree 
Disagree 
Strongly disagree 
(d) Flexibility and ability to pick one's own hours of work 
• 
• 
• 
• 
Strongly agree 
Agree 
Disagree 
Strongly disagree 
(e) Intellectual stimulation 
Peter Tenni 
• 
• 
• 
• 
Strongly agree 
Agree 
Disagree . 
Strongly disagree 
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(f) Helping people 
• Strongly agree 
• Agree 
• Disagree 
• Strongly disagree 
(g) --Good work conditions 
• Strongly agree 
• Agree 
• Disagree 
• Strongly disagree 
(h) Job security 
• Strongly agree 
• Agree 
• Disagree· 
• Strongly disagree 
5.6 Hypothetically, if you were to receive a windfall of $100,000 
and could only use it on 2!1!f! of the following things, what 
would you use it for? _ -
For my business 
• More employees · 
+ More technology 
• Skill development 
+ Debt reduction 
• Buildings/equipment 
For my financial security 
+ Debt reduction 
+ Buildings/renovation addition~ 
• Investment of some sort 
For my leisure activities 
• A holiday I yacht I sports car or similar 
Altruistic Purposes 
+ Donate to Charity or similar 
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9.5 APPENDIX 5: PILOT STUDY INFORMATION 
TECHNOLOGY SURVEY 
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PROMISE Pilot Study: Pharmacy Owner Information Technology Survey 
PROMISe Pilot Study 
Pharmacy Owner/Manager Information Technology 
Survey 
This survey is designed to provide us some information about the computer system in your 
pharmacy and your pharmacy' s use of Information Technology. 
Name: 
Pharmacy: 
Pharmacy Owner(s): 
1. About the Computer System at vour pharmacy 
1. 1 Do you have someone in the pharmacy responsible for the 
computer system? 
+ Yes Go to next question 
+ No Go to question 1.3 
1.2 How would you rate the IT skills of the person responsible 
for the computer system? 
+ Expert 
+ Pretty Good 
+ Gets by 
+ Novice 
1.3 Do you have an agreement (formal or otherwise) with an IT 
service provider? 
+ Yes 
+ No 
+ Don't know 
P:\My documents\Promise !\Pilot Studies\Rex Pilot Studies\Questionnaires\Final IT Survey 300404.doc 
Peter Tenni 
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PROMISE Pilot Study: Pharmacy Owner Information Technology Survey 
1.4 Do you have Microsoft Office® installed on· a computer in 
your pharmacy? 
+ Yes 
+ No 
lfYes, what version 
+ Office xp 
+ Office 2000 
+ Office 97 
+ Don't know 
+ Other (please specify) _______ _ 
1.5 Are the computers in the pharmacy networked? 
+ Yes 
+ No 
1.6 Is you computer system protected by uninterrupted power 
supply (UPS) 
+ Yes 
+ No 
+ Don't know 
1. 7 Do you have a firewall? 
+ Yes 
+ No 
+ Don't know 
1.8 Do you backup your data?_ 
+ Yes - How Often 
+ Daily 
+ Weekly 
+ Monthly 
+ Other 
+ No - go to question 1. 11 
P:\My documents\Prom1sel\P1lot Stud1es\Rex Piiot Studies\Questionnaires\Final IT Survey 300404.doc 
Peter Tenni · . · . . 
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PROMISE Pilot Study: Pharmacy Owner lnforrhation Technology Survey 
1.9 When did you last check that your backup worked? 
• Never 
+ Last year 
+ Last month 
+ Last week 
1.10 What types.of files do you back up? 
+ Server 
+ All workstations 
+ ·Some workstations 
+ Financial records 
+ Patient records 
1.11 Where· do you keep your backup disks/tapes? 
+ On-site 
+ Off-site 
1.12 Do you have Antivirus software?' 
+ Yes:- How often tjo you update it 
+· Daily' 
+ Weekly 
+ Monthly 
+ Other 
+ No 
. ' 
1.13' Do YOI! use login passwords for all your workstations?. 
+ Yes 
+ No 
1~ 14 Do you carry out regtJlar maintenance on your computers? 
+ Yes 
+ No 
P.\My documents\Pronusel\P1lot Studtes\Rex Piiot Stud1es\Questionnaires\Fmal IT Survey 300404.doc 
PeterTenrn 
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PROMISE Pilot Study: Pharmacy Owner Information Technology Survey 
1.15 Do you have the Internet connected? 
+ No 
+ On one computer 
. + On all of the network 
1.16 What type of internet connection do you have? 
+ Dial up Modem 
+ ADS LIB road band 
+ Satellite 
1.17 Are you PK/ enabled? 
+ Yes 
+ No 
+ Don't know 
-2. About the use of Computers in your pharmacy 
2. 1 Have you explored any of the following uses for IT? If so 
have these been successful? 
Use for IT Explored? Has this been 
Finance and administration (e.g. MYOB) • Yes • No 
Stock control and ordering 'f Yes • No 
Managing_customer information (e.g. + Ye~ • Database for Baby Club) No 
Security (Shop surveillance) +·Yes • No 
Training for staff within pharmacy + Yes • No 
Professional development + Yes • No 
Marketing + Yes • No 
P:\My documents\Prom1sel\Pilot Studies\Rex Piiot Stud1es\Quest10nnaires\Final IT Survey 300404.doc 
Peter Tenni 
successful? 
+ Yes • 
No 
• Yes • No 
+ Yes • 
No 
• Yes • No 
+ Yes • 
No 
+ Yes • No 
+ Yes • No 
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PROMISE Pilot Study: Pharmacy Owner Information Technology Survey 
2.2 Are you looking at using IT in any new areas, if so which?_ 
· + Yes Please specify 
+ No· 
P.\My documents\Promisel\Pilot Stud1es\Rex Piiot Studies\Questionnaires\Fmal IT Survey 300404.doc 
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PROMISE Pilot Study: Pharmacy Owner Information Technology Survey 
2~3 Do you have any of the following software available in your 
pharmacy? 
+ eMims 
+ eAMH 
+ eAPP 
-+ AusDI 
+ REX drug interactions 
• Electronic Therapeutic Guidelines 
+ Other decision support or clinical information software (please specify) 
2.4 Which drug interactions program do you use to check for 
~rug interactions? 
+ Built into dispensing system 
. + Other (please specify) 
2.5 For the last piece of software you purchased how did you 
decide _what to buy (you may tick more than one_ box)_? 
+ Sales representative/vendor approach 
+ Peer recommendation 
+ Conference/Trade Fair 
+ Perceived ease of use 
+ Compatibility (with other software/hardware) 
+ S,upport provided 
+ Training 
+ Price 
+. Other, please specify ____________ _ 
P:\My documents\Promisel\Pilot Stud1es\Rex Piiot Stud1es\Questionnaires\Final IT Survey 300404.doc 
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PROMISE Pilot Study: Pharmacy Owner Information Technology Survey 
2.6 Which of the following statements best describes your 
approach to changing software? . 
+ I am loathe to change software once Ws implemented on my system 
+ I often look for better ways of doing things 
+ If it doesn'fdo/can't do.what I want then I'll shop around 
+ I would change software if I could clearly see the benefit in doing so 
+ . None of the above - any comment? 
' . 
2. 7 .On average how· would.you rate the proficiency of your staff 
in using IT? 
2. 7 .1 .Pharmacists 
·+ Experts 
+ Pretty Good 
+ G~t ~y 
+ Novice 
2.7.2 Other Staff 
+ Experts 
+ Pretty Goqd 
+ Gets By 
+ Novice 
*****~**End of Survey, Thank-you for your Time********. 
P:\My documents\Prom1sel \Pilot Stud1es\Rex Pilot Studies\Questionna1res\Fmal IT Sur.vey 300404:doc 
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9.6 APPENDIX 6: PILOT STUDY POST STUDY 
QUESTIONNAIRE 
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PROMISe Pilot Study; Post Study Questionnaire 
PROMISe Project Pilot Study 
Post Study Questionnaire 
Section 1. Demographics 
Name: 
Pharmacy: 
1.1 Employment status : 
0 Pharmacist 
0 Full-time 
0 Owner 
0 Part Time/ Locum/Casual 
0 Graduate Pharmacist 
School of Pharmacy 
1.2 Did you attend the education session relating to this project, hosted by the 
University of Tasmania? 
0 Yes 0 No 
1.3 Did you view the training presentation on the CD provided in the manual for this 
project? 
0 Yes 0 No 
1.4 Did you undertake the validation case scenarios on the project website? 
0 Yes 0 No 
Section 2. Documentation of Clinical Services 
2.1 Did you document your clinical services prior to this project? 
0 Yes 0 No 0 
Peter Tenni 
Sometimes 
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PROMISe Pilot Study; Post Study Questionnaire 
If Yes, where did you docui!1ent these activities? 
q Scraps of paper 
D . Dedicated book 
D Pptient file 
D On computer, i.e Notes section or previous .intervention recording 
software 
D Other (please specify) ____________ _ 
2.2 When you first heard about this project, what barriers did you perceive W?UI~ 
prevent you from recoraing your clinical services? You may select more than one 9ption 
- - - -
D" lack of motivation 
D workflow restrictions 
D lack of clinical knowledge 
D forgetfulness 
D lack of time 
D concerns about how the software would work 
D none 
D Other (please specify) _· -,-----.,-,-----.,-------,-------
2.3 During the· PROM I Se P.ilot' Study, approximately what percentage of clinical 
services that you performed, do you believe that you documented? 
D 
D 
D 
D 
D 
Peter Tenni 
100% 
75% 
50% 
25% 
10% or less 
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PROMISe Pilot Study; Post Study Questionnaire 
2.4 What barriers did you find in recording your clinical services? 
You may select more than one 
0 lack of motivation 
0 workflow restrictions 
0 lack of clinical knowledge 
0 forgetfulness 
0 lack of time 
0 The software was difficult to use 
0 none 
·0 Other (please specify) 
2.5 During the PROMISe Pilot Study, what factors influenced which of your. clinica.1 
services you documented? You may select more than one option 
D higher perceived importance 
D · availability of time 
D presence of observer 
0 Other (please specify) -------------
Section 3. Time spent on Clinical Services 
3.1 During the PROM I Se Pilot Study, what proportion of your tim.e. at wor~ was spent 
involved .in clinical services (either documenting or sorting out actual or potential 
drug related problems)? 
Peter Tenn1 
0 
0 
0 
0 
Less than 5% 
5 to 20% 
20 to 50% 
More than 50% 
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PROMISe Pilot Study; Post Study Questionnaire 
·3.2 During the PROMISe Pilot Study, how long (on average) do you think it took you 
to perform a single clinical service (including the documentation process) 
0 Less than 1 minute 
o· 2 to 5 minutes 
0 6 to 10 minutes 
0 11 to 30 minutes . 
0 More than 30 minutes 
Section 4. Payment for Clinical Services 
4.1 Do you believe clinical services should be remunerated? 
0 ·ves 0 No 
4.2 If payment for clinical services was implemented, rate each of the payment options 
below according to how much you would agree with that option. Also, please write 
an amount you think would be appropriate for ea·ch option 
421 . . h h A payment to eac /J. armacy or eac h I" . I c 1rnca service d d _ocumente . 
Appropriateness of payment model Amount 
I I I I I I I I 1 · I I 
Strongly agree Strongly disagreE 
422 A . . paymen t t h h . tf o eac /J. armac1s oreac c 1rnca service d t d ocumen e . 
Appropriateness of payment model Amount 
I I I 1· . I I i I I I I 
Strongly agree Strongly disagreE 
4.2.3 A payment to each 'pharmacy based on the total time spent on each 
clinical service documented. 
Appropriateness of payment model Amount 
I I I I I I I I -I I I 
Strongly agree Strongly ~isagreE 
- . 
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4.2.4 A payment to· each pharmacist based on the total time spent on each 
clinical service documented. 
Appropriateness of payment model Amount 
I I I I I I I I I I I 
Strongly agree Strongly disagreE 
4.2.5 A set, across the board, payment for each pharmacy for documenting the 
services, unrelated to number or duration of services. 
Appropriateness of payment model Amount 
I I I I I I I· . I I I I 
Strongly agree Strongly disagreE 
4.2.6 An increase in the. oyerall dispensing fee for all· prescriptions to compensate 
for these "add on" services. 
Appropriateness of payment model Amount 
I .I I I -1 I I I I I I 
S,trongly agree Strongly disagreE 
4.2.7 An increase in the dispensing fee for original (non.:.repeat) prescriptions, as . 
th l"k I t th " dd " ey are more 1 e1y o require e a on s~rv1ces. 
· Appropriateness of payment model Amount 
I I I I I I -I I I I I 
Strongly agree Strongly disagreE 
' ' 
4.2._8 An increase in the· dispensing. fee for prescriptions for drugs with a high 
frequency of clinical services (eQ warfarin). 
Appropriateness of paymerit model Amount 
I I I I I· I I I I I I 
Strongly agree Strongly disagreE 
4.2. 7 Any other payment system that you would propose (please specify)? 
Peter Tenni 
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Section 5. Your general 'opinions relating to clinical services 
Place a cross anywhere on the line or tick the box to indicate your opinion on the following 
statements; , 
5.1 Documenting of cognitive services helps to demonstrate the ability of pharmacists 
to improve medication therapy . 
.____. _________________ .... -I D Unsure 
Strongly agree Strongly disagree 
5.2 Documenting of cognitive services helps to _demonstrate th~ ability of pharmacists 
to reduce health care costs. 
----------------------------------1 ___....· I D Unsure 
Strongly agree Strongly disagree 
5.3 Participating in this project made me more aware of I focussed upon identifying 
Drug Related Problems. 
I I I I - I 
Strongly agree 
I . I I - _ 
Strongly disagree 
D Unsure 
5.4 I believe that I would require an update .in clinical knowledge in order to optimise 
iny ability to ide-ntify Drug Related Problems. 
I I I I I I I I I D Unsure 
Strongly agree Strongly di~agree 
5.5 The cognitive service recording program was easy to use. 
I I I I !· I I· I I I I D Unsure 
Stron~ly agree _ Strongly disagree 
· 5.6 The sequence for do9umenting a cognitive service, including accessibility to the 
interventions screen, was logical and easy. to follow. 
_! I I 1 · I . I I I I . I I' 0 Unsure . 
Strongly agree Strongly disagree 
5.1 The Classification system and options were logical and relevant. 
I I I ·1 ·1 I I I I I I D Unsure 
Strongly agree Strongly disagree 
Peter Tenn1 
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Section 6. Further Comments 
If y~u wish to make further comments, regarding any aspect of tht? PROMISe Pilot Study, 
or any.aspect of the software or training, please use the space below. . 
lf'you would rather that these comments be treated anonymously, please separate this 
sheet from the rest of the survey and return it in the second reply paid envelope attached 
·**********************End of Survey****************** 
Thank you for your time 
Peter Tenni 
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- .D .. O.C.U.M.E.N.T. 
(a Classification system fot drug-related problems and their resolution) 
1. Type of.Drug Related Problem 
Categon: {Tyl!e) . Sub-Tyl!e Subtype Scope Notes {When the code should be used, when not Code to use it and examples) 
When to Use: 
When there are no obvious adverse clinical effects of the 
two drugs together, but it is either inappropriate or very 
u.nusual to see them prescrifled or used together as they _ 
are from :the same. therapeutic class 
This also covers the specific compliance situation where . 
Drug a person may be inappropriately takmg two brands of 
selection the same drug. 
(Problems Examples of when to use: 
D related to the Duplication Dl • Patient prescribed ranitidine plus pantoprazole 
choice of drug 
• ~atient prescribed Berotec and Vento/in inhalers 
prescribed or. 
• Patient taking Aratac and Cordarone at the 
taken) same time 
• Patient taking Vioxx sample provided by doctor 
as well as the Vioxx dispensed at the pharmacy 
When Not to Use: 
If the drugs involved are not of the same therapeutic, 
class, then use "Drug Interaction (D2) ". 
When.to Use: 
When there are no obvious adverse clinical effects of the 
drug interaction, but the interaction is serious enough to 
check if the_ doctor knows. of it. 
When there is a likely serious interaction between the 
patient's existing therapy and a newly prescribed or used 
drug, but the patient hasn't yet commenced taking the 
new drug. 
Drug 
. Examples of when to use: 
selection 
(Problems • Patient commenced on tramadol who is already 
D related to the Drug D2 taking fluoxetine interaction .. Patient ceases amiodarone while continuing on 
choice of drug warfarin · 
prescribed or 
• Patient requests to purchase an_over the counter 
taken) antacid when taking ~etracycline 
When Not to Use: 
If the interacting drug is of the same therapeutic class as 
·part of the patient's existing therapy, then use 
"Duplication (DI/'. 
If the interaction is causing, or is suspected of causing a 
noticeable effect of any sort, then use "Caused by drug · 
interactzon (T2) ". 
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Categon: '(Ty~e) Sub-Ty~e Subtype· Scope Notes (When the code should be used, when not Code to use it and examples) 
When to Use: 
When the prescriptwn was intended to mean a different 
drug and there was an error 
When the drng being taken was prescribed correctly put 
was dispen.sed as the wro.ng drug 
Examples of when to use: 
Drug • Patient supplied with and taking Hydrea 2 m, 
selection labelled as Hydrene 2 m 
(Problems • Doctor prescribes chlo~romazine 200mg ba but 
D related to the Wrong drug b3 intended carbamazepine 200mg bd 
choice of drug· When Not to Use: 
prescribed or If the drug is felt to be inappropriate becau!fe of specific 
taken) patient parameters such as poor renal function, then use 
"Other Drng selection problem (DO)". 
If the drug prescribed is unavailable for dispensing 
(either because your pharmacy has no stock or the 
m·anufacturer/distributor has no stock) then use "Non-
clinical (NO)". 
When to Use: 
When the formulatwn of the product zs inappropriate or 
' 
incorrect zn terms of the in_tended u.s~ of the product. 
Also covers the specific situatwn where an error by the 
prescriber results in an absurd set of instructions (eg, · 
ventolin inhaler, apply three times a day). 
Examples of when_ to use: 
• Vancomycin oral capsules presqibed to treat 
Drug systemic infection · 
selection • Ear drop product ordered or supplied for an eye 
(Problems problem 
D related to the. Wrong D4 When Not to Use: 
choice of drug .dosage form If the.patient has a physical problem with the 
pres_cribed or. admzmstration of the dosage form as it_ is intendeg to be 
taken) used (eg. swallowing a particular form. of the medication 
whole, cannot appropriately insert suppositories, 
arthritis limiting the use of an inhaler) then use 
"Difficulty using dosage form (C4) ~'. 
If the difficulty is related to a technical problem with the 
use of an administration device such as an aerohaler, 
then use "demonstration of device (E3)" 
If the difficulty is not a technical one, and related to lack 
of understanding of the use of the dose form, then use 
"Confasion about therapy or condition (E2)" 
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Category (Tyne} Sub-Tyne Subtype Scope Notes (When the code should be used, when not Code to use it and examnles) 
When to Use: 
When a drug or drug group 1s prescribed for the patient 
Drug to which there has previously been a ma1or adver~e 
reaction. 
selection Examples of when to use: 
(Problems 
Previous A patient is prescribed Augmentin Duo who has a D related to the AD Rf allergy D5 documented allergy to penicillins 
choice of drug 
prescribed or When Not to Use: If a patient develops an adverse effect after commencing 
taken) a drug, then "other adverse effect problem (TO)" would 
be the best code to use. 
When to Use: 
When there is a contraindication to the use of a drug 
because of an underlying condition in the pr;ztient. 
When a less expens1.ve or alternative brand 1s substituted 
purely for cost reasons 
When a drug is felt to be unnecessary based on the 
conditions the patient has. 
When the drug being used is oui of date or deteriorated 
zn some other way. 
Drug 
When you believe a more effective drug 1s' available and 
you suggest it instead of the current therapy. 
selection 
(Problems Other drug Examples of when to ·Use: 
D related to the selection DO • Maxolon prescnbed and doctor contacted to 
choice of drog problem change to Pramin (Specify) 
prescribed or • Patient has Anginine tablets for use that are 
taken) over 2 years old and have been stored incorrectly. 
• Patient commenced omeprazole when they were 
taking Celebrex for a s.ore knee. Celebrex has 
been ceased, but they are still taking 
omeprazole. 
When Not to Use:. 
If a less expensive brand is substituted because the 
ordered brand is unavailable, then use "Non-clinical 
(NO)". 
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Category (Tyl!e} Sub-TyJ:!e Subtype Scope Notes-(When the code should be used, when not Code to use it and examnles) 
When to Use: 
When the total daily dose of a medication prescribed zs 
too high for the patient, either based on previous dosage 
or reference dose ranges. 
Includes the situatlon where the dose is too high because 
of a particular parameter of the patient such as renal 
Over or fanction weight, age 
underdose This includes situations where the dose .that is prescribed 
Prescribed is too high by unintentional error. 
0 
(Pr~blems 
Dose too Examples of when to use: 
related to the high 01 • Patient is prescribed Diamicron MR_ 180mg in 
e_rescribed the morning 
dose or • Patient is prescribed dexamethasone 50mg ·daily 
schedule of the (doctor was thmking of prednisolone dose) 
drug) • Patient prescribed spironolactone 1 OOmg bd for 
heart failure 
When Not to Use: 
If the patient lS taking too high a dose as a result of not 
following the appropriate directions, then u~e "Taking 
too much (C3) ". 
When to Use: 
When the dose prescribed is either too low based on 
reference' dose ranges or too low based on previous 
therapy. 
This includes situations where the dose that is prescribed 
Over or is too low by unintentional error 
underdose 
Prescribed Examples of when to use: 
(Problems • Locum doctor prescribes Karvea l50mg daily, 
0 related to the Dose too 02 when previous therapy was meant to be 300mg low dally 
erescribed 
• Prescription for prazosm O.Smg bd for dos_e o; hypertension 
schedule of the 
drug) When Not i<! Use: 
If the actual dose per day is suitable, but .the duration is 
too short, then use "Other Dose problem (00)" 
If the patient is taking too low a dose of a drug as a 
result .of not following the appropriate. directions, then 
use ''Taking too httle (C2) ".: 
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Category (Tyne) Sub-Tyne Subtype Scope Notes (When the code should be used, when not Code to use it and examples) 
When to Use: 
When the total dose of a medication is suitable, but the 
frequency or the dosage schedule is inappropriate. 
'' Over or Examples.of when to use: 
underdose 
• Simvastatin ordered as 40mg in the morning Prescribed 
• Diamicron MR prescribed as three times daily (Problems 
0 related to the Wrong 03 • Phenytoin prescribed as 1 OOmg three times a frequency day, previously been on 300mg at night. Qrescribed 
dose or When Not to Use: 
schedule of the If the frequency prescribed results zn an excessively high 
drug) a dose of the drug being prescribed, then use "Dose too high (OJ)". 
If the frequency prescribed results zn an excessively low 
dose of the drug being prescribed, then use "Dose too 
low (02)" 
When to Use: 
Over or When the duration of use of the product is too short or 
underdose too long. 
Prescribed 
.Examples of when to use: 
(Problems Other Dose • Patient prescribed cephalexin 500mg tds for 3 0 related to the Problem 00 days for cystitis. 
Qrescribed . (Specify) 
dose or When Not to Use: 
schedule of the If the patient zs not taking the appropriate dose of a product as a re~ult of a lack of understanding of the 
drug dosage regimen, then a compliance related code would 
be more appropriate 
When to Use: 
When there is suspected overuse of a particular, 
potentially abusable, product is intentional. Includes the 
situation where the prescription appears to be a forgery. 
Compliance 
(Problems Examples of when to use: 
related to the • Patient presents a third prescription for . 
c way the Potential 'drug Cl Panadeine Forte within 2 weeks, each of the abuse prescriptions was written by a different doctor. 
patient takes Patient lives in one town, sees a doctor for a prescription 
the for oxazepam in another town and presents it for 
medication) dispensmg in a third town. 
When Not to Use:, 
If the overuse is due to an appropriate increase zn use 
because of increased symptoms, then use "Condition not 
adequately treated (Ul)" 
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Catego:a (TyJ!e} Sub-Tme Subtype Scope Notes (When the code should be used, when not Code to use it and examples) 
When to Use: 
When the pati~nt uses too little of a medication as a 
result of forgetfulness or lack of understanding of the 
dosage regimen prescribed. 
Examples of when to use: 
.. Patient taking metformin only when required 
Compliance rather than regularly 
(Problems .. Patient-using Transiderm-Nitro patches o~y 
related to the every few days, not regularly 
_C way the Taking too C2 little When Not to Use: patient takes If the u_nderuse is appropriate because of the resolution 
the of symptoms or a condition, then use "Other Drug 
medication) · selection problem (DO)" and specijj; that the drug may 
no longer be required. 
If the patient has a 'phvsical problem with the 
administration of the dosage form as it'is intended to be 
used ( eg. swallowing a particular form of the med1catzon 
whole, cannot appropriately insert suppositories, 
arthritis_/imiting the use of an inhaler)then use 
''.Difficulty using dosage form (C4)" 
When to Use: 
When th~patient uses too much of a medzcation as a 
result of forgetfulness or lack of understanding of the 
dosage regzmen prescribed. 
Examples of when to use: 
• Patient pres~nts requestmg a second ventolin 
-inhaler 11 days after the previous one was 
Compliance provided. 
(Problems • Patient continuing. to tcike 50mg daily of 
related to the . . - prednisolone, had forgotten to commence a 
c way the Taking too C3 dose reduction schedule as instructed by the mm;:h doctor. patient takes 
• Patient believes they have forgotter- a the 
medication .and takes a second dose on the 
medication) same day. 
When Not to Use: 
If the overuse _is due to an appropriate increase (n use 
because of increased symptoms, then.use "Condition not 
adequately treated (UJ)" 
~ 
If the ove1:Use consists of inapproprzately taking two 
different brands or forms of the same ingredient 
unknowingly, then use "Dupbcation (DJ)". 
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Category {Tme) Sub-Ty(!e Subtype Scope Notes (When the code should be used, when not Code · to use it and examples) 
When to Use: 
When the patient has a physical problem with the 
administration of the dosage form or device as it is 
intended to be used (eg. swallowing a particular form of 
the medication whole, cannot appropriately insert 
suppositories, arthritis limiting the use of an inhaler) 
Compliance Examples of when to use: 
(Problems • Patient cannot swallow her slow release diltiazem 
related to the Difficulty capsules 
c way the using dosage C4 • Patient with scoliosis cannot insert suppositories 
patient takes form • Controllec:l release tablet ordered for a patient 
the who must crush all oral medications 
medication) 
When Not to Use: 
If the difficulty is related to a_ technical problem with the 
use of an administration or monitoring device such as an 
aerohaler, then use "demonstration of device (E3) ". 
If the difficulty is not a technical one, and related to lack 
·ofunderstanding of the use of the dose form, then use 
"Confusion about therapy or condition (E2) '.'. 
When to Use: 
When the patient zs aware of the way to take the drug, is 
physically able to take the drug, and understands its 
purpose, but does not wish to take it. 
Compliance Examples of when to use: (Problems 
• Patient unwilling to use mirtazapine after reading 
related to the Other 
Compliance the package insert. c way the Problem co 
patient takes. (S:pecify) When Not to Use: 
the If the compliance zssue results zn two drugs of the same 
medication) therapeutic class. bezng taken inadvertently, then use 
"Duplication (DJ)''. 
If the patient does not wish to take the medication 
because it is causing an adverse event of some sort, then 
a toxicity or adverse event category (T) would be 
·appropriate. 
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Categoa (T:yl!e) Sub-T:yl!e Subtype Scope Notes {When the code should be used, when not Code to use it and examples) 
When to Use: 
When the patient has a symptom or disease condition 
that is either not being treated, or not being treated 
Untreated adequately. 
' indications · 
(Problems Examples of when to use: 
relating to Condition • Patient taking Hydrene and Coversyl for 
u actual or not U1 high blood pressure, but blood pressure adequately continues to be high 
potential treated 
• Patient develops nausea as part 9f a viral 
conditions that illness and requires addition of 
require, antinauseant medication. 
management) 
When Not to Use:-
If the patient requires additional therapy as a 
preventative strategy (eg potassium. when on a loop 
diuretic), then use '~Preventive therapy required (U2) ". 
Untreated 
indications 
(Problems Other 
relating to Untreated When to Use: 
u actual or indication VO When you.think the patient has any other problem 
potential Problem 
relating to actual or potential conditions that requires 
(Specify) management. 
conditions that 
require 
mana~ement) 
When to Use: 
When, in the absence of any adverse effects, you belzeve 
that drug level monitorin~ is required. 
Examples of when to use: -
• Elderly woman on digoxin; who has not 
Monitoring h~d a blood test for two years 
(Problems .. Patient on carbamazepine 200mg twice daily who has not had a blood test for 12 
related to months. 
M monitoring the Drug levels Ml - • Patient commenced on phenytoin 3 weeks 
efficacy or ago and you recommend a blood level 
adverse effects 
of a drug) When Not to Use: If the patient is expenencmg an adverse effect of some 
sort, which you believe is due to elevqted drug levels, 
then use "Caused by dose too high (TI)". 
If the need for drug level monitoring comes about as a 
result of a newly commenced drug, then use "Drug 
interaction (D2) ". The monitormg then becomes a 
recommendation, not the primary problem. 
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. Category {T~e) Sub-TyJ;!e Su~type Scope Notes (When the code should be use4, when not Colle to use it and examples) 
When to Use: 
When, in the absence of any adverse effects, you believe 
that a laboratory test is required (e g. Potassium, 
creatinine, white cell count, INR) 
Also covers the situation where you undertake the 
monitoring in question and provide a recommendation 
follow1'!g the result (eg INR monitoring and suggestin,g 
a change ofwaifarin dose) 
Monitoring Examples of when to use: 
(Problems • Patient recently increased frusemide dose 
related to from 40mg daily to 120mg daily without a 
M monitoring. the Laboratory M2 change in potassium' replacement. Monitoring 
• Patient commenced on Anuodarone- and efficacy or you recommend a thyroid function test 
adverse effects 
of a drug) When Not to Use: 
If there are adverse effects associated with the 
parametf}r, then use "Other Toxicity problem (TO)", and 
specifY the parameter to be tested and the symptom or 
sign. (eg, patient with leg cramps, suggest magnesium 
level) 
If the need for laboratory level monitoring co_mes about 
as a result of a newly commenced drug, then use "Drug 
interaction (D2) ". The monitoring th.en becomes a 
recommendation, not the primary problem. 
When to Use: 
When, in the absence of any advet:se effects, you believe 
that non-laboratory momtl:xdng is required. (eg BP, BSL, 
temperature, weight) 
Also covers the situation where the test is undertaken as 
Monitoring a screening process 
(Problems Examples of when to use: 
related to 
·Non- • A patient with heart failure has an M monitoring the Laboratory M3 appropnate increase in his dose of 
efficacy or monitoring frusemide and you advise him to weigh 
adverse effects himself each day for the next week. 
of a drug) When Not to Use: 
If you recommend monitoring of a parameter (eg weight, 
BSL) as· a result of another drug problem, then that 
recommendation should be recqrded in the 
Recommendation code section. The type ojproblem ihat 
leads to this recommendatf on may vary. 
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Categoa (Tyne) Sub-Tyne Subtype Scope Notes (When the code should be used, when not Code to use it and examples) 
Monitoring 
(Problems When to Use: 
related to Other When the patient has another problem related to the 
M monitoring the Monitormg MO monitormg of his drugs for either efficacy or adverse Problem effects. 
efficacy or (Specify) When the patient should be having monitoring done, but 
adverse effects has problems with attending the laboratory, or paying 
of a dru~) for the test or equipment needed. 
When to Use: 
When the patii;mt has a reasonable understanding of 
their condition, but requests further iriformation about 
their. medication. 
Education or Examples of when to use: 
Information • Patient requests information about 
(Problems alendronate and you provide a CMI 
E related to 
Patient drug 
knowledge of information El When Not to Use: request If the patient requests information primarily aboilt the 
the disease or disease state, rather than a drug, th'en use "Disease 
its management or advice (E4)" 
management) If the p~tient does not request t~e information, but you 
discover that they need the informatzon zn the course of 
your routine dispensing, then use "Confusion about 
therapy or condition (E2) ". 
If the request is not about a specific drug, but a 
therapeutic device, then use "Demonstration of device 
(D3)" 
When to Use: 
When the patient does not understand the reasons for the 
use of a medication or a fundamental aspect of the 
condition they have, but they still take the medication as 
directed (ie correct dose and time) 
Examples of when to use: 
Education or • When.providmg a new prescription for 
Information metoprolol for a patient with newly 
(Problems diagnosed hypertension, you find that she Confusion believes that the drug may cure the 
E related to . about E2 condition and she can stop the drug in a knowledge of therapy or few months. 
the disease or condition 
its When Not to Use: 
management) If the patient requests further information, then use either "Drug mformation request (El)" or "Disease 
management or advice (E4)" as appropriate 
If the confusion would have (or did) resulted in a change 
in compliance (either taking too much or too little of the 
medication), then an appropriate compliance code 
should be selected. 
If the request is not about a specific drug, but a 
therapeutic device, then use "Demonstration of device 
(D3r 
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Categoa {Tyl!e) Sub-Tyl!e Subtype Scope Notes (When the code should be used, when not Code to use it and examples) · 
When to Use: 
When the patient has a technical problem with the use of 
Education or an adrnznistration or monitoring device. (eg inhaler, BSL 
Info.rmation Monitor, turpuhal~r) 
(Problems Examples of when to use: 
E related to Demonstrati E3 • A patient 'is changed from a metered dose · knowledge of on of device inhaler to f1I1 aerohaler and requests a 
the disease or demonstration of how to use the device. 
its 
when Not to Use:· 
management) If the patient understands how to use the device, but has 
a physical reason for not being able to use it, then use 
"Difficulty using dosage form (C4) ". : 
When to Use: 
When the primary purpose of the interaction with the 
patient was to inform them of critical aspects of the · 
management or prevention of a disease or condition. 
Education o·r Also covers the situation where the patient requests the 
information. . . Information 
(Problems 
Disease Exampl~s of when to use: 
related to E knowledge of management E4 • You couD.sel a patient with heart failure or advice about fluid restriction 
the disease or 
• You provide information about weight loss · its or smoking cessation for a person who has 
management) cardiovascular disease. 
When Not to Use: 
If the patient.request information primarily regarding a 
drug, then use "Drug information request (El)". 
Education or 
Information 
(Problems Other When to Use: 
related to Education or When another health care worker (e.g. a doctor or I; lnfqrmation EO knowledge of Problem another pharmacist) requests information. Also covers 
the disease or 
·(Specify) any other education or information related problem. 
its 
. manaf;!ement) 
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Categon: (Tme} Sub-Tyl!e Subtype Scope Notes (When the code should be used, when not Code to use it and examples) 
When to Use: 
When an illegible prescription requires clarification. 
When the prescription does not meet PBS requirements. 
When the drug is unavailable from the manufacturer .or 
is out of stock temporarily. 
When the dose of the medication is not specified on the 
prescription. 
Non-clinical When the prescriber is riot authorised to prescribe that 
(Problems particular medication. 
N related to Not sub-
When the patient has problems getting to pharmacy or 
administrative classified NO 
collecting prescriptions. 
aspects of the Examples of when to use: 
prescription) • 'Physeptone Smg tablets not available, substitute 
1 Omg tablets with dose adjustment 
When Not to Use: 
If a less expensive or alternative brand zs subs(ituted 
purely for cost reasons, then use "Other drug selection 
problem (DO)" and specify brand substitution for cost 
reasons. 
'' When· to Use: Toxicity or When the patient h_as signs or symptoms that suggest an 
Adverse adverse reaction that is likely to be dose related 
reaction· 
(Problems Examples of when to use: 
related to the • Patient has increa'sed their dose of tramadol and 
presence'Of ·develops headache, sweating and agitation 
signs or Caused by • Promethazine and amitriptyline together 
.T dose too T1 causing worsenmg of dry mouth symp~oms 
which are 
high 
• Patient prescribed diamicron MR three times 
suspected to ' 
daily and has significant hypoglycaemic 
syml?toms 
be related to 
an adverse When.Not to Use: 
effect of.the lfthe patient does not have any signs or symptoms of 
drug) adverse effects and you believe the dose is too high, then 
use "Dose too high (01)" 
Toxicity or When to Use: When the patient has signs or symptoms that suggest an 
Adverse , adv,erse reaction that relates to the presence of an 
reaction interacting drug 
(related to the· 
Exa~ples of when to use: 
. - presence of 
signs Caused by • Patient taking warfarin develops an elevated 
T /symptoms drug T2 'INR, after commencing metronidazole 
which are interaction • Patient taking perindopril and frusemide, who 
suspected to 
commences diclofenac and develops renal 
dysfunction 
be related to When Not to Use: 
an adverse If the patient has an interacting drug present, but there 
effect of the are no signs or symptoms of the interaction causing' an 
drug) adverse effect, then use "Drug interaction (D2)". 
12 
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Category (Tme) Sub-Tme Subtype Scope Notes {When the code should be used, when not Code to use it and examples) 
When to Use: 
Toxicity or When the patient has signs or symptoms that suggest an 
adverse reactzon tfJat is likely to be related to a 
Adverse particular drug, but doesn't seem to be dose relate~ or 
reaction related to an interaction. 
(Problems Covers the situation where the patient develops an 
-related to the adverse reaction such a_s a rash after commencing a 
presence of Other drug. 
T signs or 
Toxicity/Ad 
Examples of when to use: 
_verse Effect TO 
symptoms problem • Patie.nt develops a rash after commencmg on 
which are 
.(Specify) Augmentin Duo 
suspected to • Patient develops hypotension after commencing 
be related to prazosin, even though the dose is controlling the 
an.adverse prostatic hypertrophy 
effect of the 
When Not to Use: drug) Should not be used if there are no signs or symptoms of 
adverse effects. 
13 
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2. Actions to Investigate the Problem 
What did the Scope Note~ Action Code (When the code should be used, when not to use it pharmacist do in order and examples) 
to sort out the 
problem? When to Use: 
Note 1: lrJUltiple actions When the pharmacist consults a textbook or other 
written reference material) 
are possible for one Examples of when to ~se 
situation and each action Investigation: 
• Printed versions of Martindale, AMR or PP 
may occur multiply Written Al guide 
Note 2:.Each of these ·material When Not to Use: 
actions will have a time If the reference material is electronically accessed 
value.allocated to them from the local computer system, use 
after the pilot study "Inve:ftigation:software (A2) ". 
When to Use: 
When the pharmacist consults decision support 
software that is located on the computer or server in 
the pharmacy. 
Investigation: Examples of when to use A2 • eMims, electronic AMR, Electronic therapeutic Software Gmdelines 
When Not to Use: 
If the electronic resource requires an internet 
connection to obtain it, then use "Investigatwn: 
Internet (A3)". 
When to Use: 
When the pharmacist consults deciswn support 
software that is located on the internet. 
! 
Examples of when to use 
• . Pharmacist conducts a PubMed search 
• Pharmacist is a subscriber to an internet based 
set of resources such as Medscape, or a 
University hbrary service 
Investigation: A3 When Not to Use: Internet If the information source is not from the internet, 
then use another investigation source (either Al, A2, 
A4 or AS): 
If the mternet is used to make email contact with 
another healthcare professional for assistance, then 
use "Investigation· Other (AS)'!. 
If the internet is used to make email contact with the 
National Prescribing Service or other State or 
Natwnal information support service, then use 
"Contacted State or National Drug infom:zation 
service (A4)" 
14 
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What did the 
pharmacist do in order Scope Notes 
to sort out the Action Code (When the code should be used, when not to use it 
·problem? 
and examples) 
When to Use: 
When the pharma'cist contacts the National 
Prescribing Service or one of the State Drug 
Information Services for information. 
Contacted Examples of when to use 
Drug A4 • Pharmacist emails the NPS. to determine Information information about a new drug that has not yet 
Service been released. 
When Not to Use: 
In the pharmacist contacts a colleague who they 
think may know something about the problem, then 
use "Investigation: Other (A5) ". 
When to Use: 
When the pharmacist consults another pharmacist or 
health professional to investigate the problem. 
When the pharmacist contacts the maniifacturer or 
supplier of the product for ieformation. 
Examples of when to use 
• Pharmacist nngs the pharmacy where the 
prescnption was previously dispensed to clarify 
Investigation: an issue. A5 • Pharmacist contacts a colleague who works at Other (specify) the same pharmacy to clarify the problem. 
• Pharmacist contact the HIC to determme the 
details of a particular Authority scnpt · 
arrangement. 
·When Not to Use: 
If the health professional that is contacted is someone 
who works for the NPS or a state or national drug 
ieformatwn service, then use "Contacted State or 
National Drug information service (A4)" 
15 
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What did the 
pharmacist do in order Scope Notes 
to sort out the Action Code (When the code should be used, when not to use it 
problem? and examples) 
When to Use: 
When the pharmacist needs to contact the prescriber 
in order to clarify the prescriber's intent, provide 
new information from a patient encounter or to 
discus~ recommendations the pharmacist may wish to 
make. 
Examples of when to use 
Contacted A6 • Pharmacist rings the doctor t<;> confirm that the prescriber dose mcrease for trarnadol was intentional, as the 
patient was unaware of any change. 
When Not to Use: 
.. If as a result of investigating the problem you refer 
the patient to the prescriber, but do not contact the 
prescnbe~first, then the referral is a 
recommendation and you should use "Refer to 
prescrzber (Rl 0) ". 
When to Use: 
When a discussion with the patient takes place that is 
primarily aimed at clarifying a drug related problem. 
Examples of when to use 
• Pharmacist receives a script from the patient and 
Discussion finds the dose is different from the last time the 
with patient or A7 patient had the 'drug dispensed, then checks with 
carer 
the patient that the dose change was intentional. 
When Not to Use: 
If the discussion with the patient is within the usual 
course of the prescription being received or giving 
out, then it is not considered an action. For example, 
"Can you pleqse wait while I contact the doctor" is 
not a discussion with the patient/carer. 
Corrected When to Use: 
without AS When the problem is a simple issue that requires 
discussion correction (often administrative). 
When to Use: 
When the pharmacist undertakes any other 
investigation or activity in order to clarify the actual 
or potential drug related problem. 
Other Action AO (specify) Examples of when to use 
• Pharmacist contacts the hospital to determine the 
dosages of the discharge drugs that were 
supplied. 
16 
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3. Recommendations to Resolve the Problem 
What did the Scope Notes (When the code should be used, when not to use it pharmacist 
·Recommendation Code and examples) 
recommend as a 
solution to the When to Use: 
problem? When the pharmacist conducts a detailed counselling 
or education session with the patient or carer that is 
specifically targeted at resolving the problem that 
Note 1: multiple has been identified. Includes the provision of a written summary of 
recommendations medzcatzons af!d their timing such as a medipal or 
possiqle for one medprof 
situation 
Examples of when to use 
• Patient was not taking metformin correctly, 
pharmacist gave details of how to take it in 
Education or relation to food, how long it lasts and also gave 
counselling session Rl information regarding the complications and 
management of chabetes. 
When Not to Use: 
If the discussion with the patient is to determine the 
nature of the problem, rather than propose a 
resolution recommendation or further education, 
then it is an investigative action arid you should use 
"Discussion with patient or carer (A 7) ". Note that a 
conversation or discu:fsion with the patient may 
involve both investigation of ihe problem 
("discussion with patient(carer(A7)) and an 
education/counselling session to resolve the problem 
identified (Education/counselling session (Rl) 
When to Use: 
When the pharmacist recommends that the total daily 
dose of the medication is either increased or 
decreased. 
Examples of when to use 
. R2 • Pharmacist recommends that the dose of Dose change Diamicron MR be reduced. 
When Not to Use: 
If the total daily dose of the product does not change, 
but you recommend the schedule changes, then use 
"Dose frequency or schedule change (R9) ": 
17 
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What did the Scope Notes 
pharmacist Code 
(When the code should be used, when not to use it 
Recommendation and examples) -
recommend as a 
solution to the When to Use: 
problem? When the pharmacist suggests that the drug is 
ceased, ezther temporarily or permanently. 
Examples of when to use 
• Pharmacist suggests patient does not take a 
medicat10n for a day and to go to the doctor to 
Drug cessation R4 discuss the problem. Note in this case you should 
also select "Refer to prescriber (Rl O)" 
When Not to Use: 
If the drug dose is changed or some other 
manipulation of the drug or dose is undertaken, then 
the appropriate code should be used. 
If a drug is stopped in order to start another one for 
the same indication, then use "Drug change (R3)" 
When to Use: 
When the active ingredient of the medication and its 
total dazly dose is not changed, but the formulation is 
changed. 
E~amples of when to use· 
Drug formulation • Pharmacist suggests a change from a metered 
change RS dose inhaler to an aerohaler 
• The pharmacist suggests a change from cream to 
ointment as the cream is not available 
When Not to Use: 
If the formulatzon change also results in a change in 
the total daily dose of the medication, then use "Dose 
change (R2)". 
When to Use: 
When the pharmacist suggests that the patient 
undertake some non-laboratory monitoringfor 
efficacy or adverse effects from the medica(zon 
Examples of when to use 
Monitoring: non- • Pharmacist. suggests the patient weigh 
laboratory R6 themselves daily while they are taking an increased dose of frusem1de for heart failure. 
When Not to Use: 
If the monitoring involves laboratory-based test of 
some sort, then use "Monitoring: Laboratory test 
(Rl2)". 
18 
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What did the Scope Notes (When the code should be used, when not to use it 
pharmacist Recommendation Code and examples) 
recommend as a 
solution to the When to Use: 
problem? When the pharmacist suggests a change in brand of 
the drug (same drug same dose). 
Examples of when to use 
• Maxolon unavailable, pharmacist suggests that 
Drug brand change R8 Pramin could be substituted. · 
When Not to Use: 
In the change in brand is to a different formulation of 
the same active ingredient, then use "Drug 
formulation change (R5)". 
When to Use: 
When the total daily dose of the product remains the 
same, but the pharmacist suggests a change in the 
number of times a day, or the timing of the doses 
each day. 
Examples of when to use 
Dose • Pharmacist suggests changmg valproate from lg 
frequency/schedule R9 twice daily to 500mg four times daily to reduce 
change gastric upset. 
• Pharmacist suggests change m timing of 
Isosorbide mononitrate from morning to night to 
cover unstable angina during the night: 
When Notto Use: 
When the change results in a change m the total daily 
dose of the medication, use "Dose change (R2)" 
When to Use: 
When the problem is of sufficient seriousness for the 
patient to see the prescriber again in order to resolve 
the problem 
Examples of when to use 
'' • Patient presents with a rash from the recently 
commenced antibiotics. You tell the patient to 
cease the capsules and refer her back to the 
Refer to prescriber 
prescriber for some different antibiotics. Note 
RlO should also select "Drug Change (R3)" and 
"Drug cessation (R4)". 
When Not to Use: 
If the patient goes back to the prescriber simply to 
get a new prescription, as a result of you discussing 
the problem with the prescriber then this code should 
not be selected. 
If the pharmacist discusses other issues with the 
prescriber, this is an action and you should select 
"contacted prescriber (A6) ". 
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What did the Scope Notes 
pharmacist (When the code should be used, when not to use· it Recommendation Code and examples) 
recommend as a 
solution to the When to Use: 
problem? When the pharmacist suggests to the prescriber that 
they undertake some laboratory monitoring for 
efficacy or adverse effects fr,om the medication. 
Examples of when to use 
Monitoring: R12 • You contact the prescriber to suggest that he Laboratory test · check the INR in a patient takmg warfarin who 
has commenced amiodarone. 
When Not to Use: 
If the·monitoring relates to a test that can be done at 
home (eg BSL) then use "Monitoring· non-laboratory 
(R6)". 
When to Use: 
When the pharmacist commences the process for a . 
Home Medicines Review for the patient. 
Examples of~hen·to use 
• You recommend a' HMR for patient who has Refer for R13 s1gmficant problems with understandmg of their 
medication review med1cat10ns. 
When Not to Use: 
Whenyou undertake an "ad hoe" review of the 
medications and-generally assist with the patient's 
un{ierstanding, use "Education Counselling session 
(RJ)" 
When to Use: 
When you suggest the use of a dose administratwn 
aid such as a Dosette box or a Webster pack. 
Examples of when to use 
• You recommend a Webster pack for a patient 
Commence dose who has significant problems with understandmg 
administration aid R14 of the schedule and timing of their medications. 
When Not to Use: 
If you provide a written summary of the patients 
medications and their schedule (eg medprof or 
med1Pal) in addition ·to the dose administration aid, 
then also select "Education/Counsellmg session 
(Rl)". · 
When to Use: 
Other When the pharmacist ~akes any other 
recommendation Rl5 recommendation that is not mentioned on this list to 
(specify) resolve the problem. 
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4. Acceptance of Pharmacist's Resolution of the Problem (Outcome) 
Did the clinical activity Scope Notes Outcome (When the code should be used, when not to use it and 
actually re.suit in a examples) 
change of management, When to Use: 
or was the suggestion When the pharmacist is unaware of what happened after he made 
deemed not relevant in the recommendatwn(s). 
this case? Examples of when to use 
Note 1: If at the time of Unknown • You suggest that the patient go and see the doctor and they say 
clinical activity the they will think about it. 
outcome is not known, • You leave a message for the doctor to contact the patient about 
the incident is flagged a problem. 
for later addition of the 
outcome. When to Use: 
When all of the recommendation(s) that the pharmacist makes are 
accepted 
That is: Were the Examples ofwhen to use . 
pharmacist's 
• YOU contact a doctor to suggest reduction of the dose of 
recommendations 
Accepted tramadol and he accepts your suggestion. implemented? 
• You take the time to explain fully the medicat10ns and disease 
a patient has (Educ~tion Counselling (Rl)). 
When Notto Use: 
If you make multiple recommendations and not all of them are 
accepted, ihen use "Partzally Accepted" 
When to Use: 
when the pharmacist makes multiple recommendations, and only 
some of the recommendations that were made are accepted. 
Examples of when to use 
Partially • You contact a doctor to suggest reduction of the dose of digoxin and a repeat blood level of digoxin. He agrees with the Accepted reduction in dose, but thinks the blood level would be a waste 
of time~ -
• You suggest to the patient that they withhold their ibuprofen 
for a few days and go pack to the doctor and ~sk for a differen~ 
medication. They decid,e to stop the drug for a while, but 
choose not to go to the doctor. 
When to Use: 
When all of the recommendation(s) that the pharmacist makes are 
rejected 
Not accepted Examples of when to us~ 
• YOU contact a doctor to suggest reduction of the dose of 
tramadol and he says that he still wants to use that dose as the 
patient's pain warrants .it. 
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5. Clinical Significance of the Problem 
If the pharmacist had not Significance . Code Scope Not~s 
intervened/provided a 
clinical activity, what When to Use: 
was the When there is no consequence to the patient. 
possible/potential Nil so Examples: 
outcome if therapy had • Prescription mcomplete, contacted doctor and 
continued? (a subjective obtamed directions 
rating, predicting the 
clinical severity if action 
When to Use: 
was not taken). When the consequence to the patient are related to costs 
That is: How serious or information only 
was/could have been Low Sl Examples: 
the problem? • Pramm substituted for Maxolon 
• Provided CMI onFosamax at request of patient. Note 1: Situations rated 
as high (S4) will require 
additional information to When to Use: 
be entered into a notes When the consequences to the patient are that they have 
field improved a minor symptom, or if the intervention had not 
occurred they would have developed a minor symptom. 
Mild S2 The symptom should be such that it does not require a 
doctor's visit to treat. 
Examples: 
• Patient commences on a codeine based analgesic and 
you recommend to take prophylactic stool softeners 
When to Use: 
When ifthe intervention did not occur, it was likely that 
the patient would have had to go to the doctor because of 
the consequences. Also covers the situation where you 
need to refer the patient to the doctor because of the 
Moderate S3 seriousness of the situation. 
Examples: 
• The patient was inadvertently taking twice the dose 
of sulphonylurea tablets and would have developed 
hypoglycaemia that required a trip to the GP to treat 
the symptoms. 
When to Use: 
When ifthe intervent10n did not occur, jt was hkely that 
the patient would have had to go to a hospital because of 
the consequences. Also covers the situation where you 
need to refer the patient to a hospital because of the 
seriousness of the situation. 
When if the intervention did not occur, it was likely th~ 
High S4 patient would have had to receive assistance from a . 
regular nurse visit, or would have had to been placed into 
residential care of some sort. Also includes the situation 
where the intervention prevents the additional nursing 
.care or delays the admission to residential care. 
Examples: 
• The patient was inadvertently taking double the dose 
of amiodarone and was taking warfarin. Presented 
with bleeding. 
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5. Other Information Regarding the Problem 
Notes This section is to add free text notes, to more thoroughly explain 
actio.n(s) or the reason(s) for them. 
Note 1: Notes may be required to clarifj; any of the "other" categories 
in the Type, Action and Recommendation sections 
Note 2: Situations rated as of high clinical significance will require ' 
additional-information such as other drugs, any medical information, 
reasons for perceived severity. 
Time How long did it take to perform the clinical activity? (Approximate minutes 
time spent conducting the clinical activity) 
Note 1: If values have been assigned for the various activities that are 
timed, this could be a summation function which would not need to be 
entered. 
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9.8 APPENDIX 8: PROMISE STUDY PHARMACY 
ENROLMENT INFORMATION 
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PROMISe 
Pharmacy Recording of Medication Incidents, and."'Serw.ic 
electronic documentation'system 
'•r ·'·'.•· '.· •. -
Dear 
Potential Participation in PROMISe Project 
The PROMISe project, is investigating the recording of community pharmacist's clinical 
interventions. This project is funded by the Pharmacy Guild of Australia and is being 
carried out by the Unit for Medication Outcomes Research and Education, based at the 
University of Tasmania. 
All WiniFRED users in the Melbourne area are being approached to participate in a three 
week data collection period in April 2005. Pharmacies and pharmacists will be 
remunerated appropriately for their time and for each intervention documented . Each 
pharmacist participating will be paid $420 to participate in the training and orientation 
sessions and each pharmacy will receive a participation fee of $500. In addition, 
pharmacies will be remunerated ($15) for half of the interventions that they document 
during the test period. Based on our pilot studies, the average remuneration for 
interventions would be $60 (4 interventions) per 100 prescriptions. Therefore in a 
pharmacy which employs 3 pharmacists and dispenses 200 prescriptions a day 
participation in the trial could result in as much as $2000. 
The participating pharmacies will have an update installed on their dispensing system 
which allows the electronic recording of interventions. Full training will be provided to 
each pharmacist participating, this will take between 4 and 6 hours, at least half of the 
training can be completed online at the participants own pace. 
Interventions by community pharmacists occur commonly and are not currently recorded. 
With an easy to use recording system, such as the DOCUMENT system, used in the 
PROMISe project, there is potential that in the future recording these interventions may 
attract remuneration. 
Full software and technical support will be provided by PCA/Nu systems. There will be 
regular visits by members of the UM ORE project team to assist with any other issues with 
the DOCUMENT system. 
More information about the project can be found at www.promise.id.au 
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Pharmacy Enrolment Form 
If you are interested in participating, please return the by fax to (03) 62267627 
or email as an attachment, with the relevant changes, to PROMISe team 
The following information will be used only to stratify your pharmacy within the population 
of pharmacies that will be considered for participation. No information will be divulged to 
parties other than the direct members of the research team. 
Pharmacy Name 
WiniFRED Site Number (if known) 
Contact person (the main pharmacist actively 
involved in PROMISe) 
Location (Type Y in the relevant box) 
Local shopping centre (<25 shops) 
1. Which of the following describes 
Major shopping centre (>25 shops) 
Strip 
the location of this pharmacy? Medical Centre 
Hospital 
Other (please specify) 
2. How many hours and days per Total number of hours per week 
week is the pharmacy open Number of days each week 
3. PROMISe II will run for three 
weeks, how many regular 
pharmacists would there be 
workinq durinq this period? 
Number of Terminals (Type Y in the relevant box) 
4. How many dispensing terminals One 
operate in your pharmacy? Two 
Three 
Four or more 
Operating System (Type Y in the relevant boxl 
5. What operating system does the Windows xp 
dispensing computer operate on Windows 2000 
Windows 98 or earlier 
Thank you for your interest, we will contact you in the near future with further details The 
PROMISe Project Team 
Peter Tenni 627 I Page 
Clinical Interventions in Australian Community Pharmacies 
9.9 APPENDIX 9: PROMISE STUDY CLINICAL 
PROBLEM SOLVING TOOL 
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::i 
Draft Case Study for 
Clinical Problem Solving Assessment 
Instructions 
The following powerpoint presentation is built 
with hyperlinks attached to the various selections. 
As you select an option, you will be taken to 
another point in the presentation, where you 
select another option and so on. 
Scoring the case will depend on the number of 
problems you identify along the way, and the 
recommendations you make to resolve any 
problems you identify. 
Please be careful to not inadvertently move 
forward or back a slide, as this will take you out of 
your loop into some other place. 
You may find it useful to take note of the route you 
take through the presentation (note the number in 
the top left hand corner) and also keep track of 
"' useful information that you find out along the way. 
N 
-u 
Cl.I 
l.O 
(1) 
Click below to Start 
? 
• 
A 54 year old man presents you with a new prescription 
for Avandia (Rosiglitazone) 4mg twice daily. He has taken 
the rosiglitazone at a dose of one daily for the last month , 
and tells you that he has just been to the doctor, who said 
to increase to twice daily. He also has a new prescription 
for frusemide 20mg daily which he needs dispensed. 
Which ONE of the following would you do first? 
A 1-FincfaLiiframih-e-patienthispreviC>Listreatm_e_rit-i0-r---·---·1 
1 diabetes, more information regarding other medical . 
l GQrn:H1iOD§_g_DQ_§YDJPt9mJ?, Q[)Q(e_gen_tJ~_$_L.§, ---------- __ _l 
~-···ois.pense·· ·t118 . prescri.iJtionas . writtenwit11·-ap.pra-priate ··· ······-
counselling regarding monitoring of BSLs in diabetes. 
.f_j Contact the prescriber, primarily to find out the reason 
for the addition of the frusemide . 
D Contact the prescriber, primarily to find out current 
liver function tests. 
1a 
"'O 
ro 
rt 
ro 
., 
-l 
ro 
::i 
::i 
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w 
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""O 
OJ 
IO 
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You find out that the patient has been on glibenclamide, 
which originally started at once daily, but has been 
increased gradually to 1 Omg bd over the last 3 years. 
His BSLs have increased over the last three years (now 
in the 8s and 9s), and the doctor has recently added 
Avandia in an attempt to control them. He has had 
unstable angina and atrial fibrillation in the past. His 
other current medications are: 
•lsosorbide Mononitrate 60mg m 
•Digoxin 125mcg m 
•Glyceryl trinitrate spray prn 
•Glibenclamide 1 Omg bd 
•Aspirin 1 OOmg m 
•Metoprolol 50mg bd 
Which ONE of the following would you now do? 
Al Contact the prescriber, primarily to find out the 
patient's blood pressure and heart rate. 
.!!..J Dispense the prescription as written with appropriate 
counselling regarding monitoring of BSLs in diabetes. 
c I Contact the prescriber, primarily to discuss the 
I addition of frusemide and possible causes of his 
I 
l Qe_dem.9., ___ -·- ····················-· -·- ·--···············- ····--·············--··············-··········- ......... ···-···· -··············· 
D Contact the prescriber, primarily to inform him that 
beta blockers are contraindicated in diabetes. 
-····- ···1 
1b 
When you talk to him about monitoring, he tells you that 
he tests his BSL once daily regularly. The results have 
been in the 8s and 9s for the last 6 months or so, and 
the doctor hopes that this new medication will start to 
have an effect. For the moment, he feels that there has 
been no real change. 
Which ONE of the following would you now do? 
A Find out from the patient his previous treatment for 
diabetes, more information regarding other medical 
[ gQnct.iJiQ0$ _9.n9 .. §YmPJ9m$,9.0ct rnG.en16S.l_§_, ___________ _ 
B Provide him with the medications and reassure him 
that they will start to work in a month or so. 
~ Contact the prescriber, primarily to find out the reason 
· for the addition of the frusemide. 
o f con-tact- tti-8iJrescrib-er~ J)riiTiari-1ytodisc_u_ss-1ti-e___ ----- -i 
! patient's diabetes management and to obtain a HbA1c \ Lrn$.v1L . -----·- ________________________________________________ ! 
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1c 
""CJ 
(1) 
,..,. 
(1) 
.., 
-l 
(1) 
::J 
::J 
The prescriber tells you that the patient has developed 
mild swelling of the ankles and mild shortness of breath 
(although he is overweight) and that he feels the 
addition of frusemide is warranted. He thinks that the 
patient may be developing some early heart failure as a 
result of his underlying cardiac conditions (hypertension, 
AF and IHD). 
Which ONE of the following would you now do? 
..8.J Continue the discussion with the doctor, primarily to 
discuss the patient's diabetes treatment. 
JU Dispense the prescription as written with appropriate 
counselling regarding monitoring of BSLs in diabetes. 
_g_J Continue the discussion with the prescriber primarily 
°' I to determine the heart rate and blood pressure. 
w 
........ 
""O 
OJ 
lO 
ro 
D 1-cantin-Liethe-cii.scus-sio_n_witilt-he._pres.cribe-rpr.imari1;;---····, 
i to discuss other possible causes of the patient's 
I L 9~<:t'2m9. ,_ _________________ -------------·- _____ . r 
..i 
1d 
The doctor is aware that rosiglitazone may cause liver 
dysfunction. He tells you that this patient's liver function 
tests were normal before commencement of 
rosiglitazone and are due to be checked again next 
week. 
Which ONE of the following would you now do? 
A r· con-tinue -ihe-discuss-ionw~hihepre-scriber: - primariiy·-
1 to find out the patient's past medical history, other 
l_m~oLG9.ti_on§ 9.no 6.S.J,, __ rn§Y!t§:. __ _ __ ________ --··------ __ , 
B Dispense the prescription as written with appropriate 
counselling regarding monitoring of BSLs in diabetes. 
C I Continue the discussion with the prescriber, primarily 
to find out the reason for the addition of the frusemide. 
···-···--·-····-·----··-·-·-··-·-·-···-·--·--·-·········-·-··-·····-··--·-·-··-····-··-----···-··-····-·····--·--·-···---········-·-······-··-··----·-··--·---·1 
D I Continue the discussion with the prescriber, primarily I 
1 to discuss the patient's diabetes management and to I 
l ___ QQ1qini:.L!::LP._6JC_r?._§~1L. ______________________ --·· _ . ___________________ ! 
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Clinical Interventions in Austrtalian Community Pharmacies 
Blood Pressure is 148/98mmHg and heart rate is 65bpm 
and irregularly irregular. 
Which ONE of the following would you now do? 
~J Contact the prescriber, primarily to discuss 
antihypertensive management. 
1LJ Dispense the prescription as written with appropriate 
counselling regarding monitoring of BSLs in diabetes. 
..f..I Contact the prescriber, primarily to find out the reason 
· for the addition of the frusemide. 
D fcontaci-111e-r;r:escriber,prima-ri1yto -tindoui-iile-·-··---···· 
I patient's past medical history, other medications and 
l .. 6S'=_rn$.~lt§,____ __ -------·----·· ---·-----· --· .. 
2b 
The prescriber is somewhat taken aback, as the patient 
has had diabetes for a number of years and no-one has 
ever had a problem with him being on beta blockers. He 
tells you that he would rather continue with the beta 
blockers as they are probably helping with his ischaemic 
heart disease, AF and blood pressure. 
Which ONE of the following would you now do? 
A r-c0-r1t1-11u-e-it1_e_discus-sionw.iit1it18-r;r:0-5c;;:iber:-Tri-ar:ci0r: ---1 
I to find out the patient's current blood pressure and I l .. he_9.rLr;;iJe_,______________ ____ _ .. __ ___ _ I 
B Dispense the prescription as written with appropriate 
counselling regarding monitoring of BSLs in diabetes. 
C I Continue the discussion with the prescriber, in order 
to find out the reason for the addition of the frusemide. 
...................... - ...... : .. - ..... - ........ _,_,, ___ .... _ ......... :- .... - .......... -·-·:·-.. -·---.. ·-: .. ·-·--.. ·-·-.. - .... - .... ·--·-:·--·-.. -:--.. -·---;---.... 1 
D I Continue the d1scuss1on with the prescriber, pnmanly J 
I to discuss the patient's diabetes management and to I 
[ 9_pJ9in..~Ltlb .. ~J..G_r.e§Mlt________________________ ___ __ _ ________ _j 
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When you are giving out the medications, the patient 
asks you if you know of any side effects of the new 
medications (the Avandia and the frusemide), as his leg 
swelling has only started in the last month. 
Which ONE of the following would you now do? 
A I Look up side effects of the two drugs in eMIMS. 
B I Tell the patient that the main side effects of frusemide 
! are based on fluid and electrolyte loss, and that those l qfrn§JgliJ9?:9n~9rnreJ9J~qJ9hyp9glyc;;i.emi;;i. , . ; 
£..l Contact the prescriber, primarily to find out the reason 
O"I ! for the addition of the frusemide. 
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o I Tell the patient that these are both well tested drugs 
and that side effects are rare. 
2d 
The doctor tells you that his diabetes control has 
gradually waned over the last three years, despite 
increases in his sulphonylurea dose. The patient's most 
recent HbA1c was 7.8%. The prescriber has added 
rosigli tazone as he understands it is supposed to be less 
likely to cause hypoglycaemia and weight gain. 
Which ONE of the following would you now do? 
A fAcceptihaTth_e.dlabetes coniroTisreasonai)-ieancT ·-- ·1 
I dispense the prescription as written with appropriate I 
Lc9YD.§~1Jing_ rnggr9ingm9nit.9ring _9t.!?SL§_in _ill?ReJ~§ , __ _l 
B Suggest alternative management of his diabetes 
this result indicates poor control. 
'
··-·····-···-····-·····-················-···············-····-·········-·······:··········-·····-························-····-····--········ .. ··············--········-·-·-····:·····-·-·····-;---··-····--·····-·-·-·-·····-·-·-··-······1 
c Suggest alternative management of his diabetes as I 
, adverse effects of his current management are i 
l_~vi9~nt ... _ -·-··-··-···--··-·· _ -··-·-·-----·- ---·----·-··----------·-! 
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Clinical Interventions in Austrl.alian Community Pharmacies 
You point out to the doctor, that although the patient 
may well have early heart failure, that there may be drug 
related reasons for the recent development of oedema. 
He asks you which of the patient's drugs would be most 
likely to have caused oedema, or caused early heart 
failure to develop. 
Which ONE of the following would you suggest? 
A Metoprolol is contraindicated in heart failure and may 
worsen the symptoms of early heart failure. 
s 1·rt1e····c;0n1t;ir1ati.on.0Tmetar;r:0ic;·1·anci .. cii·9·c;x·in .. m.a·y·be ····· 
1 causing bradycardia, which may exacerbate sub-l GUnig9Jb~9dJ9.iJ!d.rn .. 9n.9 .G._c::BJ.§_e cl in ica I oedema. 
c The rosiglitazone may be contributing to his oedema. 
.
r:;---·-·-.. -·-----·----· .. ·--·--·--·-·-··-·---·--.. ---·------.. -·-, 
D 1 The use of Aspirin, being a non-steroidal I I antiinflammatory agent, may contribute to his oedema j 
! I l..._,,,, __ ,,,, .... _,_,,, ___ ,,,_,_,_,_,,,,,_,_, ___ ....... __ , __ .,, .. , __ .... - ... - ...... __ . __ .. ,_ ........ - ....... -.......... _ ..,_ ................ _,,,,,_,,,_,_,_,,,,,, .. ,_ ............ ,_,,,,_,,,,,_ ............ J 
2f 
The prescriber is somewhat taken aback, as the patient 
has had diabetes for a number of years and no-one has 
ever had a problem with him being on beta blockers. 
The patient monitors his glucose often and finds that he 
does not get hypoglycaemic events very often. 
He tells you that he would rather continue with the beta 
blockers as they are probably helping with his ischaemic 
heart disease, AF and blood pressure. 
Which ONE of the following would you now do? 
A Continue the discussion with the prescriber, primarily 
to discuss the patient's diabetes management and to 
obtain a HbA 1 C result. 
B I You are happy with the doctor's explanation. Return 
to the case study to examine a different problem. 
c You are happy with the doctor's explanation. End the 
case here. 
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Clinical Interventions in Austr!,alian Community Pharmacies 
Avandia 
MIMS Abbreviated Prescribing Information 
Rostglitazone maleate 
GlaxoSmithKline Austrelia 
Section: §LIU Hypoglycaemic agents - Endocrine and Metabolk: Disorders 
Pregmmcy Category: BX. 
AOMC @ 
Permitted in spon 
~ Thiazolidmedione. Type 2 diabetes; monotherapy or+ autfonytureas Of metformin 
 Ovuhlti · · insulin resistance (eg µolycyshc OYaries), heart failure incl risk of: monrtor hepatic funciton , switching 
thefapyfrom tr one; moderate to re hepatic impairment. pregnancy, lactation. children 
!"""'-""'.-'""'"!"~-.c;;:ma. hepatic s; hypercholesterolaemia, anaemia , weight gam. others. Sff full PI 
La six 
MIMS ~bbrevlated Prescribing lnt;matlon J 
Frusemide • 
Ayentis Pharma 
Sect ion: .2{f) Diuretics - Cardiovascular System 
Product Images:~. Las1x M 20 mg 
Pregnancy Category: ~ 
ADAAC lll 
Bonned in soort 
UH.;. Loop dmrettc Oedema; hypertension, rapid diuresis (1nj) 
Oedema related to 
rosiglitazone use 
Contraindjcations· Renal shutdown, increastng azotaemia. oliguria: hepatic coma. electrolyte depleting conditions. sulfonamide sensitivity , 
severe untreated hypokalaemia, hyponatraemia, hypcwolaemia. hypotension. infants wi1h jaundice: bolus inj , ladation 
~Potassium supplementation. metabolic alkalosis; hepatic cirrhosis , ascites, hypoproteinaemia. seYere renal impairment 
concomitant curare, surgery; prolonged use, high doses, monitor fluids, electrolytes. caldum. glucose, renal function. prostatic hypertrophy, 
micturirion disorders. sodium restriction . diabetes: SLE. gout, elderly. pregnancy, premature infants 
Adverse Reactions· Electrolyte imbalance incl decreased K, Ca, Mg; ototoxicity; hypovolaemia, GI upset: dlzzinesa. rash: Jaund1ee. 
elevated transamtnases, haematological reactions (rare), others. see full PI 
~Cardiac glycosides, steroids; salicylates: neuromuscular blockers: lithium: antibiohcs. an1 icorwlsants: ethacrynic acid. 
cisplatin; NSA!Os, sucralfate (+/- 2 hours), other antihypertensives esp ACE inhibitors : others, see full PI 
A 
B 
-
Which ONE of the following would you now do? 
Provide the patient with copy of this information and 
ask him to go back to the doctor regarding his need 
I for frusemide. End the case here. 
Contact the prescriber to discuss the patient further. 
i 
..... ! 
3b 
The patient is concerned, because he knows that the 
Avandia is a relatively new drug and that it has some 
"nasty side effects", most importantly liver disease. 
He asks you if he could please have a copy of any 
information relating to this new drug. 
Which ONE of the following would you now do? 
A Look up side effects of Avandia in eMIMs and provide 
a copy to the patient. 
s 1·· feiTilim .. ii1at.tt18 . doctori·s-aware .aTih.eprat>Tems -witll 
i the Avandia and if he wants more information he 
l $0Q1,JIQJQ.IKJQ hi$ QQGtQL.J;ng th~ .~~~.~ h~r~ ~-
c I Reaffirm with the patient that the drugs are safe and 
! that the doctor is monitoring for any problems. 
l.J;:ri_Q.Jh~ .. .. ~.~.!?..~Lh~rn. ..................... .................... . ............. . . ..... __ ............ -- ··-·-·· ·-
·-1 
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Clinical Interventions in Austr!.alian Community Pharmacies 
The doctor is aware that his recent management 
requires improvement and it is for this reason that he 
has added the rosiglitazone. He doesn't feel that a 
month is enough time to give it a chance to show its full 
effect, and would prefer to continue for another month, 
with appropriate monitoring of BSLs and then he will re-
check the HbA1c after this. 
Which ONE of the following would you now do? 
A I Suggest that although rosiglitazone may improve his 
I diabetes management, there are more effective 1 
l __ 9.ltfil_rrn1LY~§~---------·--------------·-----·-----·-- _________________ J 
ru Accept the doctor's plan of action and dispense the 
! prescription as written with appropriate counselling 
l r_~_g_ill9Lo.g_mgnit9ri.ng __ 9t6.S.L§in 9J9.P.~J~§,. _ .... _ _ . 
C j Suggest that althoughrosiQlitazone-may_i_m_prove-his----, 
1 diabetes management, the rosiglitazone may be I 
l_Qau§Log_f!n-1!9.Y.~J§~ _~ff~.Gtlbfilr~g1,.1j_r~§. m9.mm~m~_o1._I 
3d 
The doctor does not think that his oedema is related to 
his beta blocker, heart rate or aspirin use. His last blood 
pressure was 148/98mmHg and his heart rate was 
65bpm. He intends to continue the metoprolol, digoxin 
and aspirin unless there is a valid reason to re-consider 
their use. 
Which ONE of the following would you now do? 
A I Continue the discussion with the prescriber, primarily 
to discuss antihypertensive management. 
s 
1 
Acc-ept ·1ile <:iaciar;s pia11· oTa-ciia·n a r1ci ciispenseiile- -- 1 
I prescription as written with appropriate counselling 1 
Lrng9_rg_ing _mgnit9ri.o_g_9fJ~$.L§.in .9.i.9..P~J~§ ,__ __ ···········--- ___ J 
c The rosiglitazone may be contributing to his oedema. 
DI Continue the discussion with the doctor in order to I 
j find out more about the patient's other medical I 
L. P.I.QQl~m.§, ___________________________________________ J 
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You discuss the issue of cholesterol with the patient. 
He tells you that he has had several cholesterol tests in 
the past, and his doctor is amazed at how good his 
levels are, given his weight. His last test was only last 
month, when he started the new antidiabetic medication. 
He maintains a healthy diet as much as possible, but 
has found it difficult to lose any weight. 
Which ONE of the following would you now do? 
A rReassure-the-patie-ni-iti-at -his-·cholesteroi is-being. -
I managed appropriately and to continue his healthy 
l_qJ~t_ B.e.tYr_n_JQ C.~§~JQ_ §.e.J~~t_c:,1n9the.rl§_i;;ye., _ __ _ _ . 
B I Contact the doctor to suggest the addition of a HMG 
Co-ASE inhibitor to the patient's management. 
····-······-········--- ................... -............. _ ............................................................................................................................ ···················-·····-······· .. £J Advise the patient that there are some new anti-
°' I obesity agents available and that he may wish to 
~ L9L~G~_$§_1b_~_$.§_ W.i1hbl$. QQGtQL. . -·-·· 
";I; D End the case here. 
lO 
ro 
3f 
You discuss the issue of digoxin blood levels with the 
patient. 
He tells you that he has only ever had one or two levels 
since he started digoxin around 4 years ago. The patient 
finds that when he goes to the doctor, he is mostly 
concerned about his heart rate. His last heart rate that 
he can remember is 65bpm. 
A 
Which ONE of the following would you now do? 
Reassure the patient that his digoxin is being 
managed appropriately and reconfirm that he is aware 
of digoxin adverse effects to look for. Return to Case 
to select another issue. 
s 1 contaciille-C!o-ciariosu99-85i._a_di_9oxinleve1-asllis----, 
heart rate is too low for someone with AF. 
-····-·····-········-······-······-······- ·············-·····--·-·······--·-·····-·· ... ·········•···--- ·······-·-·····-·····--···-··--·--·- ____ j 
c rconiaci"ille·d-o-ciorio-sugge-sta--digoxi-nlevef asthere ___ l 
i have been significant reductions in the reference 
[ _r:gng~_§_Lo __ m_g_§LL9.R9-rnJgri~_§_,_______ ______________________ _ ___ , 
D End the case here. 
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Clinical Interventions in Austltalian Community Pharmacies 
The doctor does not agree that anything other than 
insulin would be more effective than an insulin sensitiser 
such as rosiglitazone and does not wish to alter his plan 
of management unless there is a specific reason to do 
so. 
Which ONE of the following would you suggest? 
A 1··· AcceiJtiile··· a0c;10r:;spia_n_ot aciion.ana····a;spense··1119 
I prescription as written with appropriate counselling 
Lceu~m;fJn.g _mooJ1Qr.ing _oL6_$_L§_in 9i9.l.?~Je§ , ___ _ __ _ __ 
B rs_u-ggest- thatafihoug-h-rosigllta~o~e- may- improvehis ····· 
i diabetes management, the ros1gl1tazone may be 
LG.~.HJ§ilJ9Jl.0-9o_verne_~Jfe-9Lth9-tJ_~qqJrn_§ m9-n9-germmt . 
4b 
You point out that he has a history of AF and is currently 
managed with digoxin, metoprolol and aspirin. His 
current heart rate is 65bpm and he is still in AF. 
The main issue you have with his AF treatment is which 
of the following? 
A fHi-s ileart·r:·aie.silolllcTt>esiower, anci-ilisciose-ot - -- - , 
I digoxin or metoprolol should be increased, or a CCB 
t_§QQqJg p_~_ ggq~g ' -- --- -·- ---- - - ------ _________________________ ) 
_ru !he fact that he is still in AF means his treat~ent is ! 
1 inadequate and he should commence on am1odarone ! 
L.in_pr_~f~rnng~J.9Jhe __ q!gg_xin,__ _ --· -----------·----·-------- _ _j 
c Given his risk factors for stroke, he should be fully 
anticoagulated. 
D His AF management is fine, select a different problem 
to discuss. 
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Clinical Interventions in AustJalian Community Pharmacies 
The doctor is aware of the patient's current weight and 
cholesterol and the impact of these factors on 
cardiovascular disease. He is monitoring the cholesterol 
level and the patient's weight closely, and does not feel 
that either of these factors warrant drug treatment at this 
stage. He is hoping that with improved glucose control, 
that his lipids may be even better controlled and that his 
weight may fall. 
Which ONE of the following would you suggest? 
..8.J Accept the doctor's plan of action. Reassure the 
patient. Return to case to select another issue. 
B I End the case here. 
-
4d 
The doctor is aware of the requirement for digoxin 
monitoring and the recent change in reference range of 
digoxin in most laboratories. He points out that the 
reduced range applies to patients with heart failure 
without AF, and that the levels have not been reduced 
as markedly for AF patients. He is aiming to maintain his 
heart rate below 70bpm with his current digoxin and 
metoprolol therapy. 
Which ONE of the following would you suggest? 
A I Accept the doctor's plan of action. Reassure the 
patient. Return to case to select another issue. 
B I End the case here. 
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Clinical Interventions in Austt+.alian Community Pharmacies 
You have identified one of the major 
problems in this case study. 
• He has hypertension that requires 
improved management. 
Which ONE of the following recommendations do you 
think would be most appropriate? 
A I Increase his dose of metoprolol to 1 OOmg bd and 
! ..JD.9Dil9LSE,_ ............  
B I Add verapamil at a dose of 160mg daily and monitor 
I BP. 
L-·-······-·····-······-·-········-·-············-········-··-···- ............... ··············································-·····-·-··-·············-··········-······· 
Add perindopril at a dose of 2mg daily and monitor 
·····-······-······-············-··············-····· ...................................................................................................... ·········-···········-·····-······· ·················-········ 
D ' Add bendrofluazide at a dose of 1 Omg daily and 
UTI9-r.JJ19Ll?.E,_______________ _ --·----· __ ·-·-- . __ --· 
E I Increase the dose of frusemide to 80mg each 
.... ! 
! 
UI!QrnLo_g ,______ __ ___ ________ ------········---·- ......... _ ___________! 
Are there any other problems you wish to address in 
this case? 
-·-····-- ··-----------··1 lr······················-·············-··-····················-·····-···-·1 2 j Yes, return to i 
l_g§_§_~_§tq_qy_ _ ___ _] 
__ GQ.§~ . .h~.r~ -----·-· 
5b 
_l_ 
You have identified one of the major 
problems in this case study. 
• He has oedema, for which the doctor 
has prescribed frusemide, and this may 
be induced by rosiglitazone. 
Which ONE of the following recommendations do you 
think would be most appropriate? 
··········-·····-··········-·····-·····················-····-············;·····-···:···········-···········-·····-··········-·············-······--·················-··:·····-·--····················-·-·····-··---···-·········--···-···-··-·-···-···········1 
A I Cease the ros1glltazone and substitute acarbose to i 
Lm~n_9g~hl§Ql9t>~J~§ , ___ _ __ ·----- _____________ .! 
l······················-···································-·················-························································-··············-····-··················-·············-········-···········-··--·-·-··-·-··-····---·········-·-·-··---·····-···-1 B Reduce the dose of rosiglitazone and see if his 1 L9.~9~m.9. .im.P.rnY~§ , ··-·- _____ __ _ _________________ ! 
c ! Cease the rosiglitazone and substitute insuiinto - -I 
Ll!!?D9.Q~ _hJ§ _Qj§_Q~t~§,_____ __ _ _ ___ ___ _______ -------·---·- j 
··············-··········-········ . . ......... ... ...................... .. . . . ................................................................. _ ................... _ ............. ················-·-············-·········-·······--····· DI Cease the rosiglitazone and substitute metformin to 
1 
LrDQD?9~ .hi§ _Qi9-P_~t~§,________________ __ _ _____________ ___! 
E ~ ~~~~\ir~~~~tt~:~~~~~1!~~~.::~::~~~:'.'.ea~:'.~:~:~~~-~=~~~::~:J 
Are there any other problems you wish to address in 
this case? 
r .. -·····-·-·····- .......... ·-···-·····-·····-···-·-·--···-··1 
1 II No finish the I 
! .. G9..§_~_ .h~I~ ·············-····.J 
r-·-----······-·--·--···----1 
2 Ii Yes, return to I 
I I L.9_(!§~ _.§.tl,l_Qy ___ J 
Clinical Interventions in Austrtalian Community Pharmacies 
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• 
You have identified one of the major 
problems in this case study. 
He has atrial fibrillation with significant 
other risk factors for stroke and should 
be fully anticoagulated. 
Which ONE of the following recommendations do you 
think would be most appropriate? 
A I Commence enoxaparin and warfarin , cease the [ 
l .. ~o-9~9J213-rio _ _w._b~n_w.9_rf<!rln _r_12;:!gb.~§ _9_Jh~m.R.~ldJlgJNJ3. .. J 
B [~~~;~~t~:.~~:t;ii~~~~~ ~~:~::~~~~i~::~:~- 1~:~ 
.................................................................................................................. ..................... ... 
C I Add clopidogrel to the aspirin , this is much safer than 
L;:!99Jng w9r:f_grin., .. ··············-············-······ .............. ................. .......  
D Commence warfarin and continue aspirin. 
' 
......... , .. ,_, __ .. ,, ... __ .. ,,_, __ ,,,,_, __ ,,,,_,_,,,,,.,,_, __ ,,_,_,_,, ___ ,,,,,_ .................... _,_,,,,,_,,,,,,,,_,,,,,_ ................ _ ................ _ ............... ,_ .. ,,, .. ,_, ............... _.,,,,_ ......... , 
E Substitute clopidogrel for the aspirin and this should 
LPE2§_~..fflgl~[l_t_ __________ ._,____ .. -· .. -
°' Are there any other problems you wish to address in 
~ this case? 
-0 
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1 1·Notinis-t1t11-e -1 
! .. ..9-9...§? _b.~I!L _ ............ J 
Yes, return to 
case stud 
6a 
54year old man with diabetes, hypertension, oedema, 
unstable angina and atrial fibrillation. 
Prescribed 
•Rosiglitazone 4mg bd 
•Frusemide 20mg m 
•lsosorbide Mononitrate 60mg m 
•Digoxin 125mcg m 
•Glyceryl trinitrate spray prn 
•Glibenclamide 1 Omg bd 
•Aspirin 1 OOmg m 
•Metoprolol 50mg bd 
Which of the following issues would you like to 
discuss next (besides those you have already addressed)? 
A I Blood pressure management 
s 1--u-se-ot "beta-·t>focl<ersin-ciiab-etes ______ --- ------------ 1 
Treatment of his AF 
Lipid levels 
Need for a digoxin level 
Need for regular liver function tests 
G I Diabetes management 
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:J 
Recommendations for Hypertension 
Management 
=:.. A Increase his dose of metoprolol to 1 OOmg bd and 
monitor BP. 
His heart rate is 65bpm and a further reduction may 
increase beta blocker symptoms 
B I Add verapamil at a dose of 160mg daily and monitor 
BP. 
His heart rate is 65bpm and in combination with his 
digoxin and beta blocker may cause bradycardia. He also 
already has oedema which could be exacerbated by 
verapamil 
r--·--·-·-·--------·------·--·-·-·-·----.... _ .. ______ .. _,_ .... _. ___ .. _____________ .. ____ ...... --.-· .. --.. -··-·-.. ·---·-·--·-·-.... , 
C I i Add perindopril at a dose of 2mg daily and monitor BP. ! 
1
1
· ACEls are the drugs of choice in diabetic patients with 1 
, hypertension due to their renoprotective effects. ; 
l.---·-------------·-·--·--·----···-··-·····-··--·····-·-------····--·-·--··-·····-·····-·····-···-····-··-··-··-·····-···-····---·-·-----·-··-·-·····-··-·--·-·-···-····-·..! 
D I Add bendrofluazide at a dose of 1 Omg daily and 
monitor BP. 
A lower dose than this may be suitable, but at this dose, 
thiazides may have adverse consequences on glucose 
management. 
r-----------------·-·-·--·---·--·-·--· .. ·----··--·----, 
CJ) E 
~ 
N 
I Increase the dose of frusemide to 80mg each morning. ! 
I Frusemide is generally considered too short acting to I 
I have a long-lasting effect on blood pressure and should i 
iJ 
ClJ 
lO 
ro 
I be reserved for management of oedema. l 
L.----·-·-··---·---------··-------·-·-·---····--·------·--··-·····--···-·-····-······-·····-·-··-............ .J 
1 Back to Case to find more problems 2 ii No finish the J t_g9se_h~rn _______ J 
7b 
Recommendations for Diabetes 
Management 
A I Cease the rosiglitazone and substitute acarbose to 
manage his diabetes. 
Acarbose would be less effective and is more suited to 
postprandial hyperglycaemia 
B Reduce the dose of rosiglitazone and see if his 
oedema improves. 
May be a suitable alternative, but his BSLs require 
improvement. 
~ ! Cease the rosiglitazone and substitute insulin to 
· manage his diabetes. 
Is a major lifestyle change, but may be suitable if oral 
therapy is proven ineffective. 
D I Cease the rosiglitazone and substitute metformin to 
manage his diabetes. 
This is the most appropriate initial step, with monitoring 
of renal function, BSLs and oedema. If ineffective, then 
insulin may be necessary. 
E 1 r-cc;·11til1Lie.tt19.rasi9iiiazone:·a-ria -fr-eai-ille_a_edema-as ·--·-1 
I required with frusemide. 1 
! A reversible exacerbating factor for heart failure should 
! be addressed wherever possible, rather than treating the 
I ! symptom. 
L1 1r =~~ ~~:t~~::~~~~:f;~;:~~= ~;~~=~;~~~~;~:~~:1 --·--2rf;j0-nn=rs-f1=ffle==r1 l__g_9se b~rE! ______ j 
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(J) 
,..... 
(J) 
..., 
-I (J) 
Recommendations for AF Management 
~- A I Commence enoxaparin and warfarin, cease the 
enoxaparin when warfarin reaches a therapeutic INR. 
Anticoagulation is not urgent, so no real requirement for 
enoxaparin to be used initially. 
O'I 
~ 
w 
iJ 
OJ 
\0 
ro 
1""0-----------·----·-----------------·-·-···-··-·-----··-·--·--·---1 
8 II Commence warfar.in and cease aspirin when INR I l reaches therapeutic range. I 
I Aspirin would be more effective than warfarin in I 
I treatment of ischemic heart disease and so should be I 
I t" d I i con mue . I 
I I [._--········- ·····-·-····--··-·-············-·-···········-············- ······································································································-·····-···········- ·············-······-·-······ . 
C I I Add clopidogrel to the aspirin , this is much safer than 
adding warfarin. 
The combination of clopidogrel and aspirin is not as 
effective as full anticoagulation for the prevention of 
stroke in patients with AF. 
D I Commence warfarin and continue aspirin. 
This is the most appropriate recommendation. The 
combination of aspirin (for his IHD) and warfarin (for AF) 
would reduce his stroke risk optimally. 
E 1 i SubstituteCiopjdogrelfor thea-spi-iin-and this should be 
I I sufficient. 
I I Clopidogrel is unlikely to be more effective than aspirin 
1 in stroke prevention in AF, and is less effective than 
I warfarin. 
I \ w~~~~'.~~~:E1 - 2r:!~~:~1 
l 
End 
You have now completed the case study. 
The patient were three major drug related 
problems to address. 
1. He has oedema which may be induced by 
rosiglitazone. This may be alleviated by 
changing to an alternative oral antidiabetic 
agent , preferably metformin. 
2. He has hypertension that requires 
additional management, preferably by the 
addition of an ACE Inhibitor. 
3. He has atrial fibrillation and based on his 
risk factors for stroke, he should be 
receiving warfarin for AF in addition to 
aspirin for IHD. 
• Other issues in this case may be pursued, 
but your score for the case is based on the 
identification of these three problems and 
the recommendations you made to 
address them. 
Your Score for this case is: I •••••• 0/o 
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9.10 APPENDIX 10: PROMISE STUDY PHARMACIST 
DEMOGRAPHICS QUESTIONNAIRE 
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Demographic for on-line validation 
Section 1 About you and your background 
The following information is important to enable us to determine how your 
background influences the way the intervention scenarios are classified . 
Gender 
Male 
Female 
Age (years) 
<20 
20-25 
26-30 
31-40 
41-50 
51-60 
over60 
Your Education Background 
Year of Graduation 
Please enter the year you completed your undergraduate pharmacy degree. 
Not yet graduated (l ink to section Undergraduate 
Pre-registration Training 
Where did you undertake you pre-registration training 
o Community pharmacy 
o Hospital pharmacy 
o A combination of Community and Hospital pharmacy 
o Other (please specify) _________ _ 
Have you since gained any further clinical qualifications 
o Yes (please specify) _____________ _ 
o No 
Are you accredited to conduct medication reviews 
o Yes 
o No 
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Practice Profile 
Please enter the number of full-time years in each different practice setting 
Practice setting <2 years 2-5 years >5 years Nil 
Community pharmacy 
Hospital pharmacy 
Medication reviews 
Other (please specify) __ 
Have you worked in pharmacy outside Australia? 
o No 
o Yes 
Continuing Education 
How many hours of CE/CPD would you complete, on average, each year 
o <10 hours 
o 10-25 hours 
o 25-50 hours 
o >50 hours 
o Don't know 
o None 
Section 2. About Your Main Area of Work 
The following questions relate to the practice setting where you spend the majority 
of your time practicing as a pharmacist. 
1 Main Area of Current Practice 
Please indicate the ONE area of practice where you spend the majority of your 
time practicing as a pharmacist. 
o Community pharmacy ( link For community pharmacists 
o Hospital pharmacy (link For hospital pharmacists 
o GP division liaison pharmacist {link Other 
o Medication Reviews {link Other 
o University or other tertiary educational institution (link Other 
o Other (please specify) {link Other 
NOTE: this is where questionnaire divides between hosp/community 
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For community pharmacists 
What is your current role in community pharmacy 
l:l Owner 
l:l Employee 
l:l Locum 
l:l Other 
--------~ 
2 How long have you worked in your current position 
______ years 
3 When you work in this area, what proportion of the time do you do so 
l:l Full-time 
CJ Part-time 
l:l Other ___________ _ 
4 What is the post code of the main area where you work 
5 When you are at work, how many other pharmacists also are present at 
your practice at the same time? 
l:l None, I am the sole pharmacist 
l:l One other pharmacist 
CJ 2-4 other pharmacists 
l:l 5 or more other pharmacists 
6 How many hours do you work at this practice on average per week? 
<10 hours 
10 to 20 hours 
20 to 40 hours 
over 40 hours 
7 Of this time what proportion is spent on administrative tasks 
l:l <10% 
l:l 10-50% 
l:l 51-75% 
l:l >75% 
8 On average, approximately how many prescriptions would you dispense or check 
per hour at work? 
Peter Tenni 
1-9 prescriptions per hour 
10-15 
16-20 
21-30 
31-45 
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Over45 
Not appropriate to my area of practice 
For hospital pharmacists 
1 What proportion of your time relates to clinical activities 
0 <25% 
0 25-50% 
0 50-75% 
0 >75% 
2 How long have you worked in your current position 
______ years 
3 When you work in this area, are you working 
o Full-time 
o Part-time 
o Other 
4 What proportion of clinical interventions wou ld you currently document 
0 <25% 
0 25-50% 
0 50-75% 
0 >75% 
5 When you are at work, how many other pharmacists also are present at your 
practice at the same time? 
o None, I am the sole pharmacist 
o One other pharmacist 
o 2-4 other pharmacists 
o 5 or more other pharmacists 
Other 
1 Do you also spend time in any other area of pharmacy practice 
o Yes 
o No (go to opinion section) 
On average how many hours per week would you spend in this second area of 
practice 
o <10 hours 
o 10 to 20 hours 
o 20 to 40 hours 
o over 40 hours 
Is th is time spent in 
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CJ Community pharmacy For community pharmacists 
CJ Hospital pharmacy For hospital pharmacists 
CJ Other _____ _ 
Undergraduate 
Which year of pharmacy will you be completing in 2005 
CJ lst year 
CJ 2nd year 
CJ 3rd year 
CJ 4th year 
CJ Other (please specify) ________ _ 
What area of pharmacy practice do you see yourself working in, in five years time 
CJ Community pharmacy 
CJ Hospital pharmacy 
CJ Research 
CJ Other (please specify) ________ _ _ 
CJ Not working in pharmacy 
Thankyou for taking your time to complete this survey 
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9.11APPENDIX11: PROMISE STUDY VALIDATION 
SAMPLE SCENARIOS 
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Scenario 1 
A regular patient comes in with repeat for metformin 500mg 1g three times a 
day. You notice from the dispensing history that it has been 7 weeks since he 
last had this script filled . Your discussion with the patient reveals that he has 
been taking tablets only when sugar is high. You explain to him the disease 
process of diabetes and provide information on metformin. You recommend 
he start taking the dose prescribed by the doctor and go and see the doctor 
soon to have his HbA1C measured . 
Categorisation 
Compliance - taking too little 
This gentleman has been prescribed the correct drug at the correct dose, but 
has chosen to not take the medication as prescribed. This may be because 
he is confused about the need for regular intake of this type of medication, 
because he is forgetful, or he has simply chosen to take tablets as 
infrequently as possible. The correct categorisation of this intervention based 
on the information supplied, as most people have indicated would be 
'Compliance - taking too little' 
The actions recorded for this intervention should include 
lnvestiqation - patient history 
Discussion with patient or carer 
The recommendations made by the pharmacist 
Education/ counsellinq session 
Referral to prescriber 
Monitorinq - Laboratory test 
Significance 
Moderate 
The perceived level of significance of this intervention has varied greatly, 
ranging from low to high, and a case could be argued for each. It is perhaps 
not unusual for a person to skip tablets, but the likelihood of this action 
causing hospitalisation in the near future is low. It is more likely to require a 
visit to the prescriber and therefore should be documented as of moderate 
significance. 
Who detected the problem 
The problem was detected through pharmacist intervention. The pharmacist 
identified that the patient was taking sub-optimal doses due to compliance 
issues. In this situation the long term benefits of the intervention would be 
significant and could include cost saving to the patient and the broader health 
system by avoidinq the complications of diabetes. 
Scenario 2 
A 55 year old man with diabetes and ischaemic heart disease presents a new 
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prescription for sildenafil (Viagra) 50 mg. His other medications include 
isosorbide mononitrate, metformin, glipizide, amiodarone, aspirin , perindopril 
and metoprolol. You are aware that sildenafil should not be used with nitrates 
You contact his doctor and discuss the situation and suggest that the Viagra 
is ceased and an alternative commenced 
Categorisation of the situation 
Drug selection - interaction with existing therapy 
In this scenario , a prescription has been presented for a drug that potentially 
could interact with the gentleman's existing therapy, and should be classified 
as 'Drug selection - interaction with existing therapy', as many people have 
done. By definition , this is not an adverse drug reaction as he has not taken 
the interacting drug and is therefore not displaying any adverse effects or 
symptoms. Categorising th is situation as 'Drug selection - other' would be 
satisfactory if the details of the problem were specified in the notes section . 
The actions recorded for this intervention should include 
Contacted prescriber 
The recommendations made by the pharmacist 
Prescription not dispensed 
Refer to prescriber 
A change in drug 
Significance 
High 
This combination of drugs is contra indicated and can lead to very serious 
consequences if they are taken together. For this reason, it is reasonable to 
indicate that this intervention is of high significance. 
Who detected the problem 
In this situation the pharmacist identified the potential drug interaction with the 
patient's current therapy. The avoidance of the drug interaction provided 
significant benefits to the patient. 
Scenario 3 
A prescription for a 12 year old boy for amoxycillin 250mg/5ml, 4ml three 
times a day for acute otitis media. You check the dose in the product 
information and find that it is meant to be 500mg three times a day. You 
discuss the situation with the boy's mother and contact the prescriber, you 
suggest that the dose is increased. 
Categorisation of the situation 
Over/underdose - dose too low 
Most people have categorised th is intervention correctly as 'Over- or under-
dose prescribed - dose too low' 
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The actions recorded for this intervention should include 
Investigate written material 
Contact prescriber 
Discussion with patient or carer 
The recommendations made by the pharmacist 
Dose change 
Significance 
Moderate 
If this antibiotic was taken at the prescribed dose it is likely that the infection 
would not resolve, and a repeat visit to the general practitioner would be 
required. For this reason, it is best to indicate this intervention is of moderate 
siqnificance. 
Who detected the problem 
The underdose of the antibiotic was detected by the pharmacist, the relevant 
patient factors were assessed by the pharmacist and a more appropriate dose 
of antibiotic was recommended . This pharmacist initiated intervention had the 
potential to prevent a further visit to the GP 
Scenario 4 
A 56 year old man comes into your pharmacy complain ing of drowsiness. He 
tells you he commenced mirtazapine one week ago and is currently taking 
30mg each night. His other medications include diazepam 1 Omg tds and 
temazepam 20mg at night. You discuss the situation with the patient and 
counsel the patient on the new medication and how it combines with his 
current medication. You recommend that he goes back to the doctor who may 
adjust the dose 
Categorisation of the situation 
Toxicity or Adverse reaction - cause by drug interaction 
This scenario is similar to scenario 2 in that there are potentially 2 interacting 
drugs, but in this case the two drugs have been taken and have caused an 
adverse effect or symptom. Therefore the most appropriate categorisation is 
'Toxicity or Adverse reaction - caused by drug interaction'. We are unsure if 
the patient was instructed to start at a half dose of mirtazapine to minimise 
side effects such as drowsiness, or exactly how much of each benzodiazepine 
he is taking. It is not appropriate to document this intervention as 'Drug 
selection - duplication' as the druqs are not of the same therapeutic class. 
The actions recorded for this intervention should include 
Discussion with patient or carer 
The recommendations made by the pharmacist 
Refer to prescriber 
Change in dose 
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Significance 
Moderate 
The significance of this intervention is probably not high; it is unlikely that the 
patient would need to be hospitalised due to the excessive drowsiness. 
Moderate would be the most aooropriate level of clinical siqnificance. 
Who detected the problem 
The patient comes into the pharmacy complaining of drowsiness, although 
they are unaware of the cause of the problem they clearly communicated that 
there was a current problem. The role of the pharmacist in this intervention 
was to identify the probable cause and advise appropriate actions. The 
pharmacist was able to help resolve the problem but they were less involved 
in the initial detection of the problem. 
Scenario 5 
A 65year old woman presents a prescription for prednisolone 5mg daily for 
management of polymyalgia rheumatica. She is frail and appears to weigh 
approximately 45kg . Although she tells you that she is taking calcium 
supplements, you believe she is still at risk of osteoporosis. You consult their 
dispensing history to estimate how long she has been taking prednisolone. 
You discuss your concerns about osteoporosis with the patient. You 
recommend that she goes to see her doctor for further the assessment of 
osteoporosis risk, including bone density scanning , and the potential for 
commencinq additional preventative therapy. 
Categorisation of the situation 
Untreated indication - condition not adequately treated 
This scenario has drawn a large variation in responses, but the most 
appropriate categorisation would be 'Untreated indication - condition not 
adequately treated'. The majority of respondents categorised the intervention 
correctly as an 'Untreated indication', but only 15% as a 'condition not 
adequately treated'. It could be argued that this intervention does fit into 
either category quite satisfactorily, and this is confirmed by referral to the 
scope notes. Some people suggested that monitoring is required, for 
example a bone densitometry test, but this is probably a recommendation as 
opposed to the category of intervention. It could also be argued that the lady 
only requires disease management advice regarding her diet and lifestyle 
activities. 
The actions recorded for this intervention should include 
lnvestiqation; patient history 
Discussion with patient or carer 
The recommendations made by the pharmacist 
Refer to prescriber 
A chanqe in druq = additional preventative medicine 
Monitorinq; laboratory test 
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Significance 
Mild 
The significance of this inteNention is probably 'mild - improvement in 
therapy or quality of life'. If left unchecked, the situation may lead to a 
hospitalisation post fracture, but not likely in the near future. 
Who detected the problem 
Identifying areas where preventative medicine should be included is an area 
where pharmacists can inteNene in a patient's therapy. Clinical judgement 
and skills are used to interpret the situation and in this case the multiple risk 
factors and make appropriate recommendations, such as testing and 
preventative theraov. 
Scenario 6 
An elderly male patient presents repeat scripts for diamicron and amaryl. His 
dispensing history shows patient has had diamicron for over 12months, but 
has only received amaryl in previous month. You are aware that amaryl and 
diamicron are both sulphonylureas. After talking with the patient you find he 
has been taking both the diamicron and amaryl for a month. You contact his 
doctor to determine if he intended the patient to take both medications. Your 
recommendation is to cease diamicron. 
Categorisation of the situation 
Drug selection - dupliaction 
This scenario is clearly a 'Drug selection - duplication' inteNention, as 
approximately 70% of responders have indicated. The patient has not 
reported any adverse effects from taking the combination, so this rules out the 
possibility of it being a toxicity problem. It could be a problem of patient 
confusion or misunderstanding of the doctor's directions, if the prescriber had 
advised the patient to cease the diamicron. 
The actions recorded for this intervention should include 
Investigation; patient history 
Discussion with patient or carer 
Contacted prescriber 
The recommendations made by the pharmacist 
A chanQe in druq = cessation of one sulfonylurea 
Significance 
Moderate 
The significance of this inteNention is probably moderate as a consultation 
with the prescriber for monitoring of the BSL/HbA 1 C is advisable. Many 
people indicated that this is of high significance and were probably concerned 
that the patient would develop severe hypoglycaemia requiring hospitalisation . 
The fact that he had already been taking the therapy for 1 month and has not 
reported any adverse effects, suqqests that it probably is not of hiqh 
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significance. 
Who detected the problem 
The patient presents repeat prescription to the pharmacist who interprets the 
information and determines that the request from the patient, to have both 
prescriptions filled , may not be appropriate. It is the pharmacist who detects 
that there is a problem and deals with the situation appropriately. 
Scenario 7 
A 61 year old , overweight, man has had Type 2 Diabetes Mellitus (NIDDM) for 
10 years and ischaemic heart disease (angina) . He has been prescribed 
gl ipizide each morning and metformin three times a day. He admits that he 
misses his medication sometimes (approximate ly 3-6 doses per week) 
because he simply forgets. You discuss the situation with the patient. As he 
often forgets to take his medication but seems to have a good understanding 
of why he should be taking the metformin and glipizide. You recommend that 
he start using a dosage administration aid in which a weeks worth of tablets 
can be arranged and act as a reminder to take those tablets . Also you remind 
the patient of the regular checks that a diabetic needs to have completed 
including blood tests. 
Categorisation of the situation 
Compliance -takinq too little 
This is clearly a compl iance problem and 'taking too little' the most 
appropriate selection . The scope notes clearly explain that 'difficulty using 
dosage form' is to apply to a physical problem with using a particu lar device, 
and does not re late to forgetfu lness. There is no indication that his prescribed 
medications are inappropriate, unless you fee l that tds dosing for an older 
gentleman was compl icating the issue. Monitoring (HbA 1 C) may be required 
to establish the extent of th is gentleman's non-compl iance (an 'action ' or 
'recommendation') but this is not the cause of the problem, as a few people 
ind icated. 
The actions recorded for this intervention should include 
Discussion with patient or carer 
The recommendations made by the pharmacist 
Commence dose administration aid 
Monitori nq laboratory 
Significance 
Mild 
The significance of this intervention is most likely mi ld. Explaining the 
importance of taking his medications regu larly and providing a dose 
administration aid will improve this qentleman's therapy. 
Who detected the problem 
The problem was detected by the pharmacist during counselling of the 
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patient. His forgetfulness may impact on other areas as well as his 
compliance but the pharmacists actions may assist the patient take his 
medications requ larlv and hence receive the full benefits of them. 
Scenario 8 
An 84 year old woman asks you why she has had oral thrush, you know that 
she is a chronic asthmatic using inhaled corticosteroids. You check her 
inhaler technique and notice that she does not inhale properly. You suggest 
she start using a large volume spacer device. You also give her a 
demonstration on how to use the device appropriately. 
Categorisation of the situation 
Education or information - demonstration of device 
In this scenario essential she requires a demonstration of her inhaler device to 
improve her techn ique, (Education or Information - demonstration of device) 
The majority of responders have ind icated the appropriate categories , but 
around 15% indicated that th is problem was a compliance problem as the 
person was having difficulty using the dosage form. Referral to the scope 
notes quite clearly instructs that this category is to be used when the person 
has a physical problem with the device eg arthritis limiting the use of the 
inhaler, not just using the device inaoorooriatelv. 
The actions recorded for this intervention should include 
Discussion with patient or carer 
The recommendations made by the pharmacist 
Education/ counsel linq session 
Commence dose administration aid 
Significance 
Mild 
The significance of this intervention could be regarded as mild or moderate, 
as most people have indicated . If left unchecked, the patient may have 
requ ired a visit to her GP, but at the very least the treatment of her asthma 
has been improved. 
Who detected the problem 
The patient requests further information on oral thrush and the reasons why 
they have had it. The pharmacist was able to determine one of the causes of 
the problem; poor inhaler techn ique and recommend appropriate cause of 
action. The initial presentation was initiated by the patient and therefore it was 
a reactive behaviour on the part of the oharmacist. 
Scenario I 
An 82 year old lady presents with script for ventolin inhaler one to two puffs 
fou r times a day when requi red . During counsel ling, you discover that her 
rheumatoid arthri tis is preventing her from actuating the inhaler. After 
discussinq the situation with the patient you decide to contact the orescriber 
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and suggest that th is lady may be able to more effectively use a different type 
of device to control her symptoms, for example an autohaler. 
Categorisation of the situation 
Compliance - difficulty usinq dosaqe form 
Quite clearly, this intervention should be categorised as 'Compliance -
difficulty using dosage form' as most people have indicated . It could be 
argued that the doctor cou ld have prescribed a different device that would 
have been easier for her to use (Drug selection - incorrect or inappropriate 
dosage form) as the inhaler device is clearly inappropriate for this person. A 
demonstration of the device is still not going to enable her to use it 
satisfactorily, so 'Education or Information' is not going to assist the patient to 
become more compl iant. 
The actions recorded for this intervention should include 
Discussion with patient or carer 
Contacted prescriber 
The recommendations made by the pharmacist 
Druq formulation chanqe 
Education I counsellinq session 
Significance 
Moderate 
The significance of th is intervention is mild to moderate. It is difficu lt to be 
more specific than this without additional knowledge of the patients other 
therapy, or knowledge of the severity of her asthma. 
Who detected the problem 
It was through counselling and discussion with the patient that the pharmacist 
was able to determine that there was a problem with thei r current therapy. 
The pharmacist was active in determining whether the patients current 
therapy was re levant and effective. In different circumstances the patient may 
have detected the problem for example if their asthma symptoms were 
worsening or they asked the pharmacist to demonstrate inhaler technique 
Scenario 9 
An 87 year old woman has been taking digoxin 125 micrograms daily for her 
atrial fibrillation for 3 years . Recently you have noticed that she is getting 
increasingly frail and may have lost weight. She presents a repeat 
prescription for digoxin. While you prepare the prescription she tells you that 
she has been having visual disturbance and wonders if she needs her glasses 
replaced. You recogn ise the possible side effect of the digoxin you consu lt the 
relevant software to confirm this. You discuss the situation with the patient 
and contact her prescriber. You believe that it would be best if the patient 
were examined by her doctor. In addition to this referral you believe that the 
patient should have laboratory tests to determine renal function and reduce 
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diqoxin dose 
Categorisation of the situation 
Toxicity or Adverse reaction - dose related 
In this scenario, the patient has noticed an adverse effect that can be 
attributed to her current medication therapy, although has not made the link 
between her visual disturbance and current medications. In assigning an 
intervention category, most people have indicated that the visual disturbance 
is a sign of 'Toxicity or adverse effect'. It could also be qu ite reasonably be 
categorised as 'Over- or under-dose prescribed - dose too high' as reference 
to the scope notes quite clearly explains that this category is to be used 
" ... where the dose is too high because of a particular parameter of the patient 
such as renal function. ", although the dose has been fine up until now. Some 
people have indicated that monitoring is required, and although this is true, 
this is a recommendation and not the cause of the pharmacist performing the 
intervention. 
The actions recorded for this intervention should include 
Investigation; software 
Discussion with patient or carer 
Contacted prescriber 
The recommendations made by the pharmacist 
Refer to prescriber 
Dose chanqe 
Monitorinq; laboratory 
Significance 
Hiqh 
The significance of this intervention is moderate to high. The patient felt that 
the visual disturbance was due to her glasses and may not have done 
anyth ing about it, and therefore may have been admitted to hospital. If she 
takes your advice, she wil l return to the doctor for perhaps digoxin levels , 
renal function tests and adjustment of her dose wh ich makes th is an 
intervention of moderate significance by definition. 
Who detected the problem 
In this situation it is the pharmacist who is able to identify the problem. 
Interpretation of the information presented indicated that the patient required 
assessment by their doctor to establish digoxin levels and renal function. 
Scenario 10 
A 45 year old man who is a regular patient of your pharmacy arrives for a 
repeat prescription of metoprolol for his hypertension . He has a history of 
asthma and tel ls you he has been using salbutamol inhaler 3 times daily in the 
last couple of weeks. He also uses a fl uticasone inhaler, 250mcg twice a day, 
and presents a new prescription for salmeterol. It seems that he is suffering 
from an increase in his asthma symptoms and th is could be due to the 
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metoprolol. You contact his prescriber with your concerns as an alternative to 
the metoprolol you suaaest a more suitable antihypertensive. 
Categorisation of the situation 
Toxicity or adverse reaction - caused by drug interaction 
This gentleman is displaying a symptom or adverse effect and therefore this 
intervention should be documented as 'Toxicity or adverse reaction - caused 
by drug interaction' . It could also be documented as 'Toxicity or adverse 
effect - other' as long as the details are specified in the notes section. Almost 
half of the responders indicated that this was a 'Drug selection' intervention. It 
could be argued that metoprolol is an inappropriate drug in an asthmatic and 
therefore should not have been prescribed, but reference to the scope notes 
indicates that these categories should be selected only "When there are no 
obvious adverse clinical effects ... " and there appears to be an adverse effect 
in this case. In fact , the patient has just seen his GP who has prescribed an 
additional asthma management medication, which indicates loss of asthma 
control. 
The actions recorded for this intervention should include 
Discussion with patient or carer 
Contact prescriber 
The recommendations made by the pharmacist 
A chanqe in druq 
Significance 
Moderate 
The significance of this intervention is moderate, as it will probably require a 
return visit to the GP. It is unlikely to require a hospital visit as he has been 
taking the metoprolol for at least a month , and has only been using the 
salbutamol three times a day. The deterioration of his asthma appears to be 
a slow process. 
Who detected the problem 
It seems that the patients asthma has worsened recently the pharmacist was 
able to identify that metoprolol may be a contributing factor to this . In this 
situation through counselling of the patient his increased frequency in reliever 
medication was detected. In combination with the new prescriptions it was 
proposed by the pharmacist to review the patients current antihypertensive 
medication . 
Scenario 11 
A 54 year old woman arrives at your pharmacy to collect her monthly 
omeprazole 20mg daily prescription. She mentions in the course of 
counselling that she takes it daily after breakfast, for convenience but she still 
has some reflux problems in the evening. You discuss her current problems 
and ways to reduce the incidence of reflux as appropriate, eg losing weight, 
eatinq smaller meals You encouraqe her to try takinq the omeprazole later in 
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the day to see if this resolves her current problems. You also advise her that if 
the trial is unsuccessful she should return to her doctor to discuss her therapy. 
Categorisation of the situation 
Untreated indication - condition not adequately treated 
This scenario received a wide range of categories allocated to it. The correct 
category is 'Untreated indication - condition not adequately treated', as 31 
respondents indicated . This is the reason the intervention was brought to the 
pharmacist's attention. The other suggested categories are more likely 
actions or recommendations that could be made to resolve the problem, for 
example changing the frequency of dosing to bd or the total dose taken at 
niqht. 
The actions recorded for this intervention should include 
Discussion with patient or carer 
The recommendations made by the pharmacist 
Refer to prescriber 
Dose frequency/schedule chanqe 
Education/ counsellinq session 
Significance . 
Mild 
The significance of this intervention is mild as the implementation of the 
pharmacists suggestions will improve the patient's therapy and/or quality of 
life and should not require a return visit to the GP to achieve 
Who detected the problem 
This intervention relates to inadequate treatment of the ladies current 
condition. The pharmacist is the person who has determined that their 
condition is not adequately treated. Although the patient was able to identify 
the worsening of symptoms the most significant problem was that their 
conditions remains under-treated. 
Scenario 12 
A 76 year old male patient presents repeat prescriptions for imdur, warfarin, 
clopidogrel, atenolol, ramipril , digoxin and frusemide. He mentions he doesn't 
need his amiodarone any more as the doctor has just ceased it. You are 
aware of the interaction between amiodarone and warfarin and on 
questioning ; you discover that he has not been asked to have follow-up INR 
testing. You phone his doctor to discuss the situation and recommend that 
INR testing be scheduled. During your explanation to the patient you also 
provide him with a medication profile which reflects the recent changes to his 
therapy. 
Categorisation of the situation 
Monitorinq required - laboratory monitorinq 
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It can be assumed that the patients INR had been stabilised while he was 
taking amiodarone, and it will therefore need to be readjusted now his 
amiodarone is to be ceased. INR monitoring will be required over this period 
to restabilise his warfarin therapy at an appropriate dose, therefore 
'Monitoring required - Laboratory monitoring' is the correct category. Drug 
levels of warfarin are not performed, the effect of the drug in the form of an 
INR test is carried out; hence 'drug levels' is not a suitable category. Ceasing 
one of these drugs is not going to lead to a drug interaction , and therefore 
"Drug selection - interaction' is not a suitable category in this instance. The 
amiodarone has just been ceased and no time has elapsed to allow the 
appearance of any adverse effect, therefore th is intervention does not fit 
under the 'Toxicity' banner. Hopefully the adverse effects will be avoided by 
prompt and appropriate monitoring. 
The actions recorded for this intervention should include 
Contacted prescriber 
Discussion with patient or carer 
The recommendations made by the pharmacist 
Monitorinq ; laboratory test 
Written summary of medications 
Significance 
Moderate 
The significance of this intervention is moderate to high . The patient is going 
to have to return to his GP for INR monitoring, and if the monitoring does not 
take place he may have a thromboembolic event which would lead to 
hospitalisation. 
Who detected the problem 
The pharmacist's ability to detect this problem relates to their knowledge of 
the drug interaction between amiodarone and warfarin. The monitoring 
recommended is essential to prevent a thromboembolic event 
Scenario 13 
A 56 year old woman with hypertension comes in to ask you about the change 
in her diuretic tablets (Hydrene). She brings in the bottle that was dispensed 
elsewhere and you note that the medication is hydroxyurea (Hydrea) . The 
medication is labelled as Hydrea 2 m and you find that she has been taking 
these for seven days. You contact her prescriber to make them aware of the 
situation and arrange a blood test for the patient. You provide the patient with 
the correct medications. 
Categorisation of the situation 
Druq selection - wronq druq 
Most people correctly ind icated that th is intervention shou ld be categorised as 
'Drug selection - wrong drug prescribed/supplied in error'. It is likely the 
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patient will develop symptoms if this therapy is continued, but there is no 
evidence that she has yet, therefore 'toxicity' is not an appropriate category. 
The category of 'Non-clinical' should be used for administrative type errors 
related to the script. 
The actions recorded for this intervention should include 
Discussion with patient 
Contacted prescriber 
The recommendations made by the pharmacist 
Druq chanqe - correct medication supplied to patient 
Monitorinq ; laboratory 
Refer to prescriber 
Significance 
High 
The significance of this intervention is high. The patient has been 
inappropriately supplied with a cytotoxic aqent instead of a diuretic. 
Who detected the problem 
The patient has detected the problem albeit after taking 7 days of the 
medication. The pharmacist reacts appropriately to the patient presenting the 
dispensing error. In this situation it is not due to the actions of the pharmacist 
that this problem was detected . 
Scenario 14 
The husband of a 76 year old woman brings in a script for amiodarone 200mg 
daily. You find that the script was last dispensed 2 weeks ago and question 
the early repeat. You find that the lady has been taking both Aratac and 
Cordarone for the last 2 weeks, thinking they are different drugs. You contact 
the prescriber to inform them of the situation, and you provide the patient's 
carer, her husband, with information about the generic medicine name of 
amiodarone 
Categorisation of the situation 
Drug selection - duplication 
Some people indicated that this intervention should be documented as 
'Compliance - taking too much'. Review of the scope notes for this category 
clearly states that "If the overuse consists of inappropriately taking two brands 
or forms of the same ingredient unknowingly, then use "Drug selection -
duplication". The duplication may have stemmed from the patients confusion 
or misunderstanding and this will need to be rectified . Monitoring for adverse 
effects may be required and this should be recommended , but at this stage no 
adverse effects have been reported. This eliminates the 'Monitoring' and 
'Toxicity' categories in this scenario. Categorising this intervention as 'Over-
or under-dose prescribed' is incorrect as the dose prescribed was correct. 
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The actions recorded for this intervention should include 
Discussion with patient or carer 
Contacted prescriber 
The recommendations made by the pharmacist 
A chanqe in brand 
Other written information 
Significance 
Hiqh 
When all parameters (patient age, 2 bradycardic agents, and long half-life) are 
taken into account, the significance of this intervention is high . 
Who detected the problem 
Through determining why the repeat was required after on ly 2 weeks the 
pharmacist was able to detect a problem with the patients comprehension of 
their current therapy - the duplication of two different brands of the same 
medication 
Scenario 15 
A 45 year old patient with chronic back pain was previously stabilised on 
tramadol 50mg qid. He brings in a new prescription for Tramal 200mg SR qid 
and tells you the doctor increased the dose as a result of his increasing pain. 
You contact the prescriber and recommend the dose be reduced to 200mg 
twice a day. 
Categorisation of the situation 
Over/under dose -dose to high 
Increasing the dose of tramadol in th is patient is an appropriate course of 
action , but the size of the increase and/or the dosage frequency is too much. 
There were many different categories selected , but 'Over- or under-dose 
prescribed - dose too high ' is the most su itable . The higher dose has not 
been taken yet, so no adverse effect can be noted, and the problem is not one 
of compl iance. It is not an untreated indication as the doctor has already 
addressed the inadequate treatment. 
The actions recorded for this intervention should include 
Contacted prescriber 
Discussion with patient or carer 
The recommendations made by the pharmacist 
Dose chanqe 
Significance 
Moderate 
The significance of this problem is at least moderate, and may be high 
depending on other medications and circumstances. The maioritv of 
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responders have indicated moderate or hiqh . 
Who detected the problem 
The pharmacist determines that the dose prescribed was too high and takes 
the necessary steps to resolve this issue. 
Scenario 16 
A 35 year old woman had been commenced amoxicillin 500mg tds 3 days 
previously for prophylaxis of infection after a dental extraction. She presents 
to the pharmacy to enquire about her swollen , increasingly painful jaw. You 
refer her back to the prescriber as it appears the infection has not been 
controlled, you believe a chanQe in antibiotic reQimen is required. 
Categorisation of the situation 
Untreated indication - condition not adequately treated 
As most responders indicated , this scenario should be categorised as 
'Untreated indications - condition not adequately treated ' She is receiving 
prophylactic antibiotics post dental extraction , but it appears to have not 
worked. Some people indicated that this was a 'Toxicity problem, but the 
presenting complaint is not an adverse effect of the medication, it is an 
apparent failure of the medication. It perhaps could be categorised as a 'Drug 
selection - other' problem, as long as it is accompanied by explanatory notes, 
as it appears that this may not have been the most suitable drug in this 
instance. Referral to the scope notes makes it clear that this is not a 'wrong 
drug' scenario. 
The actions recorded for this intervention should include 
Discussion with patient or carer 
The recommendations made by the pharmacist 
A chanQe in druQ 
Refer to prescriber 
Significance 
Moderate 
The significance of this intervention has been correctly listed as moderate by 
most responders, as the patient will require a return visit to the prescriber for 
additional treatment to rectify the problem. 
Who detected the problem 
The patient presents with a problem that the pharmacist then takes steps to 
resolve. It is the patient who initially identifies there is a problem. 
Scenario 17 
A 76 year old man with hypothyroidism presents with an order for thyroxine 
50mcg three daily and thyroxine 1 OOmcg three daily. On checking previous 
patient records and discussion with patient, you find that he is meant to be 
takinQ 150mcq daily. You contact the doctor to confirm the dose and correct 
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the prescription as appropriate. 
Categorisation of the situation 
Over/under dose - dose to high 
There is no indication in this scenario that the patient has taken any of the 
prescribed medication at this dose, therefore this is not a compliance problem. 
It is not unusual for a patient to be prescribed two different strengths of 
thyroxine to achieve the required dose; therefore this is not a duplication 
problem. The patient himself has not displayed any confusion about his 
therapy to this point, apart from presenting a 'script which might not be 
correct, so 'Education or Information' would not be the correct category in this 
case. Clearly the dose prescribed is too high based on previous therapy, and 
referral to the scope notes makes it clear that 'Over- or under-dose prescribed 
- dose too high ' is the most appropriate categorisation in this scenario, as 
80.2% of responders indicated. 
The actions recorded for this intervention should include 
Investigation; patient history 
Contacted prescriber 
The recommendations made by the pharmacist 
A change in dose 
Significance 
Moderate 
The sign ificance of this intervention would be moderate to high , considering 
the age of the patient and the size of the overdose. 
Who detected the problem 
The pharmacist was able to detect the problem with this prescription based on 
the information available to them. 
Scenario 18 
A 76 year old woman present with a new prescription for mirtazapine. She is 
currently receiving sertraline 1 OOmg daily. She was unclear about the doctor's 
instructions regarding the sertral ine, and was going to continue taking both 
antidepressants. You contact the prescriber to confirm their intentions, and 
advise the patient of the outcome. You discuss with the doctor that this patient 
may be suitable for an HMR. 
Categorisation of the situation 
Drug selection - duplication 
Th is scenario received a wide range of categorisation , but referral to the 
scope notes clarifies the most appropriate section , albeit in a long winded 
way. The largest number of people selected 'Education or Information -
confusion about therapy or condition' as the most suitable category, but 
referral to the scope notes directs that "If the confusion would have (or did) 
resulted in a change in compliance (either taking too much or too little of the 
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medication}, then an appropriate 'Compliance' code should be selected". 
Referral to the 'Compliance - other' scope notes directs "If the compliance 
issue results in two drugs of the same therapeutic class being taken 
inadvertently, then use 'Dupli cation"' . 'Drug selection - dupl ication' is 
therefore the most appropriate category for this scenario . 'Drug selection -
drug interaction ' can appear to be correct at first glance, but the scope notes 
clearly indicate "If the interacting drug is of the same therapeutic class as part 
of the patient's existing therapy, then use "Duplication"'. The patient has not 
taken the two drugs together therefore there are no adverse effects at th is 
point, so 'Toxicity' is not a su itable category. The doses prescribed are within 
recommended dose ranges therefore the dose prescribed of each individual 
druq is not too hiqh. 
The actions recorded for this intervention should include 
Discussion with patient or carer 
Contacted prescriber 
The recommendations made by the pharmacist 
Education/counsel linq session 
Refer for medication review 
Drug change - the relevant medication should be ceased 
Significance 
Moderate 
Most people indicated that the significance of this intervention was moderate 
which is most likely correct. If undetected, this problem was unlikely to result 
in a hospital admission , but may well have required a GP consultation 
Who detected the problem 
Without counsell ing of the patient the problem may not have been evident 
until the patient developed a symptom from whichever action they would have 
taken; cease both or take both antidepressants. The pharmacist was able to 
detect the patient problem. 
Scenario 19 
A 76 year old woman presents in January with a prescription for prednisolone 
that is dated January the previous year. You check with the doctor who tells 
you he wrote the wrong year on the script. 
Categorisation of the situation 
Nil - administrative only 
Most people agreed that th is scenario was basically an administrative error on 
behalf of the doctor, and correctly classified th is intervention as 'Non-clinical' . 
The signifi cance of th is intervention is 'Ni l - admin istrative on ly' 
The actions recorded for this intervention should include 
Contacted prescri ber 
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The recommendations made by the pharmacist 
No recommendation necessary 
Who detected the problem 
Most non-clin ical interventions resu lt in the pharmacist resolving some form of 
administrative task. In most cases the problem is self evident and easily fixed . 
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9.12 APPENDIX 12: PROMISE STUDY POST STUDY 
QUESTIONNAIRE 
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PROMISe Pilot Study; Post Study Questionnaire 
" PROMISe n: .. 
Pharmacy Recording of Medication Incidents an_d Ser-Yices 
electronic documentatio~ ~ystem 
PROMISe Project Pilot Study 
Post Study Questionnaire 
Section 1. Demographics 
Name: 
Pharmacy: 
1.1 Employment status: 
D Pharmacist 
D Full-time 
D Owner 
D Part Time/ Locum/Casual 
D Graduate Pharmacist 
School of Pharmacy 
1.2 Did you attend the education session re lating to this project, hosted by the 
University of Tasmania? 
D Yes D No 
1.3 Did you view the training presentation on the CD provided in the manual for this 
project? 
D Yes D No 
1.4 Did you undertake the validation case scenarios on the project website? 
D Yes D No 
Section 2. Documentation of Clinical Services 
2.1 Did you document your clinical services prior to this project? 
D Yes D No D Sometimes 
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PROMISe Pilot Study; Post Study Questionnaire 
If Yes , where did you document these activities? 
D Scraps of paper 
D Dedicated book 
D Patient file 
D On computer, i.e Notes section or previous intervention recording 
software 
D Other (please specify) _ _ _ _________ _ 
2.2 When you first heard about this project, what barriers did you perceive would 
prevent you from recording your clinical services? You may select more than one option 
D lack of motivation 
D workflow restrictions 
D lack of cl inical knowledge 
D forgetfu lness 
D lack of time 
D concerns about how the software would work 
D none 
D Other (please specify) _ ___________ _ 
2.3 During the PROMISe Pilot Study, approximately what percentage of cl inical 
services that you performed, do you believe that you documented? 
D 100% 
D 75% 
D 50% 
D 25% 
D 10% or less 
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PROMISe Pilot Study; Post Study Questionnaire 
2.4 What barriers did you find in recording your clinical services? 
You may select more than one 
D lack of motivation 
D workflow restrictions 
D lack of clinical knowledge 
D forgetfulness 
D lack of time 
D The software was difficult to use 
D none 
D Other (please specify) 
2.5 During the PROMISe Pilot Study, what factors influenced which of your clinical 
services you documented? You may select more than one option 
0 higher perceived importance 
0 availability of time 
0 presence of observer 
0 Other (please specify) ____________ _ 
Section 3. Time spent on Clinical Services 
3.1 During the PROMISe Pilot Study, what proportion of your time at work was spent 
involved in clinical services (either documenting or sorting out actual or potential 
drug related problems)? 
D Less than 5% 
D 5 to 20% 
D 20 to 50% 
0 More than 50% 
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3.2 During the PROMISe Pilot Study, how long (on average) do you think it took you 
to perform a single clinical service (including the documentation process) 
D Less than 1 minute 
D 2 to 5 minutes 
D 6 to 10 minutes 
D 11 to 30 minutes 
D More than 30 minutes 
3.3 During the PROMISe trial do you think you spent more time on clinical services 
than outside the trial 
D Yes 
D No 
3.4 Do you think being involved in the PROMISe trial increased the number of clinical 
services/ interventions you performed 
D Yes 
D No 
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Section 4. Payment for Clinical Services 
4.1 Do you believe clinical services should be remunerated? 
D Yes D No 
4.2 If payment for clinical services was implemented, rate each of the payment options 
below according to how much you would agree with that option. Also, please write 
an amount you think would be appropriate for each option 
4 21 A .. h h f payment to eac p. armacy or eac h 1· . c 1nica service d d ocumente . 
Appropriateness of payment model Amount 
I I I I I I I I I I I 
Strongly agree Strongly disagree 
42 2 A . . paymen t t h h . t f o eac p. armac1s oreac h I' . c 1nica service d t d ocumen e . 
Appropriateness of payment model Amount 
I I I I I I I I I I I 
Strongly agree Strongly disagree 
4.2.3 A payment to each pharmacy based on the total time spent on each 
clinical service documented. 
Appropriateness of payment model Amount 
I I I I I I I I I I I 
Strongly agree Strongly disagree 
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4 .2.4 A payment to each pharmacist based on the total time spent on each 
clinical service documented . 
Appropriateness of payment model Amount 
I I I I I I I I I I I 
Strongly agree Strongly disagree 
4 .2.5 A set, across the board , payment for each pharmacy for documenting the 
services, unrelated to number or duration of services. 
Appropriateness of payment model Amount 
I I I I I I I I I I I 
Strongly agree Strongly disagree 
4.2.6 An increase in the overall dispensing fee for all prescriptions to compensate 
for these "add on" services. 
Appropriateness of payment model Amount 
I I I I I I I I I I I 
Strongly agree Strongly disagree 
4.2.7 An increase in the dispensing fee for original (non-repeat) prescriptions, as 
th l'k I t th " dd ey are more 1 e1y o require e a on services. 
Appropriateness of payment model Amount 
I I I I I I I I I I I 
Strongly agree Strongly disagree 
4.2.8 An increase in the dispensing fee for prescriptions for drugs with a high 
frequency of clinical services (eq warfarin). 
Appropriateness of payment model Amount 
I I I I I I I I I I I 
Strongly agree Strongly disagree 
4.2.7 Any other payment system that you would propose (please specify)? 
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Section 5. Your general opinions relating to clinical services 
Place a cross anywhere on the line or tick the box to indicate your opinion on the following 
statements; 
5.1 Documenting of cognitive services helps to demonstrate the ability of pharmacists 
to improve medication therapy. 
D Unsure 
Strongly agree Strongly disagree 
5.2 Documenting of cognitive services helps to demonstrate the abil ity of pharmacists 
to reduce health care costs. 
D Unsure 
Strongly agree Strongly disagree 
5.3 Participating in this project made me more aware of I focussed upon identifying 
Drug Related Problems. 
I I I I I 0 Unsure 
Strongly agree Strongly disagree 
5.4 I believe that I would require an update in cl inical knowledge in order to optimise 
my ability to identify Drug Related Problems. 
I I I I I I I I I 0 Unsure 
Strongly agree Strongly disagree 
5.5 The cognitive service recording program was easy to use. 
I I I I I I I I I I I D Unsure 
Strongly agree Strongly disagree 
5.6 The sequence for documenting a cognitive service, including accessibility to the 
interventions screen , was logical and easy to follow. 
I I I I I I I I I I 0 Unsure 
Strongly agree Strongly disagree 
5.7 The Classification system and options were logical and relevant. 
I I I I I I I I I I I 0 Unsure 
Strongly agree Strongly disagree 
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Section 7. Further Comments 
If you wish to make further comments, regarding any aspect of the PROMISe Pilot Study, 
or any aspect of the software or training, please use the space below. 
If you would rather that these comments be treated anonymously, please separate this 
sheet from the rest of the survey and return it in the second reply paid envelope attached 
**********************End of Survey****************** 
Thank you for your time 
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**The following section was only included in those 31 pharmacies which had had 
exposure to the Aspirin drug alert 
Section 6 The aspirin drug alert 
The drug alert provided information to pharmacists about aspirin therapy in patients 
with diabetes mellitus. 
6. 1 My initial reaction to the pop-up was that it was an intrusion. 
Strongly disagree Strongly agree 
t Unsure 
6.2 I ignored the pop-up as it was of low importance to me. 
Strongly disagree Strongly agree 
t Unsure 
6.3 The message the pop-up attempted to convey was clear and easy to understand. 
Strongly disagree Strongly agree 
t Unsure 
6.41 thought the Pharmacist Information was well-presented, useful and easy to understand . 
Strongly disagree Strongly agree 
t Unsure 
6.5 I was concerned with the accuracy and evidence base of the information presented. 
Strongly disagree Strongly agree 
t Unsure 
6.6 I considered the information in the Patient Information Leaflet to be useful for the patient. 
Strongly disagree Strongly agree 
t Unsure 
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6.7 I feel comfortable to contact a doctor on a patient's behalf to discuss the need for aspirin 
prophylaxis. 
Strongly disagree Strongly agree 
f Unsure 
6.8 The pop-up message & associated material has increased my knowledge about aspirin & 
diabetes. 
Strongly disagree Strongly agree 
f Unsure 
6.9 These types of pop-ups/drug alerts are useful. 
Strongly disagree Strongly agree 
t Unsure 
6.10 Which ONE of the following is correct? The primary message of the pop-up was: 
D Low-dose aspirin is indicated for all patients with diabetes. 
D Low-dose aspirin is recommended for all patients with diabetes over the age of 50 
years OR between 30 - 50 years with ONE or more CVD risk factors AND no 
contraindications to aspirin . 
D Low-dose aspirin is recommended for all patients with diabetes over the age of 65 
years with ONE or more CVD risk factors AND no contraindications to aspirin 
P:\PROMISe\final report\Appendices\Final post pilot Questionnaire.docPage 1 Q Of 1 Q 
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9.13 APPENDIX 13: PROMISE STUDY OWNER AND 
MANAGER QUESTIONNAIRE 
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PROMISe ·:-:~:;_ 
Pharmacy Recording of Medication Incidents anq Ser.:v:ices 
electronic documentation ~Y~._!:em 
The PROMISe project 
The following questions include details about characteristics of your pharmacy. 
All information provided will remain confidential. 
Please mark in the appropriate box for each question and add details were 
requested 
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Section 1 About this pharmacy 
1 .1 The location of this pharmacy 
D Medical Centre 
D Local shopping centre (<25 shops) 
D Major shopping centre (>25 shops) 
D Strip 
D Hospital 
D Other (please specify) 
1.2 What is the approximate size of 
the pharmacy? 
D <100 m 
D 101-150 m2 
D 151-250m2 
D 251-500 m2 
D >500 m2 
1.3 How long have the current 
owner(s) owned this pharmacy 
----~ears 
1.4 When did this pharmacy become 
QCPP accredited? 
D Before 1 st Dec 1999 
D 1st Dec 1999 to 31st Jan 2001 
D 1 st Feb 2001 to 31 st Jan 2003 
D 1 st Feb 2003 to 31 st Jan 2004 
D After 1 st Feb 2004 
D Not yet accredited 
1.5 Is the pharmacy part of a 
banner/brand group 
D No 
D Yes, if so which group 
1.6 How many hours and days per 
week is the pharmacy open 
Total number of hours 
Number of days each week 
1. 7 Does this pharmacy supply an 
aged care facility 
o Yes 
D No 
Peter Tenni 
1.8 For each of the following 
categories , how many FTE (full time 
equivalent) staff work in your pharmacy 
in an average week 
FTE 
Pharmacists 
Graduate Pharmacists 
Dispensary Assistants 
Pharmacy Assistants 
1.9 On average how many 
prescriptions are dispensed per week 
by this pharmacy 
o <400 scripts 
D 400-750 
D 750 - 1250 
0 1250 - 2000 
0 >2000 
1.10 Has this pharmacy employed a 
pre-registration pharmacist within the 
last two years 
o Yes 
o No 
1 .11 What proportion of non-
pharmacist staff hold qualifications 
equivalent to or greater than Certificate 
II (Grade 2) 
o None 
o Less than 50% 
o Half of the staff 
o All or most of staff 
1.12 In the 2003/04 financial year what 
was your estimated annual turnover ($) 
o <1M 
D 1M - 2M 
D 2-3M 
D 3-4M 
D >SM 
1.13 The ownership of the pharmacy 
o Individual 
o Partnership 
o Corporate 
o Franchise 
o Other 
~-------
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1.14 Which of the following resources do you and your staff actively use 
in your pharmacy 
Resource Available Available used Not currently 
used regularly available 
occasional Iv (at least once a day) 
Australian Medicines Handbook 
APF 
Pharmacy Self Care 
Martindale 
eMIMS 
eAPP 
eAMH 
Therapeutic Guidelines 
Internet based drug information 
1.15 How would you rate the quality of your current computer hardware 
(eg screens, printers etc) 
0 Unsure 
Terrible Average Excellent 
1. 16 Which version of the Windows operating system do you currently 
use? 
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Section 2 Enhanced services offered by this pharmacy 
2.1 Services offered by this pharmacy 
Please indicate which of the following professional services are currently provided by this 
pharmacy 
Service Yes Is a fee Planning to No 
provided charged for implement 
this service 
Blood pressure monitoring Y/N 
Wound care 
Diabetes screening 
Weight management program 
Community Education 
Home med ication reviews 
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Section 3 Opinion based statements 
Please rate your level of agreement with the following statements 
3.1 This pharmacy is known for innovation among the pharmacies in the area 
D Unsure 
Strongly agree Strongly disagree 
3.2 Five-year plans for this pharmacy are a high priority 
D Unsure 
Strongly agree Strongly disagree 
3.3 It is our business strategy to avoid taking too many chances 
0 Unsure 
Strongly agree Strongly disagree 
3.4 Because conditions are changing we continually seek out new opportunities 
D Unsure 
Strongly agree Strongly disagree 
3.5 Our actions towards competitors can be termed aggressively competitive 
0 Unsure 
Strongly agree Strongly disagree 
3.6 Ideas for new services in the pharmacy from staff are supported by the management 
team 
D Unsure 
Strongly agree Strongly disagree 
3.7 The management team is closely able to predict the future needs of this business 
0 Unsure 
Strongly agree Strongly disagree 
3.8 There has been little change in our pharmacy over the last ten years 
D Unsure 
Strongly agree Strongly disagree 
3.9 The majority of staff in this pharmacy have worked here for more than 5 years 
D Unsure 
Strongly agree Strongly disagree 
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3.1 O If there were a <f(m<Y3n~Yt3~~ri'S~lfel1~ft!Sq5Wilr'ffl:H!~ ~~!prepared to take it 
on 
D Unsure 
Strongly agree Strongly disagree 
3.11 At this pharmacy it is primarily the management team who identify new business 
opportunities 
D Unsure 
Strongly agree Strongly disagree 
3.12This pharmacy and management encourages the development of innovative services 
D Unsure 
Strongly agree Strongly disagree 
3.13 We are aware and responsive to changes that other pharmacies in our area make 
D Unsure 
Strongly agree Strongly disagree 
3.14 At our pharmacy we are ambitious about the services we provide 
D Unsure 
Strongly agree Strongly disagree 
3.15 The best way to ensure a healthy future for community pharmacy in Australia is to ; 
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9.14 APPENDIX 14: PROMISE STUDY 
CONSEQUENCES TABLE 
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significant 
haemodynamicor 
myocarcfial 3 180 4.10 $3,641 4 $112 2 
comprications 
re:iu1ring 
hosp1tar!Salion 
Ocrult 
gastrointestinal 
bleeding likely ID 1 180 0.00 $0 1 $28 
re:iuire medical 
management only 
if persistent 
Overt 
gastrointestinal 
bleeding re:iuiring 2 60 1.68 $1,199 1 $28 1 
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$44 $268 ECG, Blocrls 
F70A,B;F71A, $192 $3,945 B 
$1,748 $1,776 Blocrls, 
endm:opy 
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Blocrls, $128 $1,748 $3,103 G61B 
endm:opy 
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cfigestive 06.02 5)'StErn 
cfgestive 06.03 5)'StErn 
cfigestive 06.03 5)'StErn 
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GaslroJntesti 06.0lSe.rere 
nal blea:!ing-
ConstJpafun 06.02M11d 
Constipation 06.02Moderate 
Consllpation 06.02Severe 
Gastrointesti 06.03M11d 
nalpain 
Gastrointesti 06.03Moderale 
nalpain 
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Overt 
gastrcintestinal 
bleroing With 
haem:ldynamic 
CDnsa:juence5 3 90 3.58 $2,477 2 $56 2 $192 - $2,725 G61A 
te:jlliring prompt 
me:lral 
management 
Mlkl9gnsor 
symptoms fikelyto 1 90 0.00 $0 0 $0 . $0 re:nlve without 
intavention 
Re:julling med'JCal 
management 
ancVor modJficaOOn 2 30 0.00 $0 2 $56 $56 
r:i me:lration 
regimen 
Re:iuiring 
h:lspitahsation and 
me:lral and/or 3 60 4.49 $3,158 4 '$112 $3,270 G65A,B 
surgical 
management 
M11d9gnsor 
symptoms likely to 1 180 0.00 $0 2 $56 $18 $74 Bloods re:nlve Wl!h:lut 
1ntaven!Jon 
Re:iuinng med'JCal 
management 8'"'da:mpy, 
ancVor modification 2 180 0.00 $0 5 $140 1 $128 $1,748 $2,016 
r:i med'ration Bloods 
regimen 
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Gastrointesti 06.03Severe 
nalpain 
Nausea 06.04Mild 
Nausea 06.04Modera!E 
Nausea 06.04Severe 
Diarrhoea - 06.05M11d 
Diarrhoea 06.0SModeralE 
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Re:iuinng prompt 
ma:fic:al 3 60 5.44 $3,628 1 $28 1 $128 $3,784 c:h7A management and · · 
investiaation 
Mild signs or 
symptoms hkelytn 1 7 0.00 $0 1 $28 $28 re9Jlve WJthout 
intavenbon • · 
-
Requiring mfffJCal -· 
management 2 14 0.00 $0 2 $56 $56 ancttor modlfica!Jon 
of ma:!JCation 
Re:iuinng 
hosprtarisation for 
significant 
vomiting-relata:I 3 30 3.12 $2,952 2 $56 $3,008 AVerciJe. 
ela:irotyte and 
hydration 
cnmphcations 
- -
Mild signs or 
symptoms hkelytn 1 7 0.00 $0 1 $28 $28 re9Jlve WJthout 
intavention 
Re:iuinng mfffJCal 
management 2 14 0.00 $0 2 $56 $56 ancttor modlfieation 
of ma:!JCation 
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06.05 Dianhoea 06.0SSevere 
Liver 07.01 Disre:e 07.01M11d 
Liver 07.01 Disre:e 07.0lModerate 
--
Liver 07.01 Disre:e 07.0lSevere 
08.01 Myopathy_ 08.0lMild 
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Re:juiring 
h:spilalisation fur 
significant 
vomiting-rela!B:l 3 30 3.12 $2,952 2 $56 $3,008 Average 
eledro!yte and 
hydration 
comprK:aliollS 
Mild liver cf15ea9e 
likely ID res:>lvt;? 
without 1 30 0.00 $0 2 $56 $56 
intavention 
Modaate r1Ver 
_ cflSeaSe re:iuiring 
mcxfdiration of 
medrations and 2 60 0.00 $0- 7 $196 1 $128' $18 $342 Bloods 
--
mecfral 
intayenbon 
Severe r!Ver 
cflSeaSe re:iuiring 
h:spilahsaoon and 3 90 6.70 $4,936 3 $84 1 $128 $5,148 H60A,B.C 
arute medral 
management 
Miki musde pain 
not re:iuiring 1 90 0.00 $0 2 $56 $56 
intavention 
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09.01 Rash 09.0lSevere 
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Moderate musde 
pain re:iuiring 
mcxldication r:i 
medJCabons 1 60 0.00 $0 4 $112 $59 $171 Bk:xxls,O< 
with::lutelevation in 
creatine kina!'E 
Severe myopathy 
-with ele.!ation of 
creatine kina!'E 2 30 0.00 $0 6 $168 $59 $227 Bk:xxls,O< 
raiuiring ce;sat:kxi 
cf mediration 
L..oc:ansa::t or mild 
symptoms which -
resp:ind to "over 1 15 0.00 $0 1 $28 _$28 
the counter" 
treatment 
Re::juiring mecfiral 
atlEntion and 2 60 0.00 $0 2 $56 $56 topical and/or oral 
systanic reatment 
Wdespread rash 
with signdi:ant 
consequences 
tajuiring 3 180 3.44 $2,166 4 $112 $2,278 J61Z 
hospllahsa!Jon and 
intraveoous 
systanictreatment 
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10.01 Diabetes lO.OlM1k:f 
10.01 Diabetes 10.0lModeratE 
10.01 Diabetes 10.0lSevere 
10.02 Ostroporosi 
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10.02M11d 
10,02 Ostroporosi 
s 
10.02ModeratE 
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Reduc:W control of 
cf!Sffi9:! re::iuiring 1 360 0.00 $0 4 $112 $18 $130 Bloods increasa'.I 
morntorinq 
Re:juiring 
mocfdicatbn of 
treatment regimen 
or significant 2 360 0.00 . $0 6 $168 . $18 $186 Bloods 
complicallons 
re::iuiring me:fical 
management 
· Complicati6ns of 
cfiabetes re::jUiring 3 360 5.78 $4,063. 6 $168 2 $4,231 K60A,B spe::iaflst me:lical 
at!Ention 1n hospital 
Wors:ning of Bone Densitome!Jy cflSEB9:! re::iuiring 1 360 0.00 $0 4 $112 $83 $195 item 12306-increasa'.1 12301, 
·m6nitoring 
Bloods 
Re'.juiring 
moddicatbn of · Bone 
. existing treatment Densitome!Jy 
regimen (e.g 2 60 0.00 $0 6 $168 . $83 $251 item 12306-
commencing 12301, 
treatment for an Bloods 
"at~· person) 
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nutntional 10.02 
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and 
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nutntional 10.03 
and 
metabolic 
encbaine, 
nutntional 10.03 
and 
metabolic 
encbaine, 
nutntional 10.04 
and 
~boric 
encbaine, 
nutntional 10.04 
and 
metabolic 
encbcnne, 
nutntional 10.04 
and 
metabolic 
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OstBJporosi 
s 
10.02Severe 
Hyperrak::ae 
mia 10.03Mild-
Hyperralcae 10.03Moderate 
mia 
Hyperrak::ae 10.03Severe 
mia 
Hypocak::ae 
mia _ l0.04M11d 
Hypocak::ae 
mia 10.04Moderate 
Hypocak::ae 10.04Severe 
mia 
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Resulting in 
hospitarlSalion due I60Z;I61Z;I62 to'amajor 3 90 10.7 $7,317 8 $224 $7,541 6 A,B 
a:imphc:ation (e.g. 
fracture) 
Mild signs or 
symptoms whidl 1 30 0.00 $0 1 $28 $28 re9:llve Without 
intavenllon 
Re:iuinng rne:lical 
management 
ancVor modlficatJon 2 60 0.00 $0 2 $56 $18 $74 Blocxls 
crmroication 
regimen 
Re:iuinng prompt 
mroical 3 90 3.12 $2,952 3 $84 $3,036 Average management and 
1n,~lion 
Mild signs or 
symptoms whidl 1 30 0.00 $0 1 $28 $28 re9:llve Without 
intavenlion 
Requiring mecfral 
management 
anc\for modlficatJon 2 60 0.00 $0 2 $56 $18 $74 Blocxls 
cr mroication 
regimen 
Requinng prompt 
mroical 3 90 3.12 $2,952 3 $84 $3,036 Average management and 
investirnlion 
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10.05 Hypel<alae 10.05M11d 
mia 
10.05 Hypel<alae 10.05Moderate 
mia 
10.05' Hype1<alae 
mia 10.0SSevere 
10.06 Hypothyrokl l0.06M11d ism 
10.06 Hypothyrokl 10.06Moderate ism 
10.06 Hypothyrod 10.06Severe ism 
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Mild signs or 
symptoms wh!Ch 1 30 0.00 $0 1 $28 $28 res:ilve Without -
intaven00n 
Re:iuiring meilcal 
management _ 
and/or modification 2 60 0.00 $0 2 $56 $18 $74 Bloods 
r:X medJCation 
regimen 
Re:juiring prompt 
medical 
management and 3 ,90 3.12 $2,952 3 $84 $3,036 Average invesligatbn (e.g. 
palpJtatbns, 
bradycarcfia) 
Re:juiring me:fKEI 
management by 
modification r:X 1 30 0.00 $0 1 $28 $28 
me:ficatbn 
regimen 
Re:jUJring meilcal 
management 
and/or mocflficaoon 2 60 0.00 $0 2 $56 $18 $74 Bloods 
crmedicatbn 
regimen 
Mild signs or 
symptoms bkelytn 3 90 3.12 $2,952 3 $84 $3,036 AiJerage res:ilve without 
in!Elven00n 
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meta boric 
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10.07 Hyp:>glyrae 10.07M11d 
mia 
10.07 Hyp:>glyrae 10.07ModeralE 
mia 
10.07 Hyp:lglyrae 10.07Severe 
mia 
10.08 Hypokalae l0.08M11d 
mia 
10.08 Hypokalae 10.08Mcxlerate 
mia 
10.08 Hypokalae 10.0SSevere 
mia 
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Mild signs or 
symptoms which 1 30 0.00 $0 1 $28 $28 rerolve Without 
intavention 
Ra:juiring 
addlfunal oral 
medra1 
management or 2 60 0.00 $0 2 $56 $18 $74 Bb:rls 
mocffulOOn of 
rneiic:ation 
reaimen 
Requiring 
intraitet10l5 3 90 3.12 $2,952 3 $84 $3,036 Average 
management 
Miki signs or 
symptoms which 1 30 0.00 $0 1 $28 $28 rerolve Without 
1ntavention 
Ra:juinng rneiiral 
management 
and/or modlfiCB!Jon 2 60 0.00 $0 2 $56 $18 $74' Bb:rls 
of medication 
regimen 
Ra:juiring prompt 
rneiical 
management and 3 90 3.12 $2,952 3 $84 $3,036 Average 1nvestigatbn (e.g. 
palpitaoons, 
.taa:hycarcfia) 
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kidney and 11.01 
urinary 
kidney and 11.01 
urinary 
kidney and 11.01 
urinary 
kidney and 11.02 
urinary 
kidney and 11.02 
urinary 
kidney and 11.02 
urinary 
kidney and 11.03 
urinary 
~ 
i J "Cl 
-J-9 "Cl 
i 
Urinary ll.OlM11d 
retention 
Urinary 11.0lModerate 
retention 
Urinary 11.0lSevere 
relaltJon 
Urinary 
Incnntinenc ll.02M11d 
e 
Un nary 
Incnntinenc 11.02Moderate 
e 
Urinary 
Incnntinenc 11.02Severe 
e 
Renal 11.03M11d !Jy?func:OOn 
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SymptomatX:, bJt 
rot requiring 1 30 0.00 $0 1 $28 $28 rnedral 
rnanaaement 
Re;:iuiring medk:al 2 60 0.00 $0 2 $56 $18 $74 ?lVP, Bbo:ls management 
Requiring 3 90 2.66 $2,949 4 $112 $3,061 l..D8l\,B 
c:athelertsatio 
Mild signs or 
- -
symptoms wh!Ch 1 30 0.00 $0 1 $28 $28 
_ res:ilve without 
intavention 
Re;:iuiring me:lical 
manageme_nt 
and/or modlficatJon 2 60' 0.00 $0 2 $56 $56 
et medication 
regimen 
Requiring 
hospitalisation and 
rnedk:al and/or 3 90 3.12 $2,952 - 3- $84 $3,036 Averc:t:,Je 
rurgical 
management 
Mild signs or 
symptoms which 1 90 - 0.00 $0 2 $56 $56 res:ilve W1lhout 
intavention 
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kidney and 
unnary 
kidney and 
urinary 
female 
reprodudive 
5)'SlEm 
female 
reproduclive 
5)'SlEm 
female 
reproduclive 
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~ 
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Renal 11.03 11.03Moderate. Dym.Jndion 
11.03 Renal 11.03Severe Dym.Jndion 
13.01 ContraCEplJ l3.0lM11d 
veFailure' 
13.01 Contrarepti 13.0lMcxferate · 
veFailure · 
13.01 Contracepti 13.0lSevere 
ve Fii1lure 
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Ra::iuiring riiedJCal 
management 
anq!or modtficatlon 2 180 0.00 $0 5 $140 1 $128 . $i8 $286 Bloods 
et medJCation 
regimen 
JlrutE drone in 
renal fund:Jon 
requinng prompt 3 360 7.26 $5,614 6 $168 2 $192' $5,974 L60A,B,C medJCal. 
management and . ' 
invesllQation 
:intafuence with 
cnntraceplive 
efficacy not 1 5 0.00 $0 1 $28 $28 requinng additional 
cnntracep!ive 
pri:rautJons 
InlErference with 
cnntraceplive 
efficacy that 2 ' 30 0.00 $0 1 $28 $28 requires additional 
cnntraceplive 
' 'methods be usErl 
Total cnntracep!ive 
failure res.ilting in 3 . 30 2.00 $2,466 2 $56 $2,522 040Z 
undesired 
l'llEOnancv 
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blcxxland 
blcxxl 
forming 
organs and 
immunob;Jic 
al cfrorde!s 
blcxxland 
blcxxl 
faming 
organs and 
immunob;Jic 
aldrorde!s 
blcxxland 
blcxxl 
fam1ng 
organs and 
immunqlcgic 
al cfrorde!s 
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14.01 Birth Defa± 14.0lMik:l 
14.01 Birth Defa± 14.0lModerate 
14.01 BirthDefa± 14.0lSevere 
16.01 Anaerriia l6.0lM1k:l 
16.01 Anaemia 16.0lModerate 
16.01 Anaemia 16.0lSevere 
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Minor birth defect 
that cbes not affect 1 30 0.00 $0 1 $28 $28 
thenewbom · 
Buth defect not 
affeding Cl'.lUISe of 
pregnancy but 2 60 0.00 $0 2 $56 $56 re:sult:Jng 1n 
damage to the 
newborn 
Severe birth defect 
requiring 
termination of 3 90 2.00 $2,466 4 $112 $2,578 040Z 
preqnancy 
M1k:l519nsor 
• symptomswhic:h 1 90 0.00 $0 2 $56 $18 $74 -Bloods IES'.l!ve with'.Jut 
intervention 
Requiring me:fical 
management 
artj/or mocflfic:aoon 2 90 0.00 $0 3 $84 $18 $102 Bloods 
r:f ma'.licaoon 
regimen 
Requiring 
hospital1Sation and 
blcxxl product or 3 90 4.58 $3,144 3 $84 1 $1.28 $3,356 Q61A,B.,C 
gfOINlfl fadnr 
rupport 
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blood and 
blood 
fbrming 
organs and 
immuno~ic 
al cfrordels 
blood and 
blood 
fbrming 
organs and 
immuno~ic 
al cfrordels 
blood and 
blood 
fbrming 
organs and 
immuno~ic 
aldrordels 
blood and 
blood 
fbrming 
organs and 
immuno~ic 
al drorders 
blood and 
blood 
fbrm1ng 
agansand 
1mmuno~ic 
al cfrorders 
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Bone 
16.02 marrow 16.02Mild 
suppresskln 
Bone 
16.02 marrow 16.02Moderate 
suppresskln 
Bone 
16.02 marrow 16.02Severe 
suppresskln 
16.03 Bleeding, 16.03M11d 
non-spoofi: 
Bleeding, 16.0;3 
non-spe:ific 16.03Moderate 
Climca/ Interventions in Australian Community Pharmacies 
~ i z i 
'Oil~ !;r i!j ~ i t i § i z ~I i ~ ·tf c sa. p ~ If ~I f ~1 . ~ 3' sa. sa. sa. sa. 1· ~ ~1·!r · sa. i Cl - ~i~ lif I !B ,, 9·~ J i Gff' i4: ~.Rt 3' ~ ! i ~i i l~i ! -1 -I" i DJ i4: ii ~ ·a. Gf 'l"~ mi 
Mild signs or 
symptoms whldl 1 30 0.00 $0 2 $56 $18 $74 Bloods 
res:ilve without 
intavention 
fle1uiring rne.iical 
management by 
modlfia:rtloncr 2 60 0.00 $0 4 $112 $18 $130 Bloods 
existing me:;lkatbn 
regimen 
fle1uiring 
hospitalsabon and 
blood product or 3 90 8.30 $9,359 4 $112 2 $192 $9,663 
growth factor 
support 
Mild elevation of 
INR not requiring 1 30 0.00 $o 1 $28 $28 
ad_Jusbnent of 
dc6age 
Moderate elercrtlon 
ofINR requinng 
mocflfiratbn cr 2 60 0.00 $0 2 $56 $1!3 $74 ' Bloods 
cbsecr 
anli<oagulant 
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blocxl and 
blocxl 
forming 
organs and 
immunokJgic 
al cfrorde!s 
blocxland 
blood 
forming 
organs and 
immunokJgic 
al cfrorde!s 
blocxl and 
blood 
forming 
organs and 
immunokJgic 
al cfrorde!s 
blood and 
blood 
forming 
organs and 
immunokJgic 
al cfrorde!s 
1nfedxlus 
and parasitic 
cfreases 
f ! l ! 
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Blea:!1ng, 16.03 16.03SeVere 
non-spe:ifk: 
16.04 Alle!gk: 16.04M11d 
reaction 
16.04 Alle!gic 16.04ModeralE 
reaction 
16.04 Alle!gk: 16.04Severe 
reactioh 
18.01 Infection, 18,0lM11d general 
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Severe bleeding 
re:iuiring 
hospilaUsation, 
blood product 3 90 3.12 $2,952 2 $56 1 $128 $3,136 A~ 
and/or 
haemodynamic 
support 
Mild readlon not 
re'.juiring 1 15 0.00 $0 1 $28 $28 
·intervention 
Mcxlerate alle!gic 
reaction re:iuiring 2 30 0.00 $0 2 $56 $56 IDpic:al or oral 
me:fic:ations 
Severe al!ergJC 
reaction re:iuiring , 3 60 1.32 $1,238 2 $56 $1,294 Z61Z acute rnroic:al 
management 
Mild signs or 
symptnrns whldl 1 15 0.00 $0 1 $28 $28 res:ilve without 
intervention 
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1nfe:iious 
and parasitic 18.01 
cf'193a5e5 
infa:tious 
and paraSIOC 18.01 
cf'193a5e5 
infa:tious 
and paraSIOC 18.02 
cf'193a5e5 
infa:tious 
and parasitic 18.02 
cf'193a5e5 
lnfi:dlous 
and parasitic 18.02 
cf'193a5e5 
infa:tious 
and paraSIOC 18.03 
cf'193a5e5 
~ 
i J 'tl I ~ 'tl 
~ 
Infed:lon, 
general 18.0lModeralE 
Infe:lion, 18.0lSevere general 
Urinary 
Tract 18.02M11d 
Infe:lion 
Unnary 
Tract 18.02ModeralE 
Infed:lon 
Urinary 
Tract 18.02Severe 
Infe:lion 
Obtis Ma:iia 18.03M11d 
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Moderate 
cnmphcatJOns 
re:iuiring rneiical 2 30 0.00 $0 2 $56 $34 $90 MCS 
atlEntion and oral 
anbbblics 
Requiring 
hospllahsation and 3 30 7.84 $5,946 2 .$56 $6,002 E62A,B,C;T60 intravenous A,B 
anbbiolics 
Mild signs or 
5)'lTlploms which 
res:>lve without 1 15 0.00 $0 1 $28· $28 
intervention 
Moderate 
cnmprications 
re:iuiring me.iical 2 30 0.00 $0 2 $56 $34 $90 MCS 
atlEntion and oral 
anbbiolics 
~uiring 
hospllalisaoon and 3 30 6.26 $3,920 2 $56 $3,976 L.63A,B,C intravenous 
anbbiolics 
Mild signs and 
5)'lTlptoms that will 
res:>lve wrthout 1 15 0.00 "$0 1 $28 $28 
mroical 
intervention 
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infe:fuus 
and parasrtic 
cfLSeaSeS 
infe:Dous 
and parasrtic 
cfLSeaSeS 
lllfe:tJous 
and parasitJc 
cfLSeaSeS 
infe:fuus 
and parasitic 
cfLSeaSeS 
infe:fuus 
and parasrtic 
cfLSeaSeS 
mental 
cfLSeaSe.Sand 
cf50rdefs 
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18.03 OtitlsMooia 18.03Moderate 
18.03 ' Obtis Mecfia 18.03Severe 
Ophthalmic 18.04 l8.04M11d Herpes 
18.04 Ophthalmic 18.04Moderate Herpes 
Ophthalmic 18.04 18.04Severe Herpes -
19.01 Psyd1osis 19.0lMild 
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Requiring rneiical 
inlElvention and/or 2 30 0.00 $0 2 $5~ $56 modification r:i 
rneiications 
Severe otitis media 
te.'.jUJring 
hospitahsatbn and 3 30 2.32 $1,932 2 $56 $1,988 D63A,B intravenous 
antlbbtic 
management 
Miki signs or 
symptnms likely to 
res:>lve without 1 30 0.00 $0 2 $56 $56 
mecfical 
intavention 
Requiring rneiral 
management 2 30 0.00 $0 2 $56 $56 
and/or mcxfdication 
of rneiicatbns 
Severe OOJlar 
infedbn te.'.jUiring 
hospttarisaoon and 3 30 5.91 $3,864 0 $0 2 $192 $4,056 C60A,B 
intravenous -
management 
M11dsignsor 
symptnrns whid1 1 180 0.00 $0 1 $28 $28 res:>lve without . 
intavention 
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mental 
efireases and 
disorders 
mental 
efireases and 
cfLSOrders 
mental 
efireases and 
cfLSOrcfers 
mental 
cfsaases and 
cfLSOrders 
mental 
efireasesand 
cfLSOrcfers 
mental 
efireases and 
cfLSOrders 
I ~ : I "C ~ J 8 ~ "C ~ 
19.01 Psyc:f1osis 19.0lModerate 
19.01 Psychosls 19.0lSevere 
19.02 PvlxJro/ 19.02M11d 
19.02 Anxiety 19.02Moderate 
19.02 Anxiety 19.02Severe 
19.03 Serotonin 19.03M11d Syndrome 
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Wor.:ening of 
cflSeilSe re:iuiring 2 180 0.00 $0 2 $56 $56 modlficabon et 
treatment re::11men 
Destablrisation or 
unmask!ng of 10.8 psydlosls re:iuirjng 3 360 9 $7,491 0 $0 4 $320 $7,811 U62A,B 
spa:iaUst me::fJCal 
atlEnlion 
Mild signs or 
symptnms which 1 30 0.00 $0 2 $56 $56 re&Jlve without 
intavention 
Worsening of 
cflSeilSe re:iuiring 
mocflfiratbn et 2 90 0.00 $0 4 $112 $112 
eiasting treatment 
regimen 
Requ1nng spa:iahst 3 180 4.03 $2,595 4 _$112 2 $192 $2,899 U65Z medJCal attentbn 
Mild signs or 
symptnms which 1 14 0.00 $0 1 $28 $28 re&Jlve without 
intavention 
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mental 
cf1SeNSand 
cflSOrders 
mental 
cf1SeNSand 
cflSOrders 
mental 
cf1SeNSand 
cflSOrders 
mental 
cf1SeNSand 
- cflSOrders 
mental 
cf1SeNSand 
cflSOrders 
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19.03 
19.03 
19.04 
19.04 
19.04 
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Serotonin 
Syndrome 19.03Moderate 
Serotonin 
Syndrome 19.03Severe 
Depresst0n 19.04Mikl 
Depression 19.04Moderate 
Depression 19.04Severe 
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Ra:juinng me:fral 
management 
and/or modification 2 30 0.00 $0 2 $56 $56 
a ma:lication 
regimen 
Requiring prompt 
me:fral 
management and 
investigation ( e.g 3 30 0.00 $0 2 $56 $18 $74 l3lood:; 
euphoria, tremor, 
revere anxiety, 
palpitations) 
Miki signs or 
5)'!Tlploms which 1 180 0.00 $0 4 $112 $112 regitlfe wi!hout 
intavention 
Worsening of 
cfisease J'e.iUiring 2 180 0.00 $0 5 $140 1 $128 $268 
modification a 
treatment reaimen 
- ' 
Desrabiltsation or 
unmasking of 12.4 P.;ych depression 3 360 5 $7,192 6 $168 2 $192 $7,553 U63A,B; U64Z As9:59:mnt J'e.iuinng spa:ialist 
me:fral atl:Ention 
